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ABSTRACT 
An Antibiotic Discovery Campaign Targeting VirF, the Main Transcriptional 
Regulator of Virulence in Shigella flexneri 
By 
Anthony A. Emanuele 
Chair: George A. Garcia 
 Shigella flexneri is a gram-negative enteropathogen that infects the human 
colonic epithelium.  It is estimated that Shigella spp. infect 165 million people a year 
worldwide.  Symptoms of shigellosis include bloody dysentery, dehydration, and 
ultimately death if the infection is not treated properly.  The current recommended first-
line treatment for shigellosis is ciprofloxacin; however, many new multi-drug resistant 
strains of Shigella have begun to emerge.  The emergence of these strains, along with 
the lack of novel antibiotics in the drug pipeline, makes the need for new effective 
treatments for shigellosis a priority.   
 Genetic knockout studies have shown that VirF, the main transcriptional activator 
of the Shigella pathogenesis cascade, is necessary for virulence, but not bacterial 
viability. We hypothesized that a novel anti-virulence therapy for shigellosis could be 
developed through the inhibition of VirF.  To identify inhibitors of VirF, we performed a 
high-throughput screening (HTS) campaign testing over 140,000 small molecules and 
20,000 natural product extracts using a Shigella-based, VirF-driven, β-galactosidase 
reporter assay.  Following a series of confirmation screens, we identified five 
xiv 
 
compounds from the HTS campaign that had VirF inhibitory properties.  Using tissue 
culture-based models of the S. flexneri infection process, we were able to show that 
three of compounds were able to attenuate the virulence of S. flexneri, thereby, 
validating VirF as a target for the treatment of shigellosis. 
 To further characterize the hits from the HTS campaign a series of established in 
vitro assays were adapted and optimized for VirF.   An electrophoretic mobility shift 
assay and a fluorescence polarization assay were used to monitor VirF binding to the 
virB promoter, and a fluorescence intercalator displacement assay was used to 
determine if the hits could directly bind DNA.  Using these assays, we were able to 
determine the mechanism of inhibition (blockade of VirF binding to the virB promoter) 
and preliminary structure-activity relationship trends for one of the hits, and report the 
first dissociation constant for VirF binding to the virB promoter (2.8 ± 1.0 μM). 
  
1 
CHAPTER I 
Introduction 
The Need for Novel Antibiotics 
 
“A post-antibiotic era-in which common infections and minor injuries can kill, far 
from being an apocalyptic fantasy, is instead a very real possibility for the 21st 
century.”  
-World Health Organization, 20141 
 
The misuse of prescription antibiotics and the overuse of antibiotics in livestock 
feed have greatly contributed to the rapid increase in drug-resistant bacteria in the 
environment.  This global rise of multi-drug resistant pathogens is a serious challenge to 
human health.  The emergence and spread of resistance to drugs considered to be last 
resort, such as carbapenems2-4 and vancomycin,5, 6 has resulted in infections that are 
completely resistant to all known medications.7  Exacerbating this problem is the slow 
rate at which new antibiotics are being discovered.  Since the 1960s, no new class of 
broad-spectrum antibiotics has been discovered and only five classes of narrow-
spectrum antibiotics (streptogramins: streptogramin B, oxazolidinones: linezolid, 
lipopeptides: daptomycin, fidaxomicin, and diarylquinolines: bedaquiline) have had 
compounds approved for clinical use.8, 9  Unfortunately, resistance to all five newly 
approved compounds has already been observed.10-14  While a promising new antibiotic 
has been recently discovered  (teixobactin)15 it has yet to be approved for clinical use 
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and is ineffective at targeting gram-negative pathogens.  Clearly, there is an urgent 
need for new antibiotic treatments.  
All current antibiotics negatively affect bacterial viability, and as such, any 
organisms that mutate to become resistant to the antibiotic will have a selective growth 
advantage.  This can contribute to the rapid emergence of resistant strains.  A potential 
method to combat bacterial infection while potentially minimizing the emergence of 
resistance is to target virulence instead of bacterial viability.  It is hypothesized (by us 
and others16) that targeting virulence will result in less selective pressure for the 
emergence of new drug-resistant strains as they are expected to have little or no growth 
advantage.  Also, virulence therapies should not harm the normal microbiota of the host, 
since the therapy targets virulence pathways that do not exist in the non-pathogenic 
microbiota.  This has the potential to eliminate the development of secondary infections 
often associated with previous antibiotic exposure, such as infections caused by 
Clostridium difficile.17  Although virulence-directed therapies appear promising, they are 
still in the early phases of development; however, recent studies have provided 
encouraging evidence that this strategy could be effective.  Virstatin, a small molecule 
inhibitor of ToxT (a transcriptional activator of critical virulence factors in V. cholerae) 
was shown to protect infant mice from intestinal colonization by V. cholera.18  Also, a 
series of benzimidazole compounds were shown to limit infection in a murine model of 
Yersinia pseudotuberculosis pneumonia through the inhibition of the transcriptional 
regulator of the Yersinia type III secretion system, LcrF.19-21 
Shigellosis 
Shigella flexneri is a gram-negative pathogenic bacterium that is a member of the 
Enterobacteriaceae family.  There are approximately 165 million cases of Shigella spp. 
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infection worldwide and these infections claim more than one million lives per year.1, 22  
The primary route of transmission for Shigella is fecal-to-oral, so it is not surprising that 
a majority of outbreaks occur in areas with poor sanitation conditions such as in 
underdeveloped nations or at day-care centers (children under five years of age 
represent 69% of all cases and 61% of all deaths).1  Shigella infects the human 
gastrointestinal tract by invading the mucosal cells and spreading through the colonic 
epithelium.  Upon infection, the host may experience severe bloody dysentery, 
dehydration, and ultimately death if not administered proper treatment.  The current 
WHO recommended first-line treatment for Shigella infections include quinolones, such 
as ciprofloxacin and norfloxacin;23 however, quinolone-resistant and multi-drug resistant 
strains of Shigella are being isolated.  Recently, a S. flexneri clinical isolate was 
reported in China to be resistant to ciprofloxacin, third-generation cephalosporins 
(common second-line therapy), and nalidixic acid (previous first-line therapy).24  
Although these infections are commonly thought to be isolated to developing regions of 
the world, multi-drug resistant strains of Shigella are being found across the United 
States.25, 26  The Centers for Disease Control and Prevention issued a press release on 
April 2, 2015 warning US citizens of a multi-drug resistant strain of Shigella spreading 
across the country.27  The appearance of multi-drug resistant strains coupled with the 
highly virulent nature of Shigella (exposure to only 10-100 bacteria is needed to 
establish an infection28) has caused the National Institute of Allergy and Infectious 
Diseases (NIAID) to classify Shigella spp. as a Category B priority pathogen. 
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Shigella Pathogenesis 
The essential parts of the molecular machinery required for Shigella 
pathogenesis are encoded on the 230 kb Shigella virulence plasmid.29-31  Of the genes 
encoded on this plasmid, the virF gene may be the most important.  VirF is an AraC 
family transcriptional activator that regulates (directly and indirectly) the transcription of 
all downstream virulence factors in Shigella spp.32-35  VirF directly activates two 
downstream virulence genes, virB and icsA.36, 37  VirB is a secondary transcriptional 
activator that is responsible for activating the transcription of other virulence genes, 
such as ipaB, ipaC, and, ipaD,38 whose gene products are involved in the construction 
of the Type III Secretion System (which is required for initial bacterial invasion) and 
escape from host-cell defense systems.39-41  IcsA assembles actin polymerase on one 
pole of the bacterium and propels the bacterium through the infected host cells via the 
polymerization of host cell actin; allowing the bacterium to spread to adjacent cells.42-44  
Gene silencing studies have shown that the lack of VirB expression leads to a loss of 
virulence,32, 45 and that the lack of IcsA expression blocks the intra- and inter-cellular 
movement of Shigella.46, 47  A schematic representation of the Shigella spp. 
pathogenesis cascade is provided in Figure I-1.   
VirF: Structure, Regulation, and Function 
 The three-dimensional structure of VirF has not yet been determined.  However, 
based on sequence similarity, VirF is classified as an AraC family transcriptional 
regulator.48  AraC family transcriptional regulators can function either as monomers or 
as homodimers.  VirF is believed to function as a homodimer and, by homology, has 
two domains: an N-terminal dimerization domain and a C-terminal DNA-binding domain.   
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The C-terminal DNA-binding domain is highly conserved across all AraC-family 
members and contains two helix-turn-helix (HTH) motifs that insert into adjacent major 
groove segments of the DNA.49, 50  Figure I-2 provides the first high-resolution structure 
for an AraC-family transcriptional regulator (MarA) and highlights the interactions 
between the HTH motifs and the DNA.51  The N-terminal domain, not depicted in Figure 
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I-2 (MarA has only one domain and functions as a monomer), is much less conserved 
across AraC-family members.   
Figure I-2:  Co-crystal Structure of MarA Bound to mar Promoter.51  Helix-turn-helix 
motifs are highlighted in red and are shown to interact in two adjacent 
major grooves of the mar promoter.  Each HTH motif is made up of 20 
amino acids and combined span approximately 20 nucleotides.  Upon 
binding MarA bends the DNA by approximately 35°.  The structure was 
refined to a resolution of 2.3 Å and the image depicted was made from the 
following PDB file: 1BL0.  
 
There are three classes of AraC family members: monomeric, chemically-
modulated, and physically-modulated.49, 52  MarA, depicted in Figure I-2, is an example 
of the monomeric class.  Most members of this class are involved in bacterial stress-
response pathways.52, 53  AraC is the poster child for the chemically-modulated class.  
AraC functions as a homodimer, but can only activate transcription after binding 
arabinose and undergoing a conformational shift.54  Most members of this class are 
activated by small carbohydrates, such as, RhaS and RhaR from E. coli, which are 
modulated by L-rhamnose.55  VirF is a member of the physically-modulated class and 
can only activate transcription under the correct environmental signals (pH, 
temperature, osmolarity), specifically signals commonly encountered in the host cell 
environment.38, 56-58   
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 Transcription of the virF gene is repressed by the temperature dependent 
binding of the H-NS protein to two sites in the virF promoter.58-60  H-NS binds to the virF 
promoter at temperatures below 32°C preventing RNA polymerase from binding and 
activating transcription.  However, when the temperature increases to 37°C there is a 
change in DNA topology that frees H-NS from the promoter, allowing virF mRNA to be 
transcribed by RNA polymerase.  Once VirF is expressed it can activate the 
transcription of two genes, virB and icsA.   
To activate the transcription of virB, VirF binds upstream of the transcription start 
site between positions -17 to -105 and aids in the recruitment of RNA polymerase.36  
This transcriptional activation process is further regulated by temperature and 
osmolarity.  Similarly to virF transcriptional regulation, H-NS also represses the 
transcription of virB at temperatures below 32°C.36  When the temperature shifts to 
37°C, there is a change in the local negative supercoiling of the DNA that results in the 
displacement of H-NS, the binding of VirF, and the recruitment of RNA polymerase by 
VirF.61  It has been shown that conditions of high osmolarity enhance the change in 
DNA topology,57 and that the supercoiling of the DNA is necessary for VirF to activate 
transcription (however, VirF can still bind to non-supercoiled DNA).61  It has also 
recently been shown that VirB itself can participate in positive feedback regulation at 
both the virB and virF promoters by antagonizing H-NS mediated repression.62 
VirF-mediated activation of the icsA promoter appears to be more complex than 
the activation of the virB promoter.  Recently, the lab of Dr. Maurizio Falconi has 
identified a 450-nucletoide antisense RNA, RnaG, which is transcribed in cis from icsA 
and attenuates the transcription of icsA.37, 63  As with both virF and virB, H-NS also 
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represses the transcription of icsA at temperatures below 32°C.59, 64  The exact 
mechanism of how VirF, H-NS, and RnaG control transcription of icsA is not completely 
understood; however, the Falconi lab has identified four distinct binding sites for both 
VirF and H-NS within the icsA/RnaG promoter and coding regions.37  They have also 
shown that H-NS and VirF both repress the transcription of RnaG.37  It is possible that 
RnaG serves as a fine-tune control mechanism for the icsA promoter that helps prevent 
the transcription of icsA after only temperature-mediated dissociation of H-NS.   
VirF: A Potential Anti-Virulence Target? 
Genetic knockout studies have shown that VirF is required for host cell infection, 
but not bacterial viability.65  This trait, combined with a number of other factors, makes 
VirF an attractive target for an anti-virulence therapy.  For one, the likelihood of 
resistance to VirF inhibitors developing environmentally (outside of an infected host) 
should be quite low.  Absent conditions that mimic those of an infected host, there 
should be little or no expression of VirF;38, 56-58 therefore, the VirF-selective inhibitors 
should have no effect on Shigella spp. in the environment.  Additionally, targeting 
virulence gene expression does not impair bacterial viability or impact non-virulent 
organisms,66, 67 and hence, there should be little selective pressure in the environment 
for resistance development.  Also, in the infected host, Shigella utilize VirF-induced IpaB 
to escape from macrophages.40  Inhibition of VirF should block this and increase the 
efficiency of macrophage killing Shigella and thereby reduce the development of 
resistance.  Although no one has attempted to target the VirF-activated Shigella 
pathogenesis cascade with a small molecule, there has been promising vaccine-based 
approaches.68, 69  Several researchers have used icsA-knockout strains of Shigella as 
live-attenuated vaccine candidates (bacteria can initially invade epithelial cells and 
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generate an immune response, but cannot spread intra- or inter-cellularly).70-73  In fact, 
two icsA-knockout vaccine candidates are scheduled to enter phase I clinical trials in 
the near future (Clinicaltrials.gov identifier: NCT01336699).  It may be possible that a 
small molecule targeting VirF could replicate this icsA-knockout phenotype, as well as, 
prevent initial bacterial invasion.  Of course, these are all postulates and require 
experimental testing to determine their validity. 
Research Objectives 
 It is clear that VirF is an attractive target for therapeutic intervention.  However, at 
the time this dissertation research began, VirF’s potential as a therapeutic target had yet 
to be validated.  Therefore, there were two main goals for this dissertation research: 1) 
to identify, characterize, and develop small molecule inhibitors of VirF, and 2) to validate 
VirF as a novel anti-virulence target for the treatment of shigellosis.  Over the course of 
the project, we also sought to gain a better understanding of how VirF activates 
transcription and looked to develop tools to monitor VirF activity at all levels 
(biochemical, bacterial, and cellular).  The primary objective described in each chapter 
follows: 
Chapter 2: To identify small molecule inhibitors of VirF. 
 Using our lab’s previously developed Shigella-based, VirF-driven, β-
galactosidase reporter assay,74 we tested over 100,000 small molecules in a high-
throughput screening campaign and identified five inhibitors of VirF-driven 
transcriptional activation. 
Chapter 3: To validate VirF as a potential small molecule therapeutic target. 
10 
 
We evaluated the hits from our high-throughput screen in a series of tissue 
culture-based models of the S. flexneri invasion process and determined that small 
molecule inhibitors of VirF can attenuate the virulence of Shigella.  
Chapter 4: To develop tools to monitor VirF binding to the virB promoter at the 
biochemical level. 
 We developed a homologous Shigella-based expression system to express and 
purify VirF and then characterized VirF in a series of in vitro DNA-binding assays.  We 
also determined the first experimental dissociation constant for VirF binding to the virB 
promoter (2.8 ± 1.0 μM). 
Chapter 5:  To determine the mechanism of inhibition of our hits and to identify 
structure-activity relationship trends. 
 We determined that one hit inhibited VirF activity by preventing VirF from binding 
to the virB promoter.  We also screened analogs of our most promising hits and 
identified structure-activity relationship trends. 
Chapter 6:  To identify natural product extracts that inhibit the activity of VirF or 
the growth of Shigella flexneri. 
 Using our lab’s previously developed Shigella-based, VirF-driven, β-
galactosidase reporter assay,74 we tested over 20,000 natural product extracts in a 
high-throughput screen.  We identified extracts that have inhibitory effects on VirF, 
apparent activating effects on VirF, and that inhibit the growth of S. flexneri.  Lastly, in 
collaboration with the Sherman lab (Life Sciences Institute, University of Michigan Ann 
Arbor), we identified the active components from two of our natural product extract hits. 
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CHAPTER II 
Small Molecule High-throughput Screening Campaign Targeting VirF 
AraC family transcriptional activators regulate virulence pathways in a wide 
variety of bacterial pathogens1 (e.g., ToxT from Vibrio cholerae,2 LcrF from Yersinia 
pestis,3 InvF from Salmonella typhimurium,4 and ExsA from Pseudomonas 
aeruginosa5), as such, they have become popular targets for novel antibiotic 
discovery.6, 7  Many groups have utilized high-throughput screens (HTS) to identify 
compounds that inhibit these transcription factors.8-10  A common feature of these 
screens is the use of bacterial reporter strains that monitor the transcription factor of 
interest (TFI) activating the expression of a reporter gene under the control of the TFI’s 
endogenous promoter.  For example, Hung et al. constructed a screening strain of V. 
cholera where the tetracycline resistance gene was under the control of the cholera 
toxin promoter and used this strain to identify inhibitors of ToxT.10   
To identify inhibitors of VirF, the main transcriptional activator of the Shigella spp. 
pathogenesis cascade, our lab previously constructed a Shigella-based, VirF-driven, β-
galactosidase reporter system.9  For the reporter system, an avirulent strain of S. 
flexneri, BS103, was transformed with a reporter plasmid that had lacZ (gene encoding 
β-galactosidase) under the control of the virB promoter (see Figure II-1).  In this system, 
β-galactosidase activity directly correlated to VirF activity and was monitored 
spectrophotometrically using the colorimetric substrate chlorophenol red β-D-
galactopyranoside.  Using this system, we carried out an initial 42,000 compound pilot 
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HTS at the Center for Chemical Genomics (Life Sciences Institute, University of 
Michigan Ann Arbor).   Unfortunately, the pilot screen produced an artificially high hit 
rate (3%), a large degree of variability between plates, and hits that did not reconfirm.  
Also, the initial pilot HTS was modest in size and may not have sampled a large enough 
range of chemical diversity to identify an inhibitor of VirF.   
Figure II-1:  Maps of the Reporter and Positive Control Plasmids Used in the HTS.  
Left map, pMALvirF-LacZ, depicts the reporter plasmid used in the HTS.  
The plasmid contained the malEvirF fusion gene as well as the lacZ gene 
under the control of the virB promoter.  All compounds were screened 
against this plasmid.  Right map, pMAL(ΔvirF)-LacZ, depicts the positive 
control plasmid used in the HTS.  This plasmid was used to determine the 
baseline value for 100% VirF inhibition. 
 
To improve our chances of identifying an inhibitor of VirF, we decided to extend 
our small molecule screen to include ~100,000 more compounds, for a total small 
molecule screen of ~140,000 compounds.  To address the variability issue seen in the 
pilot HTS and improve the overall accuracy of the screen, we initially contemplated 
switching from a bacteria-based assay to a biochemical assay.  However, we could not 
develop a biochemical assay monitoring VirF activity at the time of the screen.  This was 
largely due to the difficulty we had purifying VirF (see Chapter IV).   Therefore, to lower 
the variance seen in the pilot HTS, we modified the Shigella-based assay to include 
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humidified overnight incubation.  Using this modified assay, we were able to greatly 
reduce the variability of the screen and accurately test ~100,000 more compounds.  
Following a series of counter and reconfirmation screens, we were successfully able to 
identify five small molecules with VirF inhibitory properties.   
Materials and Methods 
Reagents 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise specified. CPRG (chlorophenol red β-D-galactopyranoside) was purchased 
from Roche (Basel, Switzerland). Yeast extract, bactotryptone, carbenicillin, and 
Corning microtiter plates (384 and 96 well) were purchased from Fisher Scientific 
(Hampton, NH).  Compounds selected for reconfirmation screening were purchased 
from ChemDiv (7 compounds, San Diego, CA) and Vitas-M Laboratory (3 compounds, 
Moscow, Russia).  
Strains and Plasmids 
Wild-type Shigella flexneri serotype 2a strain 2457T11 and an isogenic, virulence 
plasmid-cured derivative, BS103,12 were used in this study.  HeLa cells and L2 mouse 
fibroblasts were used for virulence assays and were grown in Dulbecco's Modified 
Eagle Medium (Life Technologies, Grand Island, NY), supplemented with 10% heat-
inactivated fetal bovine serum (Life Technologies, Grand Island, NY).  The bacteria 
were grown in tryptic soy broth (TSB) or on agar plates supplemented with 0.025% 
Congo Red agar as necessary at 37°C.  The construction of the reporter plasmids, 
pMALvirF-lacZ and pMAL(ΔvirF)-lacZ (positive control), was previously described.9  
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Small Molecule Library 
A 100,000 compound library produced by ChemDiv (San Diego, CA) was 
screened at the Center for Chemical Genomics (CCG, University of Michigan Ann 
Arbor). 
High-throughput VirF-driven, β-galactosidase Reporter Assay 
The construction and optimization of the reporter assay was previously 
described.9  Briefly, starter cultures of S. flexneri BS103 harboring either the reporter 
plasmid (pMALvirF-lacZ) or positive control plasmid (pMAL(ΔvirF)-lacZ) were grown 
overnight at 37°C with shaking in 2xTY media (16 g bactotryptone, 10 g yeast extract, 5 
g NaCl per liter of water supplemented with 100 μg/mL carbenicillin).  The next day, 20 
μL of 2xTY media supplemented with 100 μg/mL carbenicillin was added to 384-well 
plates using a multidrop dispenser (Thermo Scientific, Waltham, MA).  Compounds from 
the 100K ChemDiv library (13 μM final, n=2, 0.2 μL) were then added to appropriate 
wells using the Biomek HDR pintool instrument (Beckman, Fullerton, CA).  Overnight 
starter cultures (reporter plasmid and positive control) were diluted to OD600 = 0.012 
using 2xTY media supplemented with 100 μg/mL carbenicillin.  The diluted cultures (10 
μL) were added to the appropriate wells of the plates via the multidrop dispenser (total 
volume 30 μL). Plates were then spun-down at 1000 x g for one minute using a 
Beckman Coulter Allegra Series centrifuge.  After centrifugation, plates were placed 
overnight (approximately 20 hours) in a humidified, 30°C incubator (VWR). The 
following day, 30 μL of CPRG solution (0.5 mg/mL CPRG, 0.1% Triton X-100, 60 mM 
Na2HPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, pH 7.0) was added to each 
well.  Plates were incubated at room temperature for 10 minutes before measuring 
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chlorophenol red (CPR) absorbance (A570) in a PHERAstar (BMG Labtech, Cary, NC) 
plate reader with a narrow bandpass filter. 
Counter Screens 
Potential hits identified from the primary high-throughput screen were subjected 
to a series of stringent control screens.  First, compounds were assayed in a dose-
response study (n=2) following the screening protocol described above.  However, for 
the dose-response study, the concentration of the compounds was varied using 2-fold 
serial dilutions ranging from 100 to 0.78 μM.  Also, directly prior to the addition of the 
CPRG solution, bacteria density (OD600) was measured using the PHERAstar plate 
reader to determine if the compounds inhibited bacterial growth. 
Compounds that inhibited VirF in a dose-dependent manner, but did not inhibit 
bacterial growth (e.g., MIC50 > 100 μM) were selected for β-galactosidase inhibition 
screening.  For the β-galactosidase inhibition screening, cultures of S. flexneri BS103 
harboring either pMALvirF-lacZ or pMAL(ΔvirF)-lacZ were diluted to OD600=1.0 using 
2xTY media supplemented with 100 μg/mL carbenicillin and added to appropriate wells 
of a 384-well microtiter plate using the multidrop dispenser (30 μL).  Compounds were 
added to the plates in duplicate, and their concentrations were varied using 2-fold serial 
dilutions ranging from 100 to 0.78 μM.  Immediately following compound addition, 
CPRG solution was added to each well (30 μL).  After a 10-minute incubation period at 
room temperature, chlorophenol red absorbance (A570) was measured using the 
PHERAstar plate reader to determine if the compounds directly inhibited β-
galactosidase.  
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Reconfirmation Screen  
Fresh samples of compounds identified as hits were ordered from commercial 
vendors for a reconfirmation dose-response study.  For this study, the screening 
protocol was modified to a 96-well microtiter plate format.  Working stocks of each 
compound were made using 2xTY media supplemented with 100 μg/mL carbenicillin.  
Working stocks were added to the plates in triplicate using a 2-fold serial dilution 
technique (60 μL).  Cultures of S. flexneri BS103 harboring either pMALvirF-lacZ or 
pMAL(ΔvirF)-lacZ were diluted to OD600= 0.012 using 2xTY media supplemented with 
100 μg/mL carbenicillin and added to appropriate wells of plate (30 μL).  Final 
compound concentrations ranged from either 100 to 0.78 μM or 50 to 0.78 μM.  For 
negative controls, compound vehicle (DMSO, 1% final concentration) was added to 
wells instead of compound.  Plates were placed overnight (approximately 20 hours) in a 
humidified, 30°C incubator. The following day, bacteria density (OD600) was measured 
using a BioTek Synergy H1 plate reader (Winooski, VT) then 90 μL of CPRG solution 
was added to each well.  Plates were allowed to incubate for 7 minutes at room 
temperature (incubation time decreased, due to increase signal in 96-well plate format) 
then chlorophenol red absorbance (A570) was read using the BioTek plate reader. 
Data Analysis/Hit Selection 
Three different sets of selection criteria were used to define active compounds in 
the initial high-throughput screen.  Samples were defined as active if either: A) one of 
their A570 readings was ≥ 3 times the standard deviation of the negative controls from 
the average A570 of the negative controls (calculated on a plate by plate basis); or B) 
one of their A570 readings was ≥ 3 times the standard deviation of the plate (not 
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including positive controls) from the average A570 of the plate (not including positive 
controls, calculated on a plate by plate basis); or C) if their percent effect value 
(calculated on a plate by plate basis using both negative and positive controls) was ≥ 
30% inhibition.  Compounds that passed initial selection criteria were tested in a series 
of counter screens.  Compounds that passed all counter screens were classified as hits.  
Counter screen selection criteria were as follows: IC50≤100 μM for VirF Inhibition dose-
response study, MIC50 > 100 μM for bacterial growth inhibition, and no direct β-
galactosidase inhibition over the range of concentrations tested.  For all dose-response 
studies, data were fit by non-linear regression to following equation using Kaleidagraph 
(Synergy Software, Essex, VT): 
y=lower+[(upper-lower)/(1+10[M0-M1)*M2)] 
where M0= log of compound concentration, M1=log of IC50, M2= Hill slope, “lower” is 
defined to be the lower limit of the assay (lower = 0), and “upper” is defined to be the 
upper limit of the assay (upper = 100). 
Results 
Hit Identification 
A summary of the hit identification process is shown in Figure II-2.  The 100,000 
compounds tested in the primary screen (in duplicate) produced 640 compounds that 
were considered active based on primary selection criteria (0.64% hit rate).  Of the 640 
active compounds, 592 met selection criterion A, 39 met selection criterion C, and 9 met 
selection criterion B.  The average Z’ factor per plate tested in the primary screen was 
equal to 0.66 (Z’= 1 – ((3σc+ + 3σc-) / (| μc+ - μc- |)), where σc+ and σc- are the standard 
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deviations of the positive and negative controls and μc+ and μc- are the means of the 
positive and negative controls, respectively).  
Figure II-2:  Flow Chart Depicting the Hit Identification Process for the HTS. 
The 640 active compounds were next tested in a dose-response study (in 
duplicate) monitoring both bacterial growth inhibition (optical density) and VirF inhibition 
(CPRG hydrolysis).  Of the 640 active compounds, only 52 inhibited CPRG hydrolysis 
while not inhibiting bacterial growth over the range of concentrations tested (e.g., MIC50 
> 100 μM).  These 52 compounds were further tested for direct β-galactosidase 
inhibition and 17 of the 52 compounds inhibited β-galactosidase in a dose-dependent 
~100,000 small molecule library screened
640 “Actives” (0.64% Hit Rate)
met initial selection criteria A, B, or C 
(see Materials and Methods: Data Analysis)
16 compounds passed all counter screens
• No β-galactosidase inhibition
• No bacterial growth inhibition
• IC50 ≤ 100 μM for VirF inhibition
10 most promising compounds 
ordered for reconfirmation testing
5 compounds exhibited 
reproducible activity on testing 
freshly supplied material 
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manner.  Therefore, only 35 of 640 active compounds appeared to inhibit the activity of 
VirF.  Of the 35 compounds, only 16 had an IC50 ≤ 100 μM for VirF inhibition.  Based on 
novelty of scaffold, availability, and potential toxicity concerns we eliminated 6 of the 
compounds from further study.  Fresh samples of the remaining 10 compounds were 
ordered from commercial vendors (seven from ChemDiv, three from Vitas-M 
Laboratory) for the reconfirmation study (below).  The structures of these 10 compounds 
are shown in Table II-1. 
Table II-1.  Hits from 100K ChemDiv Screen that were Rescreened from Fresh 
Samples. 
Compound Name HTS IC50 (μM) Structure 
*25354 6 
 
3776 12 
 
19615 21 
 
144092 31 
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*These compounds were also hits in original 42,000 small molecule screen previously 
reported (Hurt et al., 2010) 
 
 
 
25073 45 
 
153578 58 
 
*24904 58 
 
16977 81 
 
*21496 89 
 
144143 91 
 
30 
 
Reconfirmation 
Each of the 10 compounds was tested in a modified 96-well plate version of the 
screening assay.  Table II-2 shows the results from the modified dose-response study.  
Out of the 10 compounds tested, only five reconfirmed.  The IC50 values of these 
compounds ranged from 66 to 14 μM.  Figure II-3 shows the dose-response curves for 
the two most potent compounds, 19615 and 144092.  The dose-response curves for the 
rest of the compounds can be found in Appendix Figure II-1. 
 
Table II-2.  Reconfirmation Compound IC50 Values and Toxicities from Fresh 
Samples.1 
Compound  Source IC50 (μM) 
2 
Bacterial Growth 
Inhibition 3 
19615 Vitas-M  14 2% @ 100 µM 
144092 ChemDiv 23 13% @ 100 µM 
144143 ChemDiv 23 14% @ 100 µM 
153578 ChemDiv 37 19% @ 100 µM 
24904 ChemDiv 66 13% @ 50 µM 
1 Compounds 25354, 3776, 25073, 16977 and 21496 did not reconfirm and were not 
tested for toxicity. 
2 Log (IC50) values and their associated errors can be found in Appendix Table II-1.  The 
estimated percent errors for each reconfirmed compound were ≤ 2%. 
3 The % inhibition of bacterial growth values are averages of 3 determinations with 
standard errors of 3%. 
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Figure II-3: Representative Dose-Response Curves from the Reconfirmation 
Study.  All concentrations were tested in triplicate.  The average %inhibition 
for each concentration is represented on the plots as solid black squares.  
Data were normalized for bacteria growth and background signal (positive 
control average: simulates complete VirF inhibition) was removed from data 
before plotting.  Curves were fit to the equation listed in Materials and 
Methods and represented on the plots as solid black lines.  A) Dose-
response curve for compound 19615.   Concentrations ranging from 100 to 
0.78 μM were tested.  B) Dose-response curve for compound 144092.  
Concentrations ranging from 100 to 0.78 μM were tested. 
 
Discussion 
A potential issue with any cell-based HTS is a problem with plate-to-plate/well-to-
well variance.  In our previous screen for inhibitors of VirF activity we had a problem 
with “edge effects”, evaporation around the perimeter of each microtiter plate, which 
produced a high degree of variability in the screen.9  This variability is evidenced by the 
low campaign Z’ factor (≈0.45) and artificially high hit rate (3%) seen in the pilot screen.  
To improve upon our previous HTS, new humidified incubators were used for overnight 
bacterial growth in the HTS.  The humidified incubation helped ameliorate the “edge 
effects” seen previously.  The campaign Z’ factor for the HTS increased significantly 
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(0.66) and a more reasonable hit rate was obtained (0.64%).  Overall, the precision of 
the screen was much improved, as depicted in Figure II-4. 
 
 
Figure II-4:  Comparison of Controls for HTS Pilot Screen and 100K Small 
Molecule Screen.  A) Graph depicts the A570 values generated for all 
controls during the pilot screen.  The red dots represent the positive 
controls (pMAL(ΔvirF)-lacZ) and the blue dots represent the negative 
controls (DMSO).  B) Graph depicts the A570 values generated for all 
controls during the 100,000 small molecule screen.  The red dots 
represent the positive controls (pMAL(ΔvirF)-lacZ) and the blue dots 
represent the negative controls (DMSO).   
 
The primary HTS identified 640 small molecules that met initial selection criteria 
for VirF inhibition, see Figure II-2.  The 640 small molecules were tested in a series of 
counter screens to eliminate any false positives that inhibited bacterial growth or β-
A 
B 
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galactosidase directly and to verify that the compounds exhibited dose-dependent 
activity.  A total of 16 compounds passed all selection criteria and counter screens.  
Based on novelty of scaffold, availability, and potential toxicity concerns, we eliminated 
six of the compounds from further study.  The remaining 10 compounds were ordered 
from commercial sources and tested in a dose-response study.  The structures and 
HTS IC50 values of the 10 compounds are shown in Table II-1.  As Table II-1 shows, 
only 5 of the 10 compounds reconfirmed when fresh, pure samples were tested.  Mass 
spectroscopy verified that the new samples of the five compounds that did not reconfirm 
were of the appropriate mass (data not shown) suggesting that the fresh samples were 
the correct compounds.  Low reconfirmation rates are not uncommon in HTS follow-up 
studies.13  A variety of factors including library compound degradation, library compound 
impurities, and compound transfer errors can increase the number of false positive 
results obtained from an HTS.  The most likely explanation for our low reconfirmation 
rate is that the active compounds from the HTS library are degradation products of the 
original compounds.  The HTS library is stored in DMSO and has been subjected to 
multiple freeze-thaw cycles, which increases the likelihood of compound degradation.  
Due to the difficulty and unpredictable nature of determining the active degradation 
products from the HTS library, we decided to move forward with only the five 
compounds that reconfirmed from new, clean samples. 
The reconfirmed compounds were considered promising for a variety of reasons.  
All of the compounds had IC50 values for VirF inhibition less than 100 μM, with 
compound 19615 being the most potent (IC50 = 14 μM).  Since these IC50 values were 
determined using a Shigella-based reporter system, we know each compound can 
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cross through the bacterial membrane and bind its target.  Compounds 144092 and 
144143 are close analogues and share a core pyrimidine scaffold, which makes them 
attractive candidates for future optimization via structure activity relationship (SAR) 
studies.  Compound 153578 has a benzimidazole core that is similar to the 
benzimidazole compounds that were shown to inhibit the virulence regulator of Yersinia 
pseudotuberculosis, LcrF.14-16  Interestingly, LcrF and VirF are both members of the 
same class of transcriptional activators, the AraC family.  Compound 24904 is a known 
plant defoliant, thidiazuron, that is reported to have low acute toxicity towards humans.17 
Lastly, none of the compounds significantly inhibited bacterial growth when tested at 
100 μM which is necessary if they are to be further developed as anti-virulence 
therapies targeting shigellosis.    
Although the results from the HTS are promising, further work must be done to 
characterize each compound.  Given that a bacterial-based approach was used to 
identify the compounds, it is possible that the inhibition seen in the assay is a byproduct 
of an off-target effect.  The most obvious off-target effects that would result in a 
reduction of β-galactosidase activity should have been caught by the control screens 
(direct inhibition of β-galactosidase, growth inhibition caused by RNA polymerase 
inhibition, or growth inhibition caused by ribosome inhibition).  However, the mechanism 
of action of each compound should still be confirmed (see Chapter V).  Furthermore, 
since our reporter assay only monitored VirF activation of the virB promoter, we do not 
know the effect the compounds have on VirF activation of the icsA promoter.  Previous 
studies have identified compounds that selectively bind to specific promoter regions to 
prevent transcriptional activation without inducing toxicity.18  Although unlikely, it is 
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possible that our compounds may selectively inhibit one promoter over the other.  To 
test this, we have attempted to make a similar β-galactosidase reporter system that 
monitors VirF activation of the icsA promoter.  Unfortunately, we have not been 
successful; most likely due to the increased complexity of the icsA promoter (i.e. four 
potential VirF binding sites, VirF binding sites after the icsA transcription start site, and 
the presence of an antisense RNA regulator).19  In the future, we plan on constructing 
reporter systems that utilize full length IcsA-reporter protein fusions to ensure that the 
full icsA promoter is present. 
In conclusion, we have developed a more precise HTS screening methodology 
and have used it to identify five small molecules with apparent VirF inhibitory properties.  
In the studies described in the next chapter, we will use these compounds to determine 
if a small molecule inhibitor of VirF can attenuate the virulence of Shigella flexneri, and 
thereby, validate VirF as a target for an anti-virulence therapy.  In later chapters 
(Chapters IV and V), we will describe the development of methodologies to probe the 
mechanism of action of each compound. 
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Notes to Chapter II 
 Parts of this chapter have been published in Emanuele, et al. Journal of 
Antibiotics 2014, 67, 379-386.20  I would like to acknowledge Dr. Julie Hurt for the 
construction of the reporter plasmids used in this study and I would also like to thank 
her for her mentoring.  I would also like to acknowledge Martha J. Larsen (Center for 
Chemical Genomics, Life Sciences Institue, University of Michigan), Tom Mcquade 
(Center for Chemical Genomics, Life Sciences Institue, University of Michigan), and Dr. 
Yi-Chen Chen (Department of Medicinal Chemistry, University of Michigan) for their 
contributions to the high-throughput screening campaign.   
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Appendix 
Appendix Table II-1.  Log(IC50) and associated error for the reconfirmation dose-
response study. 
Compound Name Log(IC50) (M) Error 
19615 -4.86 0.02 
144092 -4.63 0.02 
144143 -4.64 0.02 
24904 -4.18 0.1 
153578 -4.43 0.03 
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Appendix Figure II-1:  Representative dose-response curves from reconfirmation 
study.  All concentrations were tested in triplicate.  The average 
%inhibition for each concentration is represented on the plots as 
solid black squares.  Data were normalized for cell growth and 
background signal (positive control average: simulates complete 
VirF inhibition) was removed from data before plotting.  Curves 
were fit to the equation listed in Materials and Methods and 
represented on the plots as solid black lines.  A) Dose-response 
curve for compound 153578.  Concentrations ranging from 100 
to 0.78 μM were tested.  B) Dose-response curve for compound 
144143. Concentrations ranging from 100 to 0.78 μM were 
tested, but 100 μM and 50 μM points were excluded from fit due 
to toxicity to S. flexneri BS103.  C) Dose-response curve for 
compound 24904.  Concentrations ranging from 50 to 0.78 μM 
were tested, 100 μM was not tested due to solubility issues. 
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CHAPTER III 
Tissue Culture-based Models of the Shigella flexneri Invasion Process 
 At the time of the studies reported herein, the VirF-activated Shigella spp. 
pathogenesis cascade had yet to be validated as a therapeutic target for small molecule 
inhibition.  However, multiple studies highlighted the potential benefits and feasibility of 
targeting this pathway.  Gene silencing studies of both the virF and virB genes, 
produced strains of Shigella that were viable but incapable of infecting eukaryotic cells.1-
3  Similar studies targeting icsA produced strains of Shigella that were incapable of 
intra- or inter-cellular movement after initial host cell infection.4, 5  The potential for 
therapeutic intervention was further strengthened by the fact that several icsA-knockout 
strains of Shigella were being tested as live-attenuated vaccine candidates for the 
prevention of shigellosis.6-9  Lastly, other AraC family activated pathogenesis cascades 
had been targeted by small molecule inhibitors resulting in the attenuation of virulence 
of both Vibrio cholerae10 and Yersinia pseudotuberculosis,11 which suggested a small 
molecule inhibitor of VirF may have a similar effect on Shigella flexneri. 
 To validate VirF as a target for small molecule therapeutic intervention, we 
screened the five small molecule VirF inhibitors identified in Chapter II in a series of 
tissue culture-based assays that model the S. flexneri infection process.  With the help 
of our collaborators in the Maurelli lab (Prof. Anthony Maurelli, Uniformed Services 
University of the Health Sciences, Bethesda, MD), we initially screened the compounds 
in gentamicin protection invasion assays using HeLa cells (a human cervical cancer 
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epithelial cell line) and plaque formation assays using L2 cells (a rat lung epithelial cell 
line).  The gentamicin protection assay serves as a model for initial bacterial invasion of 
the host cells, while the plaque formation assay serves as a model for the cell-to-cell 
spread of a bacterial infection.  Since Shigella spp. are known to only naturally infect 
human or primate colonic cells in vivo,12-14 we subsequently repeated both assays in our 
own lab using Caco-2 cells (a human colonic cancer epithelial cell line); which we 
believe to be a more appropriate model for the Shigella infection process.  Using the 
Caco-2 models, we determined that small molecule inhibitors of VirF activity can 
attenuate the virulence of S. flexneri.  
Materials and Methods 
Reagents 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise specified. Yeast extract, bactotryptone, carbenicillin, and Corning microtiter 
plates (384 and 96 well) were purchased from Fisher Scientific (Hampton, NH).  
Compounds were purchased from ChemDiv (7 compounds, San Diego, CA) and Vitas-
M Laboratory (3 compounds, Moscow, Russia).  
Strains and Plasmids 
Wild-type Shigella flexneri serotype 2a strain 2457T 15 and an isogenic, virulence 
plasmid-cured derivative, BS103 16, were used in this study.  HeLa cells (Maurelli lab 
stock), Caco-2 cells (a generous gift from the Amidon Lab), and L2 mouse fibroblasts 
(Maurelli lab stock) were used for virulence assays and were grown in Dulbecco's 
Modified Eagle Medium (Life Technologies, Grand Island, NY), supplemented with 10% 
heat-inactivated fetal bovine serum (Life Technologies, Grand Island, NY).  The bacteria 
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were grown in tryptic soy broth (TSB) or on agar plates supplemented with 0.025% 
Congo Red agar as necessary at 37°C.  The construction of the reporter plasmids, 
pMALvirF-lacZ and pMAL(ΔvirF)-lacZ (positive control), was previously described 17.  
Growth Curves 
Cultures of bacteria were grown overnight in TSB, washed in phosphate-buffered 
saline solution (PBS) (Lonza; Walkersville, MD), and diluted in TSB with appropriate 
concentration of drug.  Approximately 2x104 colony forming units (CFU) were applied to 
individual wells in a 96 well plate for growth curve analysis.  Growth curves were 
performed in a BioTek Synergy2 plate reader at 37°C with constant shaking.  Readings 
of optical density at 600nm were recorded every 30 minutes for 24 hours, and data 
points were analyzed with Gen5 version 1.11.5 software. 
Cell Toxicity 
Serial dilutions of each compound were applied to 50% confluent monolayers of 
HeLa and L2 cells and monitored daily, up to 3 days, for growth phenotypes.  Physical 
signs of cell health were monitored since an OD reading could not be done with 
adherent cells (SI-Table 2).  The highest tolerable compound concentration with HeLa 
cells was then used to assess bacterial growth of wild-type Shigella flexneri 2457T, as 
well as a virulence plasmid-cured strain (BS103), by periodically measuring OD600 over 
24 hours. 
MTT Assay 
 A MTT cell viability assay kit from Abnova (Taipei, Taiwan) was used for this 
study.  Briefly, Caco-2 cells were seeded in 96-well microplates (25,000 cells per well) 
and incubated overnight at 37°C with 5% CO2 in 80 μL of Dulbecco's Modified Eagle 
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Medium (DMEM), supplemented with 10% heat-inactivated fetal bovine serum (ΔFBS).    
The next day 20 μL of DMEM supplemented with 10% ΔFBS and either DMSO or test 
compound (concentrations ranged from 50 μM to 0.8 μM) was added to appropriate 
wells.  Again, the plate was allowed to incubate overnight at 37°C with 5% CO2.  The 
following day. 15 μL of MTT reagent was added to each well and the plate was allowed 
to incubate at 37°C with 5% CO2.  After a four hour incubation, 100 μL of MTT 
solubilizer was added to each well and the plate was mixed gently on a rocker platform 
for one hour at room temperature (protected from light).  Lastly, the optical density at 
570 nm was measured using a BioTek Synergy H1 plate reader (Winooski, VT) 
HeLa Cell Invasion Assay 
 Assays were performed as previously described 18.  Briefly, bacteria were grown 
overnight, subcultured into TSB supplemented with compound when appropriate, and 
grown with agitation until reaching mid-log phase.  Cultures were standardized to an 
optical density at 600 nm of 0.35, washed in PBS and resuspended in Dulbecco’s 
Modified Eagle Medium (DMEM) (Gibco; Grand Island, NY) supplemented with 
compound when appropriate.  The input bacteria were titered on TSB Congo Red plates 
prior to applying to 6-well plates seeded to semi-confluence with HeLa cells.  The plates 
were then centrifuged at 3,000 rpm for 10 minutes and then permitted to invade for 30 
minutes at 37°C with 5% CO2.  The monolayers were washed with PBS, DMEM 
supplemented with 50 μg/mL gentamicin was then applied, and plates were incubated at 
37°C with 5% CO2 for 30 minutes.  After washing the monolayers again with PBS, 
infected cells were lysed with 0.5% Triton X-100, and the recovered bacteria were 
titered on TSB Congo Red plates after incubation at 37°C.  Percent invasion was 
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determined by calculating the total recovered gentamicin-resistant CFU per well after 
lysis divided by the total number of input bacteria per well. 
Invasion % = (total recovered bacteria) / (total input bacteria) x 100 
Caco-2 Cell Invasion Assay  
 Assays were performed in the same manner as for the HeLa cell invasion assays 
with the following exceptions.  Caco-2 cells were grown to near confluence prior to 
bacterial addition.  After bacterial addition, the bacteria were permitted to invade for 2 
hours at 37°C with 5% CO2.  After invasion, the monolayers were washed with PBS, 
DMEM supplemented with 50 μg/mL gentamicin was applied, and the plates were 
incubated at 37°C with 5% CO2 for 90 minutes (after 30 minutes fresh DMEM 
supplemented with 50 μg/mL gentamicin was re-applied). 
L2 Cell Plaque Assay 
Assays were performed as previously described 19.  Briefly, bacteria were grown 
overnight, subcultured into TSB and grown with agitation until reaching mid-log phase.  
Cultures were standardized to an optical density at 600 nm of 0.35, washed in PBS and 
diluted in DMEM.  The input bacteria were titered on TSB Congo Red plates prior to 
applying to 6-well plates seeded to confluence with L2 cells.  The 6-well plates were 
then rocked at 37°C under 5% CO2 for 2 hours.  An agarose solution consisting of 
DMEM, 10% fetal bovine serum (FBS), 50 μg/mL gentamicin, 0.5% agarose (ISC 
Bioexpress; Kaysville, UT), and compound was then applied to the monolayers.  The 
plates were incubated at 37°C under 5% CO2 for three days and then stained with 0.5% 
Neutral Red (Sigma Aldrich; St. Louis, MO) and inverted to visualize plaques.  Efficiency 
of plaque formation was calculated by dividing the total number of plaques observed 
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after staining by the total number of input bacteria.  The average plaque size was 
determined by measuring 30 plaques. 
Plaque efficiency (%) = (total number of plaques) / (total input bacteria) x 100 
Caco-2 Cell Plaque Assay 
Assays were performed in the same manner as for the HeLa cell invasion assays 
with the following exceptions. Prior to addition of bacteria, 60 mm dishes were seeded 
to confluence with Caco-2 cells.  After bacterial addition, dishes were rocked and placed 
at 37°C under 5% CO2 for 2 hours, and rocked again at the 1 hour time point.  An 
agarose solution consisting of DMEM, 10% fetal bovine serum (FBS), 50 μg/mL 
gentamicin, 0.5% agarose, and compound was then applied to the monolayers.  The 
plates were incubated at 37°C under 5% CO2 for three days and then stained with 0.5% 
Neutral Red (Sigma Aldrich; St. Louis, MO) and inverted to visualize plaques.  Efficiency 
of plaque formation was calculated by dividing the total number of plaques observed 
after staining by the total number of input bacteria.   
Plaque efficiency (%) = (total number of plaques) / (total input bacteria) x 100 
Results 
Identifying the highest concentration of compound not affecting host cell or bacteria 
survival 
As shown in Table III-1 and Appendix Figure III-1, the highest concentrations of 
compounds identified as having no significant  effect on Caco-2 cell growth or bacterial 
survival were used for Caco-2 cell virulence assays, and are as follows: 144092 (6.25 
µM), 144143 (6.25 µM), 19615 (6.25 µM), 153578 (6.25 µM), and 24904 (25 µM).  As 
shown in Appendix Table III-1 and  Appendix Figure III-1, the highest concentrations of 
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compounds identified as having no observable effect on HeLa cell, L2 cell, or bacterial 
survival were used for HeLa and L2 cell virulence assays, and are as follows: 144092 
(6.25 µM), 144143 (6.25 µM), 19615 (6.25 µM), 153578 (12.5 µM), and 24904 (50 µM). 
Table III-1.  MTT Cell Viability Assay Results for Caco-2 Cell Growth in Presence 
of Compounds.  
Concentration 
(μM) 
153578 
%Growth 
Inhibition 
19615 
%Growth 
Inhibition 
144092 
%Growth 
Inhibition 
144143 
%Growth 
Inhibition 
24904 
%Growth 
Inhibition 
50.0 18% ± 4% 65% ± 6% 50% ± 1% 45% ± 1% 14% ± 2% 
25.0 15% ± 3% 16% ± 8% 45% ± 1% 33% ± 4% 8% ± 1% 
12.5 14% ± 0% 20% ± 8% 37% ± 1% 0% ± 3% 2% ± 1% 
6.25 10% ± 9% 4% ± 5% 8% ± 4% 3% ± 1% -6% ± 11% 
3.13 -1% ± 3% 1% ± 3% 5% ± 0% 1% ± 2% 0% ± 7% 
1.56 0% ± 4% 4% ± 2% -8% ± 4% 2% ± 0% 1% ± 10% 
0.78 0% ± 10% -6% ± 8% -5% ± 7% -5% ± 9% 6% ± 4% 
 
Invasion assays 
Invasion assays were performed to identify the compounds’ effects on bacterial 
invasion of HeLa cells, by having compounds present during bacterial subculture and 
invasion period, or invasion period alone.  As Figure III-1A shows, when present during 
bacterial subculture and invasion period, 144092 was the only compound that lowered 
invasion efficiency compared to wild-type Shigella flexneri 2457T (0.14% and 0.30% 
respectively); however, it displayed no effect on invasion when present during invasion 
period alone (0.30%).  The remainder of the compounds, displayed hyper-invasion 
when compared to wild-type invasive bacteria (compounds 144143 and 19615, 2.1-fold 
increase; compound 153578, 9.6-fold increase; compound 24904, 9.8-fold increase).  
As a control, we tested the virulence plasmid-cured derivative of Shigella flexneri 
2457T, BS103, in the invasion assay in the presence of compounds.  The results show 
no BS103 surviving gentamicin treatment (data not shown). 
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Figure III-1:  S. flexneri 2457T Invasion Assay Results. A) Graph depicts %invasion 
of S. flexneri 2457T into monolayers of HeLa cells in the presence of 
compounds.  Each compound was dosed at the highest concentration that 
had no effect on cell or bacterial survival as shown in Appendix Figure 1 
and Appendix Table 1.  Compounds were given during the invasion period 
only (checkered bar graphs) and during the exponential phase of bacterial 
growth and remained present during the invasion period (solid bar 
graphs).  All experiments were conducted in duplicate.  B) Graph depicts 
%invasion of S. flexneri 2457T into monolayers of Caco-2 cells in the 
presence of compounds.  Each compound was dosed at the highest 
concentration that had no effect on cell or bacterial survival as shown in 
Table III-1 and Appendix Figure 1.  Compounds were given during the 
exponential phase of bacterial growth and remained present during the 
invasion period (solid bar graphs).  All experiments were conducted in 
duplicate.   
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Invasion assays were also performed to identify the compounds’ effects on 
bacterial invasion of Caco-2 cells.  Compounds were dosed during bacterial subculture 
and the invasion period.  As shown in Figure III-1B, compounds 19615 and 144092 
significantly lowered invasion efficiency (0.011% and 0.018%) when compared to wild-
type Shigella flexneri 2457T (0.048%), while the other compounds appeared to have 
little to no effect on invasion efficiency.  As a control, we tested the virulence plasmid-
cured derivative of Shigella flexneri 2457T, BS103, in the invasion assay.  The results 
show a very low amount BS103 surviving gentamicin treatment (0.0001% invasion 
efficiency). 
Efficiency of Plaque Formation 
Plaque assays were performed to identify the potential effects of the compounds 
on bacterial cell-to-cell spread using L2 cells, with compound present only in the 
agarose overlay.  Overall, three compounds caused significant reductions in the 
efficiency of plaque formation for wild-type Shigella flexneri 2457T relative to the no 
compound control (144092: 77%, 19615: 81%, and 153578: 76% reductions), while 
144143 had no effect on the efficiency of plaque formation, see Figure III-2A 
(Monolayers with 50µM 24904 did not survive the duration of the assay).  The average 
plaque size for 144092 was reduced to 81% of wild-type plaque sizes (0.87 mm versus 
1.08mm), while plaque sizes were unaffected by the other compounds, see Figure III-3. 
Plaque assays were also performed to identify the potential effects of the 
compounds on bacterial cell-to-cell spread using Caco-2 cells, with compound present 
only in the agarose overlay.  As shown in Figure III-2B, three compounds caused 
reductions in the efficiency of plaque formation for wild-type Shigella flexneri 2457T  
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Figure III-2:  S. flexneri 2457T Plaque Formation Assay Results. A) Graph depicts 
%efficiency of plaque formation of S. flexneri 2457T in the presence of 
compounds after initial infection into monolayers of L2 cells as described 
in Materials and Methods.  Each compound was dosed at the highest 
concentration that had no effect on cell or bacterial survival as identified 
in Appendix Figure 1 and Appendix Table 1.  Compound 24904 is not 
depicted on graph due to its toxicity towards the L2 monolayers over the 
duration of the assay. B) Graph depicts %efficiency of plaque formation 
of S. flexneri 2457T in the presence of compounds after initial infection 
into monolayers of Caco-2 cells as described in Materials and Methods.  
Each compound was dosed at the highest concentration that had no 
effect on cell or bacterial survival as shown in Table III-1 and Appendix 
Figure 1.  Compounds 153578 and 24904 are not depicted on graph due 
to toxicity towards the Caco-2 monolayers over the duration of the assay. 
All experiments were conducted in duplicate.   
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relative to the no compound control (19615: 19%, 144092: 25%, 144143: 42% 
reductions), while 153578 and 24904 were toxic to the monolayers over the three day 
incubation period. 
Figure III-3:  Size of Plaques from Plaque Formation Assay with S. flexneri 2457T. 
The graph displays average plaque size of S. flexneri 2457T in the 
presence of compounds in L2 cells and visualized by Neutral Red staining 
as described in Materials and Methods.  The concentration of each 
compound used in the assay was the highest concentration that 
demonstrated no effect on host or bacterial survival as identified in 
Appendix Figure 1 and Appendix Table 1.  No compound was used as a 
control for wild-type S. flexneri 2457T plaque sizes. 
 
Discussion 
Recent outbreaks of multi-drug resistance strains of Shigella in developed 
nations have made evident the need for new, effective treatments for shigellosis.20, 21  
Many studies have suggested that the VirF-activated, Shigella pathogenesis cascade 
could be a novel target for a small molecule anti-virulence therapy.1-11  A successful 
anti-virulence therapy targeting this pathway must be able to attenuate the virulence of 
Shigella, while not affecting bacterial viability or host cell health.  To determine the 
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potential our previously identified (See Chapter II) small molecule inhibitors of VirF had 
as anti-virulence agents, we screened the compounds in a series of assays modeling 
the S. flexneri infection process.  Before conducting these screens, we evaluated the 
cytotoxicity of each compound.  Initial cytotoxicity determinations were performed using 
phenotypic screens (as shown in Appendix Table III-1), while later cytotoxicity 
determinations were done using an MTT assay (as shown in Table III-1).  This change 
in methodology was due to a change in testing location (Uniformed Services University 
of the Health Sciences versus the University of Michigan).  The maximum non-cytotoxic 
concentrations identified from either study were than screened against two strains of S. 
flexneri, BS103 and 2457T.  As shown in Appendix Figure III-1, none of the compounds 
had any effect on bacterial growth at the concentrations tested.   
Compounds were next evaluated in HeLa cell monolayer invasion and L2 cell 
monolayer plaque assays as models for the infection process.  As shown in Figure III-
1A, one compound, 144092, was able to reduce the %invasion relative to the no 
compound control when the compound was administered during the exponential growth 
phase of the bacterial subculture in addition to being present through the invasion 
period.  The compound had no effect on %invasion when it was given at the time of 
invasion only.  The lack of effect in the latter case is most likely due to VirF activating 
virulence genes during exponential growth in the absence of the compound.  Those 
virulence proteins would then be already present when the compound was added during 
invasion, and the bacteria would still be able to invade the host cells.  The 
ineffectiveness of the other four compounds was not unexpected because all of the 
compounds were administered at concentrations below their IC50 values due to toxicity 
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towards the cell monolayers at higher concentrations.  However, it was unexpected that 
the other four compounds displayed “hyper-invasion” relative to no compound controls.  
Control assays were performed to verify that compounds were not artificially raising 
%invasion by protecting the bacteria from gentamicin.  It is possible that the compounds 
could be altering the HeLa cell monolayer in a non-observable manner making it more 
prone to bacterial infection.  Further studies will need to be performed to determine the 
cause of the “hyper-invasion”. 
Three of the compounds 144092, 19615, and 153578 lowered the efficiency of 
plaque formation by S. flexneri 2457T, indicating that the compounds attenuated the 
cell-to-cell spread of the bacteria (see Figure III-2A).  This result was surprising since 
only compound 144092 lowered the invasion efficiency of S. flexneri 2457T during the 
invasion assays.  However, only 144092 had any effect, albeit quite modest, on plaque 
size.  Plaque size is dependent upon a number of factors including cell-to-cell spread 
and bacterial growth.  Also, the plaque size is assessed after three days.  The stability 
of the compounds over that period is not known, so it is hard to interpret effects on 
plaque size without further studies. 
The hyperinvasive phenotypes seen in the HeLa cell invasion assay and the 
contradictory results obtained in the L2 plaque formation assay raised questions about 
the appropriateness of the cell lines used in these studies.  The initial choice of HeLa 
and L2 cells were made based on the standard protocols used by the Maurelli lab.  
However, the Maurelli lab does not commonly use these assays to test the efficacy of 
small molecules and were also quite surprised by the initial results.  The use of HeLa 
cells as a model for human cell biology has recently come into question due to large 
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genomic abnormalities discovered upon sequencing the full HeLa genome.22, 23  Also, 
the fact that Shigella spp. are known to infect only human or primate colonic cells in 
vivo,12-14 led to furthering questioning of the use of HeLa (a cervical cancer cell line) and 
L2 (a rat lung cell line) cells.  A more appropriate cell line to use for modeling the 
Shigella spp. infection process would seem to be Caco-2.  Caco-2 cells are derived 
from human colonic epithelial tissue and, unlike HeLa or L2 cells, are polarized in 
culture.  To more accurately assess the anti-virulence properties of our small molecule 
VirF inhibitors, the invasion and plaque assays were repeated with Caco-2 cell 
monolayers.  The use of the same cell line in both assays also allowed for more 
accurate comparisons to be made between the two studies. 
As shown in Figure III-1B, two compounds, 144092 and 19615, were able to 
significantly reduce the %invasion relative to the no compound control, while the 
remaining compounds produced little to no effect.  Interestingly, none of the compounds 
produced the hyperinvasive phenotype as seen in the HeLa cell invasion assay.  It may 
be possible that the compounds do in fact make the HeLa cells more prone to bacterial 
infection, but further studies must be done to confirm this.  Nevertheless, the Caco-2 
invasion models are more physiologically appropriate and will continue to be used in 
future studies.  Plaque formation assays with the Caco-2 cells also produced promising 
results.  As shown in Figure III-2B, three compounds, 144092, 144143, and 19615, 
were able to modestly reduce the efficiency of plaque formation, while the remaining 
compounds were toxic to the Caco-2 cells over the three day exposure period.  
Unfortunately, plaque size could not be measured in the Caco-2 plaque assay due to a 
lack of equipment caused by a change in testing location.  Unlike the previous HeLa/L2 
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cell studies, similar compounds were active in both assays. This suggests that small 
molecule inhibition of VirF transcriptional activation attenuates both the initial invasion 
and the cell-to-cell spread of S. flexneri, which is in agreement with previous gene 
disruption studies.1-5  We believe that the lack of “hyper-invasion”, the consistency 
between assays (invasion and plaque), and the physiological appropriateness of the 
model make the results obtained in the Caco-2 studies more accurate and relevant. 
It is worth noting that these compounds, directly from our HTS, have not yet been 
optimized in any way and were tested well below their IC50 values for VirF inhibition 
(due to cytotoxicity).  The fact that the compounds produced even modest attenuation of 
the infection process at the concentrations tested is encouraging.  For example, 
compound 144092 had a significant effect on invasion at a concentration of about 25% 
of its IC50 in the VirF screen.  Our VirF screening assays involve overnight incubations 
whereas the invasion assays are only incubated for a total of 4-6 hours.  The longer 
time frame of the screening assays may allow small amounts of active VirF to generate 
significant quantities of -galactosidase, resulting in a higher IC50.  In vivo there is an 
amplification factor as VirF activates VirB, which in turn activates the invasion proteins.  
Inhibition of VirF could result in a much greater reduction in the invasion proteins due to 
this amplification, which is not present in our screening plasmid.  The Shigella protein H-
NS binds to both the virB and icsA promoter regions and represses their transcription.  It 
may be that our artificial screening plasmid may be less susceptible to H-NS repression 
than the natural, 230 kb virulence plasmid making it harder to block VirF activation of 
gene expression.  Finally, it is possible, but unlikely, that the compounds might 
accumulate in the eukaryotic cells to a higher concentration than in the media. 
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Compounds 19615 and 144092 are the most promising candidates for hit-to-lead 
development as they were able to reduce initial invasion efficiency (77% and 63% 
reductions, respectively) and plaque efficiency (19% and 25% reductions, respectively) 
in the Caco-2 studies at concentrations (6.25 μM) that had no effect on bacterial or host 
cell viability.  Furthermore, 144092 and 144143 share the same pyrimidine core.  The 
differential activity of these analogs provides key insights into which regions of 
compound 144092 should be focused upon for analog development making it even 
more attractive.  It is reasonable to expect that with further optimization of the chemical 
structures, an increase in efficacy in both the invasion and plaque efficiency assays as 
well as a decrease in cytotoxicity will be achieved. 
Using our previously identified inhibitors of VirF-activated transcription (see 
Chapter II), we were able to attenuate the virulence of S. flexneri in models of bacterial 
invasion and cell-to-cell spread; thereby, validating VirF as an anti-virulence target for a 
small molecule therapeutic.  At the time this work was completed, another study was 
published that described the testing of a small molecule inhibitor of AraC family 
transcriptional activators against VirF.  Their results also confirmed that inhibition of VirF 
transcriptional activation results in the attenuation of S. flexneri virulence.  Interestingly, 
they also showed that their small molecule inhibitor was active against a variety of AraC 
family regulators.  In the future, we plan on testing our compounds against other AraC 
family members to determine their cross family activity.  It is possible that our 
compounds could reduce the virulence of other pathogens.  
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Notes to Chapter III 
 Parts of this chapter have been published in Emanuele, et al. Journal of 
Antibiotics 2014, 67, 379-386. 24  Work described here was done in collaboration with 
the laboratory of Prof. Anthony Maurelli (Uniformed Services Univeristy of the Health 
Sciences, Bethesda, MD).  I would specifically like to acknowledge Nancy Adams from 
the Maurelli lab for helping conduct the HeLa and L2 cell assays and for training me.  
Lastly, I would like to thank Dr. Arya Vijayalekshmi (Garner lab, University of Michigan) 
for help with setting up our tissue culture laboratory and Yasuhiro Tsume (Amidon lab, 
University of Michigan for providing the Caco-2 cells used in this study. 
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Appendix 
Appendix Table III-1. Cytotoxicity Estimates of Compounds in HeLa and L2 Cells. 
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HeLa and L2 cell toxicities were assessed by observing phenotype for 3 days.  Physical 
signs of cell health were monitored since an OD reading could not be done with 
adherent cells.  Phenotype descriptions are as follows: Membrane blebs: vacuole 
looking protrusions exuding from plasma membrane; Granular: dark punctate dots in 
cytoplasm; Shriveled: cells were condensed and smaller; Cell debris: no intact cells, 
only remnants of cells left behind; Confluent: >95% confluent, no obvious signs of 
cytotoxicity; Semi-confluent: ~70% confluent, no obvious signs of cytotoxicity; Over-
confluent: cells growing on top of the monolayer, no obvious signs of cytotoxicity. 
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Appendix Figure III-1:  Bacterial 
Toxicity of Compounds.  
Dilutions of inhibitors were added 
to bacterial cultures and OD600 
was monitored for 24 hours and 
plotted over time.  Compound 
concentrations were chosen as 
the highest concentration that had 
no observable effect on host cells, 
as a result, the highest 
concentrations of compounds 
identified as having no observable 
effect on host cell or bacterial 
survival were: 144092 (6.25 μM) 
144143 (6.25 µM), 19615 (6.25 
µM), 153578 (12.5 µM), and 
24904 (50 µM). 
DMSO
144092
6.25 μM
144143
6.25 μM
19615
6.25 μM
153578 
12.5 μM
24904 
50.0 μM
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CHAPTER IV 
The Expression, Purification, and Characterization of VirF 
“@#$**^-#*~** AraC protein!” 
-Dr. Robert Schleif 
 
 The quote above is taken from Dr. Robert Schleif’s bio-essay on working with the 
AraC protein over the course of his career.1  Dr. Schleif is the world’s leading expert on 
AraC, as he has been credited with developing the first purification procedure for AraC,2 
identifying the DNA-looping mechanism used by AraC to regulate transcription,3 and 
solving the first crystal and solution state structures of AraC.4, 5  Many other researchers 
who work with AraC family transcriptional regulators share Dr. Schleif’s feelings 
(including this one), as AraC proteins are notably difficult to isolate.  AraC proteins tend 
to be insoluble outside the cell, aggregate easily, and express poorly in recombinant 
systems.1  VirF, the main transcriptional activator of the Shigella spp. pathogenesis 
cascade, is no different. 
 The first promising attempt to characterize VirF in vitro was done by Tobe et al.6  
To purify VirF, a malE gene fusion tag (encodes for the E. coli maltose binding protein) 
was used to improve the solubility of the protein.  Once purified, the MalE tag could not 
be cleaved from VirF without VirF precipitating out of solution.  However, the MalE-VirF 
fusion could still bind to the virB promoter and activate transcription.6-9  Use of maltose-
binding protein fusion tags to improve solubility is now a common method used by 
researchers to isolate AraC family transcriptional regulators.10-14  In most cases, the 
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fusion tag is added to the amino–terminus of the AraC family transcription factor and 
cannot be removed without deleterious effects.  Surprisingly, the AraC family 
transcription factors remain active with the 43 kDa fusion tag.   
Isolation of wildtype VirF has proved much more challenging.  In fact, it has not 
been accomplished to this date.  Dr. Julie Hurt, a former Garcia lab member, devoted a 
large portion of her dissertation work to isolating wildtype VirF.  She tried many things 
including multiple different expression vectors, varying growth conditions, changing 
buffer systems, denaturing/refolding VirF, and co-expression with chaperones; yet, 
nothing proved successful.15  Although Dr. Hurt was not able to isolate wildtype VirF, 
she was able to optimize the purification procedure proposed by Tobe et al.6 and obtain 
MalE-VirF fusion protein that was ~70% pure.15  However, her yield was too low (≤0.5 
mg of protein per liter of culture) to practically support the optimization and development 
of in vitro assays to characterize VirF.  
 In this chapter, we describe our efforts to develop an efficient and high-yielding 
purification procedure for the isolation of VirF.  After initial attempts to optimize previous 
protocols proved unsuccessful, we engineered a novel Shigella-based homologous 
expression and purification system for MalE-VirF isolation.  This system greatly 
improved the expression of MalE-VirF which highlights the importance of expressing 
VirF in its native environment.  Once we isolated pure MalE-VirF, we developed and 
optimized two different in vitro assays which monitored VirF binding to the virB promoter 
(pvirB) and report the first dissociation constant (to our knowledge) for VirF binding to 
the pvirB (2.8 ± 1.0 μM). 
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Materials and Methods 
Reagents 
All reagents and equipment were purchased from Fisher Scientific (Hampton, 
NH), unless otherwise specified.   
Bacterial Strains 
The following bacterial strains were used in this study: Escherichia coli 
BL21(DE3) (obtained from Novagen, Temcula, CA), E. coli KS1000 (obtained from New 
England Biolabs, Ipswich, MA), and a virulence plasmid-cured derivative of wildtype S. 
flexneri, BS103 (obtained from the laboratory of Dr. Anthony Maurelli, Uniformed 
Services University of the Health Sciences, Bethesda, MD).16   
Plasmids 
The sequences of all the following plasmids were confirmed by DNA sequencing 
(DNA Sequencing Core Facility, University of Michigan). 
pMALvirF 
pMALvirF encodes for a maltose binding protein – VirF fusion protein, MalE-VirF.  
pMALvirF was constructed by cloning the virF gene into the vector, pMAL-c2x (New 
England Biolabs), as previously described.6, 9, 15   
pET19b-VirF(154-263) 
 pET19b-VirF(154-263) encodes for the C-terminal, DNA-binding domain of VirF 
with a fused N-terminal 10X His-tag.  pET19b-VirF(154-263) was a gift from Dr. Tappan 
Biswas (Tsodikov lab, University of Michigan, Ann Arbor, MI) and was constructed as 
previously described.15   
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pBAD202-MALvirF 
pBAD202-MALvirF encodes for a maltose binding protein – VirF fusion, and  was 
constructed using the pBAD directional TOPO® expression kit (Invitrogen, Carlsbad, 
CA).  Briefly, the malE-virF fusion gene was amplified from pMALvirF via polymerase 
chain reaction to include a 5’-NcoI restriction site before the start codon of malE-virF.  
The amplified gene was then subcloned into pBAD202 via a directional TOPO® cloning 
reaction.  The resulting vector was then subjected to NcoI restriction digestion (5 units, 
1 hour, 37°C) to remove the N-terminal His-Patch thioredoxin leader sequence from 
pBAD202, and form pBAD202-MALvirF.   
SDS-PAGE Analysis 
 Initial experiments were performed using the PhastSystem™ electrophoresis unit 
(GE Healthcare, United Kingdom).  Samples were diluted 1:1 with SDS-PAGE buffer 
(60 mM Tris-HCl, 2% SDS, 10% Glycerol, 5% β-mercaptoethanol, 0.01% bromophenol 
blue, pH 6.8) and were boiled for 5 minutes along with the low molecular weight 
standard (LMW, GE Healthcare, contains 6 protein markers: 97 kDa, 66 kDa, 45, kDa, 
30 kDa, 20.1 kDa, and 14.4 kDa).  The samples and LMW were then loaded onto a pre-
made denaturing 8-25% gradient polyacrylamide PhastGel™ (GE Healthcare) with SDS 
buffer strips (GE Healthcare).  Samples were run under denaturing conditions and 
visualized by Coomassie Blue staining according to the PhastSystem™ protocol. 
 Later experiments were performed using the Owl™ dual-gel vertical 
electrophoresis unit.  Samples and LMW were prepared as stated above but were 
loaded onto a denaturing polyacrylamide gel (5% stacking gel, 10% separating gel) and 
were ran in TGS running buffer (25 mM Tris, 192 mM glycine, 0.1% SDS) for 20 
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minutes at 100V followed by an additional 60 minutes at 150V. Gels were visualized via 
staining with Coomassie Blue solution (60% water, 30% methanol, 10% acetic acid, 
0.1% Coomassie Brilliant Blue) for 30 minutes, followed by destaining for 2 hours in 
destain solution (60% water, 30% methanol, 10% acetic acid). 
Protein Quantification 
 All purified protein samples were quantified utilizing the Bradford protein assay 
per vendor protocol (BioRad, Hercules, CA).  
Expression and Purification of MalE-VirF from E. coli BL21(DE3) 
 The following protocol was based on the work done by Dr. Julie Hurt.15  First, 
pMALvirF was transformed into chemically competent E. coli BL21(DE3) cells.  Starter 
cultures (5 mL) of pMALvirF BL21(DE3) were grown overnight in 2xTY broth (16 g 
bactotryptone, 10 g yeast extract, 5 g NaCl per liter of water) supplemented with 
carbenicillin (100 μg/mL) at 37°C with shaking.  The following day the starter culture 
was used to inoculate 500 mL of 2xTY broth supplemented with carbenicillin.  The 
culture was incubated at 37°C with shaking until an OD600 of 0.6 was reached, upon 
which MalE-VirF expression was induced with 1 mM IPTG.  Following an additional 4 
hour incubation at 37°C with shaking, the cells were harvested via centrifugation (6000 
X g, 15 min, 4°C) and stored overnight at -20°C.  The next day the cells were 
resuspended in 10 mL of VirF storage buffer (20 mM Tris-HCl, 0.2 M NaCl, 1 mM 
EDTA, 10 mM β-mercaptoethanol, pH 7.5) supplemented with phenylmethylsulfonyl 
fluoride (0.1 mM) and 10 μL of lysonase bioprocessing reagent (EMD Millipore, Billerica, 
MA).  Cells were slowly stirred for 10 minutes at room temperature and were 
immediately placed on ice and kept on ice or at 4°C for the remainder of the procedure.  
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Cells were lysed via sonication (6 cycles, 10 second pulse time, 2 minute intervals, max 
pulse setting) utilizing a ultrasonic XL2020 sonicator (Misonix, Farmingdale, NY).  
Following sonication, cellular debris was removed via centrifugation (20,000 X g, 4°C, 
30 minutes).  The resultant supernatant was brought up to 46 mL with VirF storage 
buffer and incubated with 4 mL of amylose resin (New England Biolabs) for 1 hour at 
4°C with agitation.  The mixture was applied to an empty 10 mL Econo-Pac ® column 
(Bio-Rad), and washed via gravity flow with 12 column volumes of VirF storage buffer 
(48 mL).  Male-VirF was eluted via gravity flow with 8 column volumes (1 mL fractions) 
of maltose elute buffer (VirF storage buffer + 10 mM Maltose).  Fractions were analyzed 
by SDS-PAGE and samples containing MalE-VirF were pooled and further purified by 
gel-filtration chromatography utilizing an S-200 column (GE Healthcare).  Fractions 
were again analyzed by SDS-PAGE and samples containing MalE-VirF were pooled 
and further purified by anion exchange chromatography utilizing a Mono-Q column (GE 
Healthcare).  Lastly, fractions were analyzed by SDS-PAGE and pure samples 
containing only MalE-VirF were pooled and concentrated utilizing Amicon Ultra-15 
centrifugal units (EMD Millipore).  Purified MalE-VirF was stored in VirF storage buffer 
supplemented with 20% glycerol in liquid nitrogen. 
Expression and Purification of VirF(154-263) from BL21(DE3) 
 The C-terminal domain of VirF, VirF(154-263), was expressed from pET19b-
VirF(154-263) in E. coli BL21(DE3) cells.  A 1L culture of 2xTY broth supplemented with 
carbenicillin (100 μg/mL) was inoculated with a pET19b-VirF(154-263) starter culture 
(1:100 inoculation). The culture was incubated at 37°C with shaking until an OD600 of 
0.6 was reached, upon which VirF(154-263) expression was induced with 0.5 mM IPTG.  
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Following induction, the culture was incubated overnight (~18 hours) at 19°C with 
shaking.  The next day, the cells were harvested via centrifugation (6000 X g, 15 
minutes, 4°C) and resuspended in 20 mL of Ni-resin bind buffer (50 mM NaH2PO4, 300 
mM NaCl, 10 mM imidazole, 10 mM β-mercaptoethanol, pH 7.5).  The cells were then 
lysed via sonication (7 cycles, 12 second pulse time, 2 minute intervals, setting 6).   
Following sonication, cellular debris was removed via centrifugation (25,500 X g, 4°C, 
35 minutes).  The resultant supernatant was incubated with 1 mL of Ni-NTA resin 
(Qiagen, Valencia, CA) for 1 hour at 4°C with agitation.  Following the incubation, the 
mixture was applied to a 10 mL Econo-Pac ® column, and washed with 40 column 
volumes of Ni-resin wash buffer (50 mM NaH2PO4, 300 mM NaCl, 20 mM imidazole, 10 
mM β-mercaptoethanol, pH 7.5).  VirF(154-263) was eluted via gravity flow with 8 
column volumes of Ni-resin elute buffer (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole, 10 mM β-mercaptoethanol, pH 7.5).  The eluate was concentrated to 3 mL 
utilizing Amicon Ultra-15 centrifugal units and applied to a Slide-A-Lyzer™ dialysis 
cassette (3.5K MWCO, 3 mL).  The dialysis cassette was stirred for 1 hour at 4°C in 3 L 
of buffer A (10 mM NaH2PO4, 100 mM NaCl, 0.05 mM EDTA, pH 7.5), followed by an 
additional hour in a fresh 3 L of buffer A, and lastly overnight in 500 mL of buffer B (10 
mM NaH2PO4, 100 mM NaCl, 0.05 mM EDTA, 10% glycerol, 0.01% Tween20, pH 7.5).  
Sample was removed from dialysis cassette and applied directly to a HiTrap Heparin 
HP 5 mL syringe column (GE Healthcare).  The column was washed with 6 column 
volumes of heparin wash buffer (10 mM NaH2PO4, 100 mM NaCl, 0.05 mM EDTA, pH 
7.5) and VirF(154-263) was eluted in 5 mL fractions of heparin wash buffer containing 
increasing concentrations of NaCl (10 fractions total that increased in NaCl 
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concentration 100 mM at a time from 100 mM to 1 M).  Samples were analyzed by 
SDS-PAGE and fractions containing VirF(154-263) were pooled, concentrated, and 
stored in VirF(154-263) storage buffer (50 mM Tris, 100 mM NaCl, 0.05 mM EDTA, 20% 
glycerol, pH 7.5) in liquid nitrogen. 
Expression and Purification of MalE-VirF from E. coli KS1000 
Expression and purification experiments were conducted using pMALvirF and E. 
coli KS1000 as previously described.8   
Expression and Purification of MalE-VirF from S. flexneri BS103 
Experiments utilized pBAD202-MALvirF to express MalE-VirF in S. flexneri 
BS103 as follows.  Using a MicroPulser electroporator (BioRad), pBAD202-MALvirF 
was transformed into electrocompetent S. flexneri BS103 cells.  Starter cultures (10 mL) 
of pBAD202-MalVirF BS103 were grown overnight in 2xTY broth supplemented with 
kanamycin (50 μg/mL) at 37°C with shaking.  The following day the starter culture was 
used to inoculate 1 L of 2xTY broth supplemented with kanamycin.  The cells were 
grown to an OD600 = 0.5.  Expression of MalE-VirF was induced with the addition of 
arabinose (0.2% final concentration) and the culture continued to shake at 37°C for an 
additional 5 hours.  Cells were then harvested via centrifugation (6000 X g, 4°C, 15 
minutes) and were stored overnight at -20°C.  The next day the cells were resuspended 
in 20 mL of amylose resin binding buffer (20 mM Tris-HCl, 500 mM NaCl, 1 mM EDTA, 
1 mM, pH=7.4) supplemented with phenylmethylsulfonyl fluoride (0.1 mM) and 20 μL of 
lysonase bioprocessing reagent.  Cells were slowly stirred for 10 minutes at room 
temperature and were then immediately placed on ice and kept on ice or at 4°C for the 
remainder of the procedure.  Cells were lysed via sonication (8 cycles, 10 second pulse 
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time, 2 minute intervals, max pulse setting).  Following sonication, cellular debris were 
removed via centrifugation (25,000 X g, 4°C, 40 minutes).  The resultant supernatant 
was then applied to a 10 mL column of amylose resin (New England Biolabs) by gravity 
flow.  Before addition of the supernatant the column was washed with 8 column 
volumes of amylose resin binding buffer.  Following addition of the supernatant, the 
column was washed with 12 column volumes of amylose resin binding buffer.  MalE-
VirF was eluted from the column in 1 mL fractions of amylose resin elution buffer 
(amylose resin bind buffer plus 15% glycerol (wt/vol) and 10 mM maltose).  Fractions 
were analyzed by SDS-PAGE.  Fractions containing MalE-VirF were pooled, 
concentrated to approximately 6.5 mg/mL using Amicon Ultra-15 centrifugal units (EMD 
Millipore), and stored in liquid nitrogen for future use. 
Analytical Gel Filtration 
Analytical gel filtration chromatography was used to determine the oligomeric 
state of purified MalE-VirF.  Briefly, MalE-VirF (0.75 mg/mL) was applied to a Superose 
12 column, which was equilibrated with amylose resin binding buffer using an AKTA 
FPLC system (both from GE Healthcare Life Sciences, Piscataway, NJ).  The sample 
was run through the column at a flow rate of 0.75 mL/min using amylose resin binding 
buffer.  Eluted proteins were detected spectrophotometrically at 280 nm.  The 
oligomeric state of MalE-VirF was determined by comparison to a previously generated 
4-point molecular weight calibration curve specific to the Superose 12 column. 
DNA Probe Hybridization 
DNA probes were utilized in both EMSA and FP assays.  The sequences of the 
oligonucleotides were based on previous studies 8, 17 and are listed in Table IV-1.  All 
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oligonucleotides were purchased from Invitrogen, except LUEGO which was purchased 
from Integrated DNA Technologies (Coralville, IA).  Each oligonucleotide was brought 
up to a final concentration of 10 μM in TE/NaCl buffer (10 mM Tris-HCl, 1 mM EDTA, 50 
mM NaCl, pH = 8.0).  For EMSA experiments, oligonucleotides were mixed at the 
following ratio: 10 volumes LUEGO, 5 volumes Top, 1 volume Bottom.  For FP 
experiments, oligonucleotides were mixed 1:1 (Top:Bottom).  Annealing was performed 
using a Mastercycler® Nexus thermocycler (Eppendorf, Hauppauge, NY) with the 
following program: 94°C for 2 minutes, cool down at 2°C/sec to 70°C and hold for 2 
minutes, cool down at 0.1 °C/sec to 20°C and hold for 2 minutes. 
Table IV-1. Oligonucleotides Used in EMSA and FP Experiments. 
Name Sequence (5’-3’) Modification 
Length 
(bases) 
pvirB Top EMSA 
AGAATATTATTCTTTTATCCAAT
AAAGATAAATTGCATCAATCCA
GCTATTAAAATAGTA 
None 60 
pvirB Bottom EMSA 
TACTATTTTAATAGCTGGATTGA
TGCAATTTATCTTTATTGGATAA
AAGAATAATATTCTCCAGACCA
GGGCAC 
None 74 
pScram Top EMSA 
TAAGTCCTAAATGGAAATTAAAT
TACGTAATTCACAAATATAGTAT
GATCATTTATATCA 
None 60 
pScram Bottom EMSA 
TGATATAAATGATCATACTATAT
TTGTGAATTACGTAATTTAATTT
CCATTTAGGACTTACCAGACCA
GGGCAC 
None 74 
LUEGO GTGCCCTGGTCTGG 5’-Cy5 14 
pvirB Top FP 
AGAATATTATTCTTTTATCCAAT
AAAGATAAATTGCATCAATCCA
GCTATTAAAATAGTA 
5’-Fluoroscein 60 
pvirB Bottom FP 
TACTATTTTAATAGCTGGATTGA
TGCAATTTATCTTTATTGGATAA
AAGAATAATATTCT 
None 60 
pScram Top FP 
TAAGTCCTAAATGGAAATTAAAT
TACGTAATTCACAAATATAGTAT
GATCATTTATATCA 
5’-Fluoroscein 60 
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pScram Bottom FP 
TGATATAAATGATCATACTATAT
TTGTGAATTACGTAATTTAATTT
CCATTTAGGACTTA 
None 60 
 
DNA Binding via Electrophoretic Mobility Shift Assay (EMSA) 
Reactions for the EMSAs were incubated in a 37°C water bath for 15 minutes.  
Reactions (15 μL total volume) were composed of 6 μL pvirB EMSA DNA probe (0.25 
μM), 6 μL of either MalE-VirF (varying concentrations) or native gel loading buffer (Tris-
HCl 0.3 M, 50% glycerol, 0.05% bromophenol blue, pH 7.0), 1.5 μL DMSO,  1 μL of 
salmon sperm DNA (0.7 mg/mL, Invitrogen), and 0.5 μL BSA (0.07 mg/mL).   A 6% 
native polyacrylamide gel (29:1 acrylamide to bis-acrylamide ratio) was made with 
0.25X TBE buffer (22 mM Tris Base, 22 mM boric acid, 0.5 mM EDTA, pH 9.5) for the 
EMSA.  The gel was electrophoresed for 1 hour at 150 V in 0.25X TBE buffer at 4°C 
before samples were loaded.  After the reaction solutions (12 μL) were loaded onto the 
gel, the gel was electrophoresed for an additional hour at 150 V and 4°C.  The gel was 
then visualized using FluorChem M gel imager (Protein Simple, Santa Clara, CA) with a 
607 nm excitation wavelength and a 710 nm emission filter. 
DNA Binding via Fluorescence Polarization (FP) 
The FP assays were conducted in duplicate in black, half-area, 96-well plates 
(Corning, Twerksbury, MA).  First, 30 μL of 5’-Fluoroscein-pvirB DNA probe working 
standard was added to appropriate wells of the microplate.  The pvirB DNA working 
standard was in TE/NaCl buffer (see above) supplemented with BSA (0.07 mg/mL) and 
salmon sperm DNA (0.7 mg/mL).  Next, 30 μL of varying concentrations of MalE-VirF in 
amylose resin elution buffer (see above) was added to appropriate wells of the 
microplate.   The final concentration of pvirB DNA was either 50 nM (for test wells) or 
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none (for blank wells) and the final concentrations of MalE-VirF ranged from 45 μM to 
0.12 μM (for test wells) or none (for control wells).   For each concentration of MalE-VirF 
tested, a blank well was also set up that included all reagents except pvirB DNA.  The 
microplate was then incubated for 20 minutes at 37°C and anisotropy was determined 
using a SpectraMax M5 plate reader (Molecular Devices, Sunnyvale, CA).  Data was 
acquired using an excitation wavelength equal to 490 nm and an emission wavelength 
equal to 520 nm.  To determine anisotropy the following equation was used:   
Anisotropy = (Fǁ - G*F┴) / (Fǁ + 2*G*F┴) *1000 
where: Fǁ = fluorescence intensity parallel to excitation source after blanking, F┴ = 
fluorescence intensity perpendicular to excitation source after blanking, and G = G-
factor (correction for polarization bias of the detection system).  After anisotropy was 
determined, data were plotted using GraphPad Prism (La Jolla, Ca) and fit to the 
following equation: 
Y = BMAX*(X/KD*X) + b 
where Y = specific binding, KD = dissociation constant, BMAX = maximum binding, X = 
MalE-VirF concentration, and b = y-intercept. 
On average, there was a 65% increase in anisotropy when VirF was added to the 
DNA.  Within a single set of experiments, the DNA (alone) fluorescence anisotropy 
values varied ~4%., whereas, between experiments these anisotropy values varied 
~15%.  The latter variation is most likely due to differences in the efficiency of duplex 
DNA formation. 
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Results 
MalE-VirF Purification from E. coli BL21(DE3) 
 Initial attempts to purify VirF relied upon expressing MalE-VirF from the 
expression vector pMALvirF in E. coli BL21(DE3) cells.  The first purification step used 
amylose resin chromatography to isolate MalE-VirF from the cellular lysate.  As shown 
in Figure IV-1A, the amylose resin did capture MalE-VirF, but also captured a variety of 
other proteins with MalE being the main impurity.  To further purify MalE-VirF, gel 
filtration chromatography was used.  The gel filtration chromatography was successful 
at eliminating the major MalE impurity, but did not eliminate the other minor impurities, 
see Figure IV-1B.  Bradford assay analysis indicated a total protein yield of 0.5 to 0.75 
mg per liter of culture with MalE-VirF making up approximately 60% - 70% of the 
sample (based on SDS-PAGE analysis).  Lastly, anion exchange chromatography was 
used to remove all other impurities from the sample (as shown in Figure IV-1C).  
Although the sample was pure at this point, the overall yield of MalE-VirF was poor.  
Typical purifications with this procedure yielded approximately 0.2 to 0.3 mg of MalE-
VirF per liter of culture. 
VirF(154-263) Purification 
 The C-terminal domain of VirF was also expressed in and purified from E. coli 
BL21(DE3) cells.  The purification procedure involved two chromatography steps:  batch 
Ni-resin affinity chromatography and heparin affinity chromatography.  The initial Ni-
resin purification isolated VirF(154-263) from the cellular lysate while the heparin affinity 
chromatography removed a majority of the contaminating proteins (See Figure IV-2). As 
shown in Figure IV-2, the 800 mM NaCl fraction from the heparin column contained the 
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most VirF(154-263) and was stored in liquid nitrogen for later use. Based on SDS-
PAGE analysis, the isolated VirF(154-263) was approximately 75% pure with Bradford 
assay analysis indicating a total protein yield of 0.1 to 0.2 mg per liter of culture. 
Figure IV-1:  SDS-PAGE Analysis of the MalE-VirF Purification from pMALvirF in 
E. coli BL21(DE3) Cells. All samples visualized with Coomassie Blue 
staining. A)  Phastgel™ depicting the contents of the amylose resin 
chromatography fractions. Lane 1: LMW ladder, Lane 2: fraction 1 off 
column, Lane 3: fraction 2 off column, Lane 4: fraction 3 off column, Lane 
5: fraction 4 off column, Lane 6: fraction 5 off column.  B) Phastgel™ 
depicting the contents of the gel filtration chromatography fractions.  Lane 
1: LMW ladder, Lane 2: fraction 12 off column, Lane 3: fraction 15 off 
column, Lane 4: fraction 18 off column, Lane 5: fraction 23 off column, 
Lane 6: fraction 27 off column.  C)  Phastgel™ comparing the pooled and 
concentrated gel filtration chromatography fractions to the pooled and 
concentrated anion exchange chromatography fractions.  Lane 1: LMW 
Ladder, Lane 2: Pooled fractions 13-30 from gel filtration, Lane 3: Pooled 
fractions 4-36 from anion exchange. 
 
MalE-VirF Purification from KS1000 and BS103 
Attempts to isolate MalE-VirF using pMALvirF as an expression vector in E. coli 
KS1000 cells, followed by purification via amylose resin chromatography produced poor 
results.  SDS-PAGE analysis showed a small amount of MalE-VirF was isolated along 
with a large amount of MalE in all fractions (See Figure IV-3A).  To improve the 
purification, an arabinose-inducible vector, pBAD202-MALvirF was constructed to 
express MalE-VirF in S. flexneri BS103 cells.  Following purification by amylose resin  
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Figure IV-2:  SDS-PAGE Analysis of the VirF(154-264) Purification from pET19b-
VirF(154-263) in E. coli BL21(DE3) Cells. All samples visualized with 
Coomassie Blue staining. A)  Phastgel™ depicting the contents of the Ni-
resin chromatography fractions. Lane 1: LMW ladder, Lane 2: fraction 1 
off column, Lane 3: fraction 2 off column, Lane 4: fraction 3 off column, 
Lane 5: fraction 4 off column, Lane 6: fraction 5 off column.  B) 
Denaturing 10% acrylamide gel depicting the contents of the heparin 
resin chromatography fractions.  Lane 1: LMW ladder, Lane 2: 300 mM 
NaCl fraction, Lane 3: 400 mM NaCl fraction, Lane 4: 500 mM NaCl 
fraction, Lane 5: 600 mM NaCl fraction, Lane 6: 700 mM NaCl fraction, 
Lane 7: 800 mM NaCl fraction, Lane 8: 900 mM NaCl fraction, Lane 9: 1 
M NaCl fraction. 
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Figure IV-3:   SDS-PAGE Analysis of MalE-VirF Purifications (KS1000 vs. BS103 
Expression). All samples visualized with Coomassie Blue staining and 
captured utilizing FluorChem M gel imager.  A)  Denaturing 10% 
acrylamide gel depicting MalE-VirF expression in E. coli KS1000 cells via 
pMALvirF expression vector. MalE-VirF is 73 kDa in weight and the main 
impurity, MalE is 43 kDa in weight.  Numbers at the top of the gel 
represent the fraction (1 mL volume) number eluting off the amylose resin 
column.  The numbers on the right-hand side of the gel correspond to the 
sizes of the LMW bands.  B) Denaturing 10% acrylamide gel depicting 
MalE-VirF expression in S. flexneri BS103 cells via pBAD202-MALvirF 
expression vector. MalE-VirF is 73 kDa in weight and the main impurity, 
MalE, is 43 kDa in weight.  Numbers at the top of the gel represent the 
fraction (1 mL volume) number eluting off the amylose resin column.  The 
numbers on the right-hand side of the gel correspond to the sizes of the 
LMW bands.    
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chromatography, pure and soluble MalE-VirF was isolated.  SDS-PAGE analysis shows 
that the fractions saved for later experiments were over 80% pure (see Figure IV-3B).  
Typical yields for the BS103 expression system varied between 1.5 – 2.5 mg of MalE-
VirF per liter of culture.  This expression/purification system was used to isolate MalE-
VirF for all in vitro studies.  Analytical gel filtration chromatography indicates that the 
purified MalE-VirF exists in solution as a monomer at concentrations used in further 
experiments, see Appendix Figure IV-1. 
MalE-VirF DNA Binding via Electrophoretic Mobility Shift Assay (EMSA) 
To monitor MalE-VirF binding to the virB promoter, an EMSA was optimized.  
Control experiments were conducted to verify that MalE-VirF was specifically binding to 
the 5’Cy5-labeld pvirB DNA probe (see Figure IV-4A) and that this binding was dose-
dependent (see Figure IV-4B).  Binding of MalE-VirF to the virB promoter could not be 
monitored unless the pH of the gel/running buffer was 9.5.  If the pH was lower than 9.5, 
the protein/DNA complex would not enter the gel matrix (data not shown).  This EMSA 
was also used to test VirF(154-263) binding to the virB promoter, however, interaction 
with the virB promoter could not be visualized under these conditions (data not shown).    
DNA Binding via Fluorescence Polarization (FP) 
For the FP assay reaction conditions from the EMSA assay were scaled to a 96-
well plate format.  Control experiments were conducted to verify equilibrium was 
reached (anisotropy signal did not increase after 20 minutes), binding was specific 
(MalE-VirF binding to labeled pvirB DNA probe could be competed by unlabeled pvirB 
DNA probe and MalE-VirF would not bind to sequence scrambled DNA probe as shown 
in Appendix Figure IV-2), and maximum anisotropy signal was achieved.  The 
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anisotropy signal generated from MalE-VirF binding to the pvirB DNA probe was shown 
to be dose-dependent (see Figure IV-5).  The FP assay was then used to determine the 
dissociation constant for MalE-VirF and the pvirB DNA probe.  The data shown in Figure 
IV-5 was fitted with a specific binding equation (see Materials and Methods) and the 
dissociation constant was determined to 2.8 ± 1.0 μM. 
Discussion 
 To enable the in vitro characterization of VirF, we sought to optimize a VirF 
purification procedure that could isolate pure, active VirF at concentrations practical for 
assay development.  Based on the previous work done by Dr. Julie Hurt, we decided to 
focus on optimizing the purification of MalE-VirF rather than trying to isolate wildtype 
VirF.15  Her work, and the work of others,6, 8, 18 showed that wildtype VirF is insoluble 
outside of the cell and is prone to aggregation.  To isolate MalE-VirF, Dr. Hurt used an 
E. coli BL21(DE3) expression system and two chromatography steps, batch purification 
with amylose affinity resin and gel filtration chromatography.  As shown in Figure IV-1, 
we were able to replicate her work and obtain MalE-VirF that was approximately 60-
70% pure with a yield of 0.5 to 0.75 mg per liter of culture.  Although the yield of this 
prep was not ideal, it was practical upon scaling for assay development.  However, the 
prep was not pure enough for accurate in vitro characterization studies of VirF. 
 The isoelectric point for VirF is predicted to be at pH 9.8 (SerialCloner Software), 
which means at physiological pH VirF is cationic.  To improve the purity of our MalE-
VirF preparations, we decided to take advantage of VirF’s cationic nature by utilizing 
anion exchange chromatography after gel filtration.  We chose anion exchange 
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Figure IV-4:  Electrophoretic Mobility Shift Assay (EMSA) PAGE of MalE-VirF 
Binding to pvirB DNA Probe.  All reactions contained varying 
concentrations of probe DNA, varying concentration of MalE-VirF, 0.7 
mg/mL salmon sperm DNA, and 0.07 mg/mL BSA.  A) EMSA image 
shows the retardation of the 5’Cy5-pvirB DNA probe (0.25 μM) when 
incubated in the presence of MalE-VirF (1 μM) and shows no 
retardation of the 5’Cy5-pScram DNA probe (0.25 μM) when incubated 
in the presence of MalE-VirF (1 μM).  B) EMSA image shows the dose-
dependent binding relationship between MalE-VirF and the pvirB probe.  
Lane 1: 5’Cy5-pvirB DNA probe (0.25 μM), Lane 2: MalE-VirF (11 μM), 
Lane 3: 5’Cy5-pvirB DNA probe (0.025 μM) + MalE-VirF (11 μM), Lane 
4: 5’Cy5-pvirB DNA probe (0.25 μM) + MalE-VirF (11 μM), Lane 5: 
5’Cy5-pvirB DNA probe (0.25 μM) + MalE-VirF (1 μM), Lane 6: 5’Cy5-
pvirB DNA probe (0.25 μM) + MalE-VirF (0.25 μM), Lane 7: 5’Cy5-pvirB 
DNA probe (0.25 μM) + MalE-VirF (0.1 μM). 
 
  
  
pvirB + VirF
VirF
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B
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Figure IV-5:  Plot of MalE-VirF Binding to the pvirB DNA probe.  For the assay, 
5’Fluoroscein-pvirB DNA probe concentration was held constant at 50 
nM, while MalE- VirF concentration was varied from 45 μM to 0.12 μM.  
The observed binding max for MalE-VirF binding was approximately r = 
75, while the observed baseline (no MalE-VirF, only free pvirB DNA 
probe) was r = 42.  The assay was conducted in duplicate.   
 
chromatography over cation exchange chromatography in hopes of minimizing the loss 
of MalE-VirF caused by poor column resolution or co-elution with other impurities.  By 
utilizing anion exchange chromatography, we ensured that all the MalE-VirF in the 
sample would quickly elute in the void volume, which it did.  As shown in Figure IV-1C, 
the addition of anion exchange chromatography drastically improved sample purity; 
however, the overall yield was reduced to approximately 0.2 mg per liter of culture.  It is 
possible that this was the actual amount of VirF present in the sample before anion 
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exchange chromatography, but the previous yield was artificially raised by the presence 
of impurities.  At this point, the purification was a week long process that produced a 
very small amount of protein that was not practical for assay development studies. 
 Previous studies have shown that AraC family regulators that function as 
monomers tend to be more soluble and can be over-expressed at higher levels.1, 19, 20  
This, combined with the fact that N-terminal truncations of AraC family members have 
been shown to still bind to their promoter regions in vitro,21, 22 led us to explore purifying 
the C-terminal domain of VirF(154-263) as an alternative to MalE-VirF.  The VirF(154-
263) purification was based on previous work done by Dr. Tappan Biswas (unpublished, 
Tsodikov lab, University of Michigan) and utilized an N-terminal 10X His-tag to purify the 
protein via Ni-resin affinity and heparin chromatographies.  Initial one liter culture 
preparation yielded approximately 0.15 mg of VirF(154-263) at 75% purity.  To increase 
yield, later preparations were scaled to eight liters of culture and produced a total of 
approximately 0.8 mg of VirF(154-263).  As similar to previous MalE-VirF preparations, 
the purification of VirF(154-263) was long, inefficient, and produced low yields. 
During the time that the VirF(154-263) purification was being optimized, Egan 
and co-workers reported a MalE-VirF purification protocol.8  In their protocol, MalE-VirF 
was expressed in E. coli KS1000 from an IPTG-inducible pMALvirF vector and purified 
in one-step via a 10 mL amylose affinity resin column.  The only differences between 
this protocol and our previous attempts at purifying MalE-VirF were the E. coli strain 
used for expression, KS1000, and the use of an amylose resin column instead of batch 
purification.  KS1000 is a Prc protease (a periplasmic protease) deficient strain of E. 
coli23 that is quite similar to the expression strains we used in previous protocols (e.g. 
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BL21, K12, TG2, etc.).  Unsurprisingly, when we used the KS1000 
expression/purification system to isolate MalE-VirF, we obtained results that we had 
typically seen for other E. coli heterologous expression systems: low overall yield and 
large amounts of MalE impurity (as shown via SDS-PAGE analysis in Figure VI-3A).  
However, the amylose resin column did eliminate a significant amount of other 
contaminating proteins that the batch purification procedure previously did not.   
A common feature in all previous attempts to isolate VirF (in any form) was the 
use of an E. coli heterologous expression system.  It is possible, although seemingly 
unlikely due to the extremely close genetic relationship between E. coli and Shigella, 
that VirF does not express or fold properly in E. coli.  To probe this possibility, we 
sought to develop a homologous, Shigella-based expression system.  Researchers 
studying virulence factor expression in Streptococcus pneumoniae had recently shown 
that a S. pneumoniae homologous expression system greatly improved the overall yield 
of isolated proteins.24  In an effort to mimic their results, an arabinose-inducible vector, 
pBAD202-MALvirF was constructed that allowed for homologous expression of MalE-
VirF in S. flexneri BS103 cells.  Arabinose-inducible vectors had previously been shown 
to be compatible with the Shigella transcription machinery.25  As shown in Figure IV-3B, 
this expression system, when used with the same amylose resin column purification 
procedure, greatly improved overall yield (approximately 1.5 - 2.5 mg per liter of culture) 
and purity of the MalE-VirF preparation (over 80% pure).  It was by far the most 
successful preparation of MalE-VirF to date and it provided adequate amounts of 
protein for the development of in vitro binding assays.  
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The complexity of the icsA promoter18 prompted us to focus our efforts on 
developing in vitro assays to monitor MalE-VirF binding to the virB promoter.  Since we 
did not know if our MalE-VirF preparations were active, we wanted to first optimize an 
assay with an easy to visualize readout.  Therefore, we chose an electrophoretic 
mobility shift assay (EMSA), a platform commonly used to visualize protein-DNA 
interactions.  The EMSA utilized a fluorescently-labeled pvirB DNA fragment which was 
74 bp long, with 60 bp corresponding to the previously determined pvirB region,6, 8, 9 and 
14 bp corresponding to a 5’-Cy5 labeled LUEGO (labeled universal electrophoretic gel 
shift oligonucleotide) site.17  Interestingly, while determining the optimal pH for the 
assay, it was observed that MalE-VirF could not enter the polyacrylamide gel matrix if 
the pH of the gel or running buffer was less than 9.5 (data not shown).  We hypothesize 
that at pH less than 9.5, the protein is too positively charged (pI ~ 9.8) to be attracted to 
the cathode that is pulling other biomolecules into the gel matrix.  Following further 
optimization of buffer and reaction conditions, the interaction between MalE-VirF and 
the pvirB was successfully visualized.  It was later shown that MalE-VirF was 
specifically binding to the 5’Cy5-labeled pvirB DNA probe and that this binding was 
dose-dependent, see Figure IV-4.  It is also worth noting that as expected the MalE tag 
did not prevent binding to the pvirB. 
To confirm and quantitate the results of the EMSA, a Fluorescence Polarization 
(FP) assay was developed.  The FP assay utilized reaction conditions similar to the 
EMSA, with the only major change being to the pvirB DNA fragment.  For the FP assay, 
the pvirB fragment was shortened to 60 bp with the LUEGO site being removed and 
was labeled with a 5’Fluoroscein instead of Cy5.  These changes increased the FP 
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signal generated in the assay by decreasing the molecular weight of the fragment and 
increasing the fluorescent lifetime of the probe.  After control experiments were 
completed, the FP assay was used to determine the KD of MalE-VirF binding to the 
pvirB DNA probe.  The data shown in Figure IV-5 was fitted and an experimental KD 
was calculated to be 2.8 ± 1.0 μM.  To our knowledge this is the first reported KD for 
VirF binding either of its promoter regions.  It has been shown that VirF only activates 
the transcription of the virB gene when supercoiled DNA is used as a template.26  
Therefore, we should note that it is possible that our experimental KD, determined with a 
linear DNA fragment may be different than the in vivo KD, under physiological conditions 
where VirF is activating supercoiled DNA.  
In conclusion, we have successfully developed tools (an efficient homologous 
expression system and two DNA-binding assays) to study the interaction between VirF 
and the virB promoter.  In the future, we plan on developing other assays that monitor 
different aspects of the VirF transcriptional activation process, such as dimerization and 
binding to the icsA promoter.  These tools will then be used to determine the 
mechanism of action for each of our previously identified small molecule VirF inhibitors 
(see Chapter V).  
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Notes to Chapter IV 
The work presented in this chapter required a great amount of time, effort, and 
sanity.  I would like to acknowledge the following people who made contributions along 
the way: Eric Lachacz (Department of Medicinal Chemistry, University of Michigan) for 
contributions made to the construction of the homologous expression vector for VirF, 
Gordon Kane (University of Michigan REU program, home institution: Beloit College, 
Wisconsin) for contributions made to the VirF(154-263) expression trials, Dr. Amanda 
Garner (Department of Medicinal Chemistry, University of Michigan) for the use of the 
SpectraMax M5 plate reader and gel imager in her laboratory, and Dr. Jennifer Meagher 
(Center of Structural Biology, Life Sciences Institute, University of Michigan) for use of 
the analytical gel filtration chromatography system.  Some of the work presented here 
was published in Emanuele and Garcia, PLoS ONE 2015, 10, e0137410.27 
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Appendix 
Appendix Figure IV-1: Analytical Gel Filtration Results.  A) Chromatogram depicting elution of MalE-VirF (11.04 
mL) from Superose 12 column.  B) Chromatogram and four-point calibration curve for 
Superose 12 column used to determine molecular weight of MalE-VirF in “A”.
A B 
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Appendix Figure IV-2: Negative Controls for FP assay. B)  Graph depicting the 
anisotropy values generated in the FP assay for the 
5’Fluorescein pScram probe alone (r = 39) and in the 
presence of MalE-VirF (r = 36). Experiments were conducted 
in duplicate with 50 nM pScram and 20 μM MalE-VirF. 
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CHAPTER V 
Mechanism of Inhibition Determination and Resulting SAR Studies 
Chapters II and III detail the identification of five promising small molecule 
inhibitors of VirF from a high-throughput screening campaign and a series of follow-up 
assays, including tissue-culture based invasion and cell-to-cell spread assays that 
model aspects of the Shigella infection process.  All five compounds inhibited VirF-
driven transcriptional activation in a Shigella-based, β-galactosidase reporter assay with 
IC50 values in the low micromolar range (14-66 μM).  Furthermore, at concentrations at 
or below their IC50s in the reporter assay, two of the compounds (19615 and 144143) 
significantly inhibited the spread of an active S. flexneri infection in a tissue-culture 
based plaque efficiency assay, and two of the compounds (19615 and 144092) also 
significantly inhibited initial S. flexneri invasion in a gentamicin protection assay.  These 
results, supported by similar results recently published by other groups,1-3 validate our 
approach by providing proof of principle that small molecules can attenuate virulence; 
however, the mechanism by which our compounds inhibit the VirF transcriptional 
activation process remains unclear. 
The exact mechanism by which VirF activates transcription is not presently 
understood.  Like AraC and most AraC family members, VirF has two domains, an N-
terminal dimerization domain and C-terminal DNA binding domain.  Both of these 
domains are necessary for in vivo transcriptional activation.4  As shown in Figure V-1, in 
order for VirF to activate transcription it must bind to the correct promoter region (either 
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the virB promoter (pvirB) or the icsA promoter (picsA)), dimerize, and recruit RNA 
polymerase.  The order of these events, indeed if they are ordered at all, is presently 
unknown.  Our small molecule inhibitors could be disrupting any of these steps of the 
VirF gene activation process.  In fact, there have been reports indicating that VirF, 
and/or homologous AraC family members, can be inhibited through the blockade of 
DNA binding1, 3 or self-dimerization.2  A clearer understanding of the mechanism of 
action of the VirF inhibitors would provide critical insight for furthering their 
development. 
Figure V-1:  Schematic Depicting Presumptive Steps in the Activation of 
Transcription by VirF.  By analogy to AraC and family members, it is 
presumed that two VirF proteins bind to two proximal DNA binding 
sites in a dimeric form to activate transcription.  The question marks 
indicate that the exact steps in this process and their order (if ordered) 
are not yet understood. 
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In the studies herein reported, we probed the mechanism of action of our small 
molecule VirF inhibitors.  We hypothesized that our inhibitors were preventing VirF-
driven transcriptional activation by either blocking VirF from binding to DNA or by 
preventing VirF dimerization.  Using the in vitro DNA-binding studies described in 
Chapter IV, we determined that one of our small molecule inhibitors (19615) blocked 
VirF from binding to the virB promoter.  To probe the ability of our inhibitors to block VirF 
dimerization, we also attempted (albeit unsuccessfully) to develop a VirF-driven, split-
GFP reassembly assay.  Lastly, we screened a series of analogs of our most promising 
chemical scaffolds (19615 and 144143/144092) and deduced initial structure-activity 
relationship trends that we will use as a basis to further optimize our inhibitors and work 
towards achieving our goal of developing a novel therapy for treating shigellosis. 
Materials and Methods 
Reagents 
All reagents and equipment were purchased from Fisher Scientific (Hampton, 
NH), unless otherwise specified.  All restriction enzymes were purchased from New 
England Biolabs (Ipswich, MA). 
Bacterial Strains 
The following bacterial strains were used in this study: Escherichia coli 
BL21(DE3) (obtained from Novagen, Temcula, CA).5   
Plasmids 
The following plasmids were generous gifts from the laboratory of Dr. Lynne 
Regan (Department of Chemistry, Yale University):  pET11a-NGFP-link, pMRBAD-link-
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CGFP, pET11a-NGFP-link-Z, and pMRBAD-Z-link-CGFP.  The other plasmids used in 
the study were constructed as described below.   
Various TOPO Plasmids 
 Plasmids were constructed using the TOPO® TA Cloning® kit (Invitrogen, 
Carlsbad, CA).  Briefly, the primers listed in Table V-1 were used to amplify the DNA 
fragment of interest with the appropriate 5’ and 3’ restriction sites via polymerase chain 
reaction. The amplified DNA fragments were then subcloned into pCR2.1TOPO via a 
directional TOPO® TA cloning reaction resulting in the formation of the plasmids listed 
in Table V-2. 
Table V-1.  Primers Used in TOPO Plasmid Construction. 
Primer Name Sequence (5’-3’) Purpose 
XhoI-VirF For 
NGFP 
CTCGAGCATGTCGGGACATAAAAACAAAAT Used to TOPO 
clone virF and N-
term virF with 5’-
XhoI site 
NcoI-VirF For 
CGFP 
CCATGGCTATGTCGGGACATAAAAACAAAAT Used to TOPO 
clone virF and N-
term virF with 5’-
NcoI site 
XhoI-MalEVirF 
For NGFP 
CTCGAGCATGAAAATCGAAGAAGGT Used to TOPO 
clone malEvirF 
with 5’-XhoI site 
BamHI-
MalEVirF Rev 
NGFP 
GGATCCTTAAAATTTTTTATGATATAAGTAA Used to TOPO 
clone malEvirF 
and virF with 3’-
BamHI site 
NcoI-MalEVirF 
For CGFP 
CCATGGCTATGAAAATCGAAGAAGGT Used to TOPO 
clone malEvirF 
with 5’-NcoI site 
AatII-MalEVirF 
Rev CGFP 
GACGTCCCAAATTTTTTATGATATAAGTAA Used to TOPO 
clone malEvirF 
and virF with 3’-
AatII site 
BamHI-
NTermVirF 
Rev NGFP 
GGATCCTTATATCGATATCGAAGTATA Used to TOPO 
clone N-term virF 
with 3’-BamHI site 
AatII- GACGTCCCTATCGATATCGAAGTATA Used to TOPO 
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NtermVirF Rev 
CGFP 
clone N-term virF 
with 3’-AatII site 
SgrAI-pvirB 
For NGFP 
CGCCGGTGATCACACCCTGTTTATTC Used to TOPO 
clone pvirB with 
3’-SgrAI site 
XbaI-pvirB 
Rev NGFP 
TCTAGACTCACATCAGAGCTCCAC Used to TOPO 
clone pvirB with 
5’-XbaI site 
 
Table V-2.  Constructed TOPO Vectors.  
pCR-TOPO-2.1-XhoI-VirF-BamHI 
pCR-TOPO-2.1-NcoI-VirF-AatII 
pCR-TOPO-2.1-XhoI-MalEVirF-BamHI 
pCR-TOPO-2.1-NcoI-MalEVirF-AatII 
pCR-TOPO-2.1-XhoI-NTermVirF-BamHI 
pCR-TOPO-2.1-NcoI-NTermVirF-AatII 
pCR-TOPO-2.1-XbaI-pvirB-SgrAI 
 
pMRBAD-X-link-CGFP Plasmids 
pMRBAD-X-link-CGFP plasmids encode for a VirF-CGFP fusion protein (with the 
C-terminal fragment of GFP(158-238) fused to the C-terminal of either MalE-VirF, VirF, 
or the N-terminal domain of VirF(1-153)).  The pMRBAD-X-link-CGFP plasmids were 
constructed by first treating pMRBAD-link-CGFP and the appropriate TOPO vector (see 
Table V-2) with NcoI and AatII in a double restriction enzyme digestion (20 U each, 40 
μL volume) at 37°C for 1 hour.  The digestion products were then separated on a 1% 
low-melting (Seaplaque) agarose gel for 2 hours at 70V.  The gel was visualized via 
ethidium bromide staining and UV light.  Bands containing linearized pMRBAD-link-
CGFP and the appropriate virF gene were excised and gel-purified with Gelase™ 
(Epicentre, Madison, WI) according to vendor’s protocol.  Following the purification, the 
virF insert was incubated with digested pMRBAD-link-CGFP in a 5:1 ratio overnight at 
16°C in the presence of T4 DNA Ligase (400 units, NEB, Ipswich, MA).  pMRBAD-VirF-
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link-CGFP was later used to make pMRBAD-CGFP-link-VirF which encodes for a 
CGFP-VirF fusion protein (with the C-terminal fragment of GFP(158-238) fused to the 
N-terminal of VirF). 
 pET11a-NGFP-link-X Plasmids 
pET11a-NGFP-link-X plasmids encode for a NGFP-VirF fusion protein (with the 
N-terminal fragment of GFP(1-157) fused to the N-terminal of either MalE-VirF, VirF, or 
the N-terminal domain of VirF(1-153)).  The pET11a-NGFP-link-X plasmids were 
constructed by first treating pET11a-NGFP-link and the appropriate TOPO vector (see 
Table V-2) with XhoI and BamHI in a double restriction enzyme digestion (20 U each, 
40 μL volume) at 37°C for 1 hour.  The digestion products were then separated on a 1% 
low-melting (Seaplaque) agarose gel for 2 hours at 70V.  The gel was visualized via 
ethidium bromide staining and UV light.  Bands containing linearized pET11a-NGFP-link 
and the appropriate virF gene were excised and gel-purified with Gelase™ (Epicentre, 
Madison, WI) according to vendor’s protocol.  Following the purification, the virF insert 
was incubated with digested pET11a-NGFP-link in a 5:1 ratio overnight at 16°C in the 
presence of T4 DNA Ligase (400 units, NEB, Ipswich, MA).   
pET11a-NGFP-link-VirF+pvirB 
The virB promoter (-130 to +54) was subcloned into pET11a-NGFP-link-VirF.  
Briefly, pCR-TOPO-2.1-XbaI-pvirB-SgrAI and pET11a-NGFP-link-VirF were treated with 
SgrAI and XbaI in a double restriction enzyme digestion (20 U each, 40 μL volume) at 
37°C for 1 hour.  The digestion products were then separated on a 1% low-melting 
(Seaplaque) agarose gel for 2 hours at 70V.  The gel was visualized via ethidium 
bromide staining and UV light.  Bands containing linearized pET11a-NGFP-link-VirF and 
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the virB promoter were excised and gel-purified with Gelase™ (Epicentre, Madison, WI) 
according to vendor’s protocol.  Following the purification, the virB promoter insert was 
incubated with digested pET11a-NGFP-link-VirF in a 5:1 ratio overnight at 16°C in the 
presence of T4 DNA Ligase (400 units, NEB, Ipswich, MA).   
DNA Probe Hybridization 
 The DNA probes used in the EMSA, FP, and FID assays were hybridized as 
described in Chapter IV.  The sequences of the oligonucleotides used in these studies 
are listed in Table V-3. 
Table V-3.  Oligonucleotides Used in EMSA, FP, and FID Experiments.  
Name Sequence (5’-3’) Modification 
Length 
(bases) 
pvirB Top EMSA 
AGAATATTATTCTTTTATCCAAT
AAAGATAAATTGCATCAATCCA
GCTATTAAAATAGTA 
None 60 
pvirB Bottom EMSA 
TACTATTTTAATAGCTGGATTGA
TGCAATTTATCTTTATTGGATAA
AAGAATAATATTCTCCAGACCA
GGGCAC 
None 74 
LUEGO GTGCCCTGGTCTGG 5’-Cy5 14 
pvirB Top FP 
AGAATATTATTCTTTTATCCAAT
AAAGATAAATTGCATCAATCCA
GCTATTAAAATAGTA 
5’-Fluoroscein 60 
pvirB Bottom FP 
TACTATTTTAATAGCTGGATTGA
TGCAATTTATCTTTATTGGATAA
AAGAATAATATTCT 
None 60 
pvirB Top FID 
AGAATATTATTCTTTTATCCAAT
AAAGATAAATTGCATCAATCCA
GCTATTAAAATAGTA 
None 60 
pvirB Bottom FID 
TACTATTTTAATAGCTGGATTGA
TGCAATTTATCTTTATTGGATAA
AAGAATAATATTCT 
None 60 
pvirB (51-60) Top FID TAAAATAGTA None 10 
pvirB (51-60) Bottom 
FID 
TACTATTTTA None 10 
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Monitoring Inhibition of VirF DNA binding via Electrophoretic Mobility Shift Assay 
(EMSA) 
 EMSAs were performed as described in Chapter IV but with compounds (100 
μM) present during appropriate reactions. 
Monitoring Inhibition of VirF DNA Binding via Fluorescence Polarization (FP) 
The FP protocol described in Chapter IV was adapted to determine the IC50 of 
the small molecule hit compounds.  Compounds (ranging from 200 μM to 3.1 μM) or 
DMSO for controls (1% final concentration) were added to the pvirB DNA probe working 
standard prior to addition to the microplates.  For IC50 determination, the MalE-VirF and 
pvirB DNA probe concentrations were held constant at 20 μM and 50 nM, respectively.  
Positive controls were established to determine 100% VirF inhibition (no MalE-VirF 
present, 50 nM pvirB DNA probe) and negative controls were set up to determine no 
VirF inhibition (1% DMSO, 20 μM MalE-VirF, and 50 nM pvirB DNA probe).  Once again 
blanks were set up to include all reagents, except pvirB DNA probe.  All reactions were 
run in duplicate.  Anisotropy was calculated as listed in Chapter IV and data were 
plotted using GraphPad Prism then fit to the following equation: 
Y = Bottom+(Top-Bottom)/(1+10(X-log(IC50))) 
where: Y = anisotropy, X=log of compound concentration, Top and Bottom = plateaus in 
anisotropy units, and log(IC50) = log of the concentration that inhibits 50% of VirF 
binding. 
Fluorescence Intercalator Displacement (FID) Assay 
The FID protocol was based on previously published studies6, 7 and was 
conducted in triplicate.  For the assay, black, half-area, 96-well plates (Corning, 
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Twerksbury, MA) were used.  First, 70 μL of ethidium bromide in Tris Buffer (0.1 M Tris 
HCl, 0.1 M NaCl, pH 8.0) was added to all wells. The concentration of ethidium bromide 
was contingent upon the length of the DNA probe that was used.  For the 60 bp pvirB 
FID DNA probe, the final ethidium bromide concentration used was 45 μM; whereas, for 
the 10 bp pvirB (51-60) FID DNA probe, the final ethidium bromide concentration used 
was 7.5 μM. Next, 10 μL of either pvirB FID DNA probes (10 or 60 bp) in TE/NaCl buffer 
(see above) or 10 μL of TE/NaCl buffer (background fluorescence control) were added 
to the appropriate wells of the plate.  The final concentrations of the pvirB FID DNA 
probes were 1.5 μM. Lastly, 20 μL of test compound (either 19615 or Berenil) in 10% 
DMSO Tris Buffer or 20 μL of 10% DMSO Tris Buffer (100% fluorescence control) were 
added to the appropriate wells of the plate.  The final concentrations of each test 
compound ranged from 12.5 μM to 100 μM.  After the addition of all reagents, the plates 
were protected from light and allowed to equilibrate for 30 min on an orbital shaker at 
room temperature.  Following equilibration, fluorescence was measured (545 nm 
emission, 595 nm excitation) using a BioTek Synergy H1 plate reader (Winooski, VT).  
The average background fluorescence was subtracted from all data generated and 
%fluorescence was calculated for all wells containing compound via the following 
formula: 
% fluorescence = Ftest/F100%*100 
where: Ftest = the average fluorescence value obtained for each test compound and 
F100% = the average fluorescence value obtained for each 100% fluorescence control. 
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GFP Reassembly Assay 
 The GFP reassembly assay was based on previously published methods.8  First, 
matching pairs of NGFP and CGFP plasmids were co-transformed into 
electrocompetent E. coli BL21(DE3) cells using a MicroPulser electroporator (BioRad) 
and grown overnight on LB plates containing carbenicillin (100 μg/mL) and kanamycin 
(35 μg/mL) at 37°C.  The next day, a single colony was selected and used to grow a 5 
mL starter culture of 2XTY supplemented with carbenicillin (100 μg/mL) and kanamycin 
(35 μg/mL).  After overnight growth at 37°C with agitation, a loopful of culture was 
streaked onto an LB plate supplemented with carbenicillin (100 μg/mL), kanamycin (35 
μg/mL), IPTG (100 μM), and arabinose (0.2%).  The plate was incubated at 37°C for 
one day, wrapped with parafilm, and then incubated another 48 hours at room 
temperature.  GFP-containing colonies were then visualized by placing the plate under 
UV light and monitoring fluorescence.   
Structure-Activity Relationship (SAR) Study utilizing VirF-Driven, β-galactosidase 
Reporter Assay 
 The 96-well plate version of the β-galactosidase reporter assay was used to test 
33 commercially available analogs of compounds 144092 and 144143 (obtained from 
Vitas-M Laboratory: Moscow, Russia and ChemDiv: San Diego, CA).  The assay was 
performed as described in Chapter II Material and Methods Reconfirmation Screen.   
Results 
Monitoring the Inhibition of VirF DNA binding by EMSA 
 Using the optimized EMSA conditions described in Chapter IV, the assay was 
used to determine if our five previously identified hits (see Chapter II) could inhibit the 
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binding of MalE-VirF to the virB promoter at 100 μM.  As shown in Figure V-2, only one 
compound, 19615, dramatically reduced binding, while the other four compounds were 
indistinguishable from the DMSO negative control.   
 
 
 
Figure V-2:  Electrophoretic Mobility Shift Assay (EMSA) PAGE of MalE-VirF 
Binding to pvirB DNA Probe in Presence of Small Molecule Hit 
Compounds.  EMSA image shows the retardation of the 5’Cy5-pvirB 
DNA probe (0.25 μM) when incubated in the presence of MalE-VirF (1 
μM).  Image also shows the effect each of the five hit compounds have 
on MalE-VirF binding.  All compounds were dosed at 100 μM, and only 
one compound, 19615, appeared to inhibit MalE-VirF binding to the 
pvirB DNA probe. 
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Monitoring Inhibition of VirF DNA Binding Via FP Assay 
 The FP assay was used to confirm and quantify the results of the EMSA.  
Consistent with the EMSA study, the five compounds were tested at 100 μM, and only 
19615 inhibited DNA binding (63% inhibition, see Table V-4).  Next, a small library of 
analogs of 19615 were purchased and screened in the FP assay.  As shown in Table V-
4, one of the 19615 analogs (598089) was essentially equal in potency to 19615 (68% 
versus 63% inhibition, respectively) and the rest of the compounds displayed lower 
%inhibition values (ranging from 43% to -5%). Lastly, to further evaluate the potency of 
19615 in the FP assay, a dose-response study was performed (see Figure V-3); from 
which an IC50 of 46 ± 2.2 μM was determined.  Applying this IC50 to the Cheng-Prusoff 
equation, Ki =IC50/(1+([Ligand]/KD)), produces a Ki for 19615 of 5.6 μM. 
 
Table V-4.  Results of 19615 Analog Testing in FP Assay. 
Name Structure 
% Inhibition 
at 100 μM 
Physical 
Properties 
598089 
 
68 ± 5 
MW: 375.46 
CLogP: 6.39 
tPSA: 46.42 
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19615 
(original HTS 
hit) 
 
63 ± 0.7 
MW: 333.38 
CLogP: 4.99 
tPSA: 46.42 
587109 
 
43 ± 1 
MW: 361.44 
CLogP: 6.05 
tPSA: 46.42 
078044 
 
42 ± 0.4 
MW: 344.41 
CLogP: 4.70 
tPSA: 40.43 
048181 
 
31 ± 0.6 
MW: 319.36 
CLogP: 4.75 
tPSA: 55.21 
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582610 
 
24 ± 0.3 
MW: 271.31 
CLogP: 3.39 
tPSA: 46.42 
050908 
 
18 ± 0.4 
MW: 299.37 
CLogP: 4.45 
tPSA: 46.42 
9660232 
 
17 ± 2 
MW: 339.35 
CLogP: 4.54 
tPSA: 55.54 
587469 
 
16 ± 0.4 
MW: 285.34 
CLogP: 3.92 
tPSA: 46.42 
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048373 
 
15 ± 0.4 
MW: 360.45 
CLogP: 6.02 
tPSA: 49.22 
569084 
 
11 ± 0.3 
MW: 289.33 
CLogP: 4.85 
tPSA: 37.19 
098754 
 
6 ± 0.1 
MW: 262.26 
CLogP: 2.96 
tPSA: 50.69 
9660235 
 
5 ± 0.2 
MW: 409.48 
CLogP: 7.26 
tPSA: 46.42 
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568180 
 
2 ± 0.1 
MW: 406.48 
CLogP: 6.13 
tPSA: 40.43 
765345 
 
1 ± 0.1 
MW: 330.26 
CLogP: 3.87 
tPSA: 50.69 
9111063 
 
-5 ± 0.1 
MW: 331.37 
CLogP: 4.14 
tPSA: 46.42 
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Figure V-3: Characterization of Compound 19615.  Plot of inhibition of MalE-VirF 
binding to the pvirB DNA probe by 19615.  Assay conducted with the MalE-
VirF concentration constant at 20 μM. An IC50 of 46 ± 2.2 μM for DNA 
binding was determined, which, by the Cheng-Prusoff equation, yields a 
derived Ki = 5.6 μM.  The assay was conducted in duplicate.   
 
DNA Affinity Determination via Fluorescence Intercalator Displacement (FID) Assay 
 To determine if 19615 was inhibiting VirF from binding to the virB promoter by 
directly binding to the DNA a fluorescence intercalator displacement (FID) assay was 
conducted.  Berenil, a known minor groove binder with a preference for AT-rich 
sequences,6, 9 was used as a positive control.  Two different pvirB probes were used in 
the study: a full length 60 bp probe, pvirB FID, and a 10 bp probe, pvirB 51-60 FID.  A 
preliminary FID screen was conducted to determine which segment of the virB promoter 
to use for the 10 bp probe and the results are shown in Appendix Table V-1.  As shown 
in Table V-5, Berenil was able to displace ethidium bromide from the pvirB DNA probes 
and lower the fluorescence signal generated in the assay to produce low %fluorescence 
values for all experimental conditions; on the other hand, 19615 was not able to 
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displace ethidium bromide from the pvirB DNA probes resulting in high %fluorescence 
values for all experimental conditions.   
Table V-5.  Results of the FID Assay. 
Compound 
60 bp pvirB FID probe 
%fluorescence 
10 bp pvirB 51-60 FID probe 
%fluorescence 
12.5 μM 19615 93% ± 3% 97% ± 2% 
25 μM 19615 97% ± 2% 97% ± 3% 
50 μM 19615 95% ± 2% 97% ± 2% 
100 μM 19615 93% ± 3% 95% ± 1% 
12.5 μM Berenil 76% ± 2% 52% ± 1% 
25 μM Berenil 67% ± 2% 51% ± 2% 
50 μM Berenil 58% ± 1% 51% ± 1% 
100 μM Berenil 48% ± 2% 46% ± 1% 
 
GFP Reassembly Assay 
 A split-GFP reassembly assay was used to try and monitor VirF dimerization.  A 
variety of plasmids were constructed that expressed various VirF proteins (MalE-VirF, 
VirF, or the N-terminal domain of VirF (1-153)) fused to either an N-terminal GFP 
fragment (1-157) or a C-terminal GFP fragment (158-238).  Plasmids were also 
designed to include the virB promoter and flip the fusion site of the C-terminal GFP 
fragment.  Maps of all plasmids, including positive (leucine zipper fusions) and negative 
(GFP fragments alone) controls, are shown in Figures V-4 and V-5.  The sequences of 
all plasmids used in this study were confirmed by DNA sequencing (DNA Sequencing 
Core, University of Michigan Ann Arbor). 
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Figure V-4:  Maps of Control Plasmids Used in GFP Reassembly Assay. 
 Appropriate pairs of GFP control and test vectors were co-transformed into E. 
coli BL21(DE3) cells.  Following a 3 day induction period on LBCARB/KAN plates 
containing 10 μM IPTG and 0.2% arabinose, fluorescent colonies were visualized using 
a UV transilluminator.  Typical results from the GFP reassembly assay are shown in 
Figure V-6.  In all trials, the GFP positive control strain would fluoresce, the GFP 
negative control strain would not fluoresce, and any VirF test strain would also not 
fluoresce.  Table V-6 lists the results of all the different plasmid combinations that were 
used in the assay. 
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Figure V-5:  Maps of Test Plasmids Used in the GFP Reassembly Assay. 
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Figure V-6: Typical Results Seen in GFP Reassembly Assay. 
 
Table V-6.  List of all Plasmid Combinations Used in GFP Reassembly Assay. 
Plasmids Type Fluorescence 
pET11a-NGFP-link and 
pMRBAD-link-CGFP 
Negative 
Control 
Negative 
pET11a-NGFP-link-Z and 
pMRBAD-Z-link-CGFP 
Positive 
Control 
Positive 
pET11a-NGFP-link-MalEVirF and 
pMRBAD-MalEVirF-link-CGFP 
MalE-VirF 
Test 
Negative 
pET11a-NGFP-link-VirF and 
pMRBAD-VirF-link-CGFP 
VirF Test Negative 
pET11a-NGFP-link-NTermVirF and 
pMRBAD-NTermVirF-link-CGFP 
VirF(1-153) 
Test 
Negative 
pET11a-NGFP-link-VirF+pvirB and 
pMRBAD-VirF-link-CGFP 
VirF with 
pvirB Test 
Negative 
pET11a-NGFP-link-VirF+pvirB and 
pMRBAD-CGFP-link-VirF (reverse) 
VirF with 
pvirB Test 
Negative 
 
Testing of 144092/144143 Analogs 
 The Shigella-based, VirF-driven, β-galactosidase reporter assay was used to 
screen 33 analogs of compounds 144092 and 144143 in dose-response studies.  
Appendix Tables V-2 through V-4 provide the IC50 values generated for each 
compound.  The IC50 values ranged from no inhibition to 23 μM.  Some compounds 
displayed toxicity towards the bacteria during the course of the assay and produced no 
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reporter signal.  Lastly, the solubility of select compounds was determined after all 33 
analogs were screened and these data are shown in Table V-7.  
Table V-7.  Solubility of Selected 144092/144143 Analogs. 
Compound IC50  (μM) 
Solubility 
(mg/mL) 
Assay Dilution 
(mg/mL) 
 
78 0.12 0.04 
 
23 0.14 0.04 
 
560 0.04 0.04 
 
45 0.23 0.04 
 
No Inhibition 0.01 0.04 
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Discussion 
Researchers at Paratek Pharmaceuticals recently identified a series of 
benzimidazole compounds,10 similar to 153578, that inhibited the ability of LcrF, an 
AraC family transcriptional activator in Yersinia (and subsequently inhibited a number of 
other AraC family proteins), to bind to its DNA promoter region.1  Egan and co-workers 
also recently found a small molecule that inhibited the ability of multiple AraC family 
members, including VirF, to bind DNA.3  These studies prompted us to focus our initial 
efforts on determining the effect our compounds had on VirF binding to its promoter. 
To probe the mechanism of action of our five inhibitors we first screened them in 
modified versions of the EMSA and FP assay described in Chapter IV.  The EMSA and 
FP assays were slightly modified to include 100 μM of compound in the reaction 
mixtures.  This concentration (well above IC50 values for VirF transcriptional activation) 
was selected to ensure that if the compounds were acting through inhibition of DNA 
binding, it would be clearly evident in the assays.  In the FP assay the MalE-VirF 
concentration was held constant at 20 µM, a concentration higher than its DNA-binding 
KD value (2.8 μM, see Chapter IV) while still sub-saturating, to balance the magnitude of 
the anisotropy signal and the sensitivity to inhibition.  As shown in Figure V-2 and Table 
V-4, only one compound, 19615, inhibited the binding of MalE-VirF to the pvirB.  
Surprisingly, 153578, the benzimidazole-derivative hit from our HTS, had little to no 
effect on DNA binding under these conditions.  These results suggest that the other four 
compounds are inhibiting VirF activity at different steps of the gene activation process 
subsequent to DNA binding.  (Another, albeit unlikely possibility is that the four other 
compounds may be metabolized in vivo to species that do inhibit VirF-DNA binding.  
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This will be determined as we continue to investigate their mechanisms of action.)  If 
different molecular mechanisms of inhibition for the different compounds are confirmed, 
then the development of multiple compounds may circumvent any resistance and/or 
toxicity issues that could arise during further optimization of any one of the compounds. 
 Next, the mechanism of inhibition of compound 19615 was further probed.  To 
determine if 19615 is a non-specific inhibitor of protein-DNA binding, a control EMSA 
was performed that revealed 19615 had no effect on E. coli RNA polymerase binding to 
the lac promoter (see Appendix Figure V-1).  An FID assay was performed to ensure 
19615 was not acting through DNA intercalation (see Table V-5), and lastly, a dose-
response study was performed using the FP assay.  As shown in Figure V-3, the dose-
response study produced an IC50 of 46 ± 2.2 μM, which when applied to the Cheng-
Prusoff equation produces a Ki for 19615 of 5.6 μM.  In Chapters II and III, we 
determined an IC50 for 19615 in the Shigella-based, VirF-driven, β-galactosidase 
reporter assay to be 14 μM and showed that 19615 inhibited the initial invasion of S. 
flexneri into Caco-2 monolayers by ~75% at 6.25 μM.  The correlation between these 
results and the Ki for inhibition of VirF binding to DNA strongly suggest that 19615 
attenuates the virulence of S. flexneri by decreasing VirF-driven transcriptional 
activation via inhibition of VirF-DNA binding.  This, combined with the fact that 19615 
was not toxic to mammalian cells or S. flexneri at the tested concentrations makes 
19615 an attractive candidate for further exploration. 
 The next logical step in developing 19615 into an anti-virulence therapy for 
treating shigellosis is to improve its potency through structural optimization.  To 
construct an initial SAR, a small library of analogs of 19615 were purchased and 
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screened in the FP assay.  The FP assay was chosen over other assays previously 
developed (e.g., Shigella-based reporter assay, tissue culture-based virulence assays) 
because it eliminates a number of complicating factors associated with measuring 
efficacy in the other assays, such as permeability and cytotoxicity.  Unfortunately, none 
of the compounds tested proved to be significantly more potent than 19615, see Table 
V-4.  It is worth noting that the goal of testing this panel of analogs was primarily to 
provide supporting evidence for the mechanism of action of 19615 and secondarily to 
find a compound that was more potent than compound 19615.  Some notable trends 
identified from the data shown in Table V-4 (see p.105 - 109) include (a) preference of a 
phenyl ring substituent over smaller alkyl chains attached to the pyrimidine (e.g., 19615 
vs. 582610 or 587469), (b) preference of side chain ether rather than amine linkage to 
pyrimidine (e.g., 587109 vs. 048373), and (c) preference for the dimethyl amine over the 
diethyl amine on the ether side chain (19615 vs. 587109 and 582610 vs. 050908).  The 
data also suggest that there is considerable space for favorable SAR development 
through the installation of additional basic side chain ethers and aromatic moieties off 
the pyrimidine ring.  Figure V-7 depicts the most promising trends that will serve as the 
starting point for later generations of 19615 analogs with the goal of developing a more 
potent inhibitor. 
 To probe the mechanism of inhibition of the other four compounds, we sought to 
develop assays that monitored the dimerization of VirF.  Analytical gel filtration studies 
showed that purified MalE-VirF exists as a monomer under the conditions the EMSA 
and FP assays are conducted (see Chapter IV Appendix).  Our previous struggles with 
purified VirF aggregation and solubility prompted us to develop a bacteria-based 
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method to monitor dimerization.  We chose to use a split-GFP reassembly assay.  Split-
GFP reassembly assays have been used by many groups to monitor protein-protein 
interactions inside the cell,11-15 including monitoring homodimerization.16  The bacteria-
based split-GFP assay was first developed by the laboratory of Dr. Lynne Regan,8, 17 
who used it to monitor the interaction between anti-parallel leucine zippers.  They 
showed that GFP fragments could not reassemble unless they were fused to interacting 
proteins; they also predicted that the assay was sensitive enough to monitor interactions 
with dissociation constants as high as 1 mM.   
 
Figure V-7: Figure Depicting Deduced SAR.  Structure shown is a hybrid compound 
containing most promising substituents and will serve as a starting point for 
future synthetic SAR studies that will probe the core heterocycle.  Region 
A:  SAR data suggest the preferred substituent at this position is an ether 
chain with a 2-3 carbon spacer and small aminoalkyl headpiece.  Region B:  
SAR data suggest the preferred substituent at this position is an aromatic 
ring, although further probing with substituted phenyl and heteroaromatic 
moieties is needed. 
 
The split-GFP reassembly assay offered us many advantages.  For one, it 
allowed us the flexibility to test multiple different forms of VirF (MalE-VirF, wildtype VirF, 
and the N-terminal fragment of VirF(1-153)) in the presence and absence of the virB 
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promoter through simple cloning procedures.  It is still not known if VirF needs to bind to 
its promoter region before it can dimerize.  The split-GFP platform, in theory, offered a 
way to answer this question.  Also, it provided a read-out that could be easily visualized 
during the development phase but could also be measured quantitatively for more 
accurate measurements of each compounds’ inhibitory effects.  Lastly, Dr. Lynne 
Regan was kind enough to send us the positive control vectors, negative control 
vectors, and empty test vectors which greatly simplified the development process.   
Unfortunately, as shown in Table V-6, no combinations of VirF test vectors were 
able to promote GFP reassembly.  Therefore, VirF dimerization could not be monitored 
with this platform.  Initial GFP assay trials had the N-Terminal GFP fragment attached to 
the N-terminal of VirF (either MalE-VirF, wildtype VirF, or VirF(1-153)) and the C-
terminal GFP fragment attached to the C-terminal of VirF (either MalE-VirF, wildtype 
VirF, or VirF(1-153)).  These trials were later repeated with the virB promoter cloned into 
the N-terminal GFP plasmid.  Lastly, the C-terminal GFP fragment was moved to the N-
terminal of VirF to probe if the GFP fragment orientation was preventing VirF 
dimerization; still no fluorescence was achieved.  It is still possible that with further 
optimization (e.g. alteration of the linker lengths between GFP fragments and VirF, 
moving GFP fragments to the C-terminal of VirF) VirF dimerization could be monitored 
with this assay; however, it is also likely that VirF dimerization will never be able to drive 
the reassembly of GFP.  Statistically, only one third of all successful VirF 
homodimerization events would allow for GFP reassembly in the assay; at best the GFP 
signal would be attenuated.  Therefore, in future studies, we plan on switching to an 
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SPR approach to monitor VirF dimerization and hopefully identify the mechanisms of 
inhibition of the remaining four compounds.   
Although we were not able to identify the mechanism of inhibition of compounds 
144092 and 144143, we were still intrigued by their properties.  In previous studies, both 
compounds inhibited VirF transcriptional activation and both inhibited either the initial 
invasion or the cell-to-cell spread of S. flexneri in Caco-2 monolayers at concentrations 
that were not toxic to the bacteria or the cells.  The compounds also appear to be 
perfect candidates for a SAR campaign since they share a core pyrimidine scaffold.  To 
identify potential SAR trends, we ordered a library of 144092/144143 analogs and 
screened them in the Shigella-based, VirF-driven, β-galactosidase reporter assay.  The 
results of the screen are shown in Appendix Tables V-2 to V-4.  Unfortunately, 
complicating factors such as cell permeability, cytotoxicity, and solubility (could not 
increase organic solvent content over 1% without deleterious effects on assay) 
prevented activity trends from being identified.  For example, as shown in Table V-7, 
there appears to be an increase in activity associated with increasing the length of the 
alkyl chain off of the sulfone until the solubility of the next compound prevents accurate 
testing in the assay.  It is now clear, that an in vitro assay will be needed to identify any 
SAR trends.  We are currently optimizing an in vitro transcription assay to re-screen this 
library of analogs. 
In this report, we have determined the mechanism of VirF inhibition by compound 
19615 and have constructed an initial SAR to be used for further development.  
However, at the present time, we do not yet have direct evidence to indicate that 
19615's effects are specific to VirF versus other AraC family transcription factors, 
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although we have determined that 19615 does not interfere with RNA polymerase 
binding to DNA.  There is precedent for small molecules to exhibit cross-reactivity 
against multiple AraC family members.10, 18, 19  To examine the specificity of 19615, we 
plan to test it (or a more potent analogue) in EMSAs against a variety of other AraC 
family regulators, such as ToxT (virulence) from Vibrio cholera, MarA (multi-drug 
resistance) from E. coli, and AraC (arabinose operon) from E. coli.  Once specificity is 
determined, we will conduct mutagenesis studies to further probe the interactions 
between the compound and its target(s).  We also plan on determining the mechanism 
of action of the other hits from our high-throughput screen, conducting a synthetic SAR 
study of 19615 to probe the core heterocyclic structure, and continuing our work 
towards the development of an anti-virulence therapy to treat shigellosis. 
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Notes to Chapter V 
I would like to acknowledge the following people who contributed to the work 
presented in this chapter:  Justin Arrendondo-Guerrero (University of Michigan REU 
program, home institution: University of the Incarnate Word, San Antonio, Texas) for 
contributions made to the GFP reassembly assay, Dr. Amanda Garner (Department of 
Medicinal Chemistry, University of Michigan) for the use of the SpectraMax M5 plate 
reader and gel imager in her laboratory, and Dr. Hollis Showalter (Department of 
Medicinal Chemistry, University of Michigan) for his organic chemistry knowledge.  
Some of the work presented here was published in Emanuele and Garcia, PLoS ONE 
2015, 10, e0137410.20 
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Appendix 
Appendix Table V-1.  FID Assay with 10 bp pvirB Probes. 
10 bp pvirB Fragment 
19615 (2 μM) 
%fluorescence 
Berenil (2 μM) 
%fluorescence 
pvirB 1-10 (5’-AGAATATTAT-3’) 93% ± 6% 45% ± 2% 
pvirB 11-20 (5’-TCTTTTATCC -3’) 95% ± 3% 66% ± 0% 
pvirB 21-30 (5’-AATAAAGATA -3’) 92% ± 1% 81% ± 4% 
pvirB 31-40 (5’-AATTGCATCA -3’) 94% ± 2% 89% ± 5% 
pvirB 41-50 (5’-ATCCAGCTAT -3’) 94% ± 1% 96% ± 2% 
pvirB 51-60 (5’-TAAAATAGTA -3’)* 92% ± 0% 67% ± 0% 
*pvirB 51-60 was selected for use in the dose-response FID assay since it was sensitive 
to Berenil (67%) and was the most sensitive to 19615 (92%) in this study.  The 
differential affinity of Berenil for the various 10 BP fragments reflects its preference for 
specific AT-rich sequences. 
Appendix Table V-2.  SAR Table for 144143 Analogs. 
 
Compound IC50  (μM) R1 R2 R3 
144143 23 Cl CH2CH3 
 
D053-0233 78 Cl CH3 
 
D053-0411 560 Cl CH2CH2CH3 
 
STK518484 79 Br CH2CH3 
 
D053-0337 No Inhibition Cl CH2CH3 
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D053-0332 No Inhibition Cl CH2CH3 
 
 
Appendix Table V-3.  SAR Table for 144092 Analogs. 
 
Compound IC50  (μM) R1 R2 R3 R4 R5 
144092 23 Cl OCH3 H CH3 Cl 
D053-0099 110 Cl OCH3 H CH2CH3 Cl 
D053-0184 194 Cl OCH3 H CH2CH2CH3 Cl 
D233-0313 207 H OCH3 H 
 
Cl 
D233-0369 195 H OCH3 H 
 
Cl 
D233-0481 570 H OCH3 H 
 
Cl 
D053-0102 165 Cl CH3 H CH2CH3 Cl 
D053-0008 112 H NO2 H CH3 Cl 
D053-0244 115 H 
 
H CH3 Cl 
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D299-0375 232 Cl OCH3 H CH3 
 
D053-0089 
No 
Inhibition 
H 
 
H CH2CH3 Cl 
D053-0106 
No 
Inhibition 
Cl H O-CH3 CH2CH3 Cl 
D053-0022 
No 
Inhibition 
H OCH3 O-CH3 CH3 Cl 
D053-0003 Cytotoxic H OCH3 H CH3 Cl 
D053-0006 Cytotoxic Cl H H CH3 Cl 
STK518445 Cytotoxic Cl H H CH2CH3 Br 
 
Appendix Table V-4.  SAR Table for Pyrimidine Analogs. 
 
Compound IC50  (μM) R1 R2 
D053-0260 61 CH3 
 
D053-0292 70 CH3 
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D053-0094 116 CH2CH3 
 
D053-0037 59 CH3 
 
STK938588 285 CH3 
 
D053-0239 No Inhibition CH3 
 
STK938480 No Inhibition CH3 
 
STK936637 No Inhibition CH3 
 
STK934554 Cytotoxic CH2CH3 
 
D053-0024 Cytotoxic CH3 
 
STK787063 Cytotoxic CH3 H 
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Appendix Figure V-1:  EMSA depicting E. coli RNA Polymerase (RNAP) Binding to 
the lac Promoter (plac) in the Presence of 19615.  EMSA 
image shows the retardation of a 5’Cy5-plac DNA probe (0.25 
μM) when incubated in the presence of E. coli RNAP (2.7 μM) 
and also shows that compound 19615 has no effect on RNAP 
binding when tested at 100 μM.  For the EMSA a hybrid 2% 
acrylamide, 1% agarose gel was used which was made with 
and ran in a 1X TGE buffer (25 mM Tris base, 190 mM glycine, 
1 mM EDTA, pH 8.3).  The sequence of the 5’Cy5-plac DNA 
probe is as follows: 5’-gtgccctggtctggTTAGGCACCCCAGG 
CTTTACACTTTATGCTTCCGGCTCGTATAATGTGTGGAATTG
TGAG-3’ (lowercase text represents LUEGO sequence, 
uppercase text represents lac promoter sequence). 
 
free plac
plac + RNAP (core enzyme)
plac + RNAP (holoenzyme)
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CHAPTER VI 
HTS of ~20,000 Marine Natural Product Extracts Against Shigella flexneri: 
Identification of Globomycin and Desferrioxamine E  
 As detailed in Chapter II and as previously reported,1, 2 we have successfully 
screened over 140,000 small molecules utilizing a Shigella-based, VirF-driven, β-
galactosidase reporter assay in an attempt to identify small-molecule virulence inhibitors 
of S. flexneri.  From the small molecule high-throughput screening (HTS) campaign, we 
identified five promising small molecule VirF inhibitors with IC50 values ranging from 14 
to 66 μM.1  While the results of our small molecule screen were promising, we believed 
a more potent VirF inhibitor scaffold might be identified by sampling a larger range of 
chemical diversity. 
Nature’s small molecules, which possess biological activities and are obtained 
from natural resources, e.g. plants, animals, and microorganisms, are defined as 
Natural Products (NPs).  Over the past century, the complexity and diversity of these 
natural product scaffolds and appended functional groups have been an inspiration to 
chemists involved in pharmaceutical discovery, developing spectroscopic technology 
and devising principles and strategies for total synthesis, both biomimetic and abiotic.3  
Interestingly, mankind has known for at least several thousand years that marine 
organisms contain substances capable of potent biological activity, but in contrast to 
investigations on terrestrial NPs the first serious work on marine organisms started 
about 60 years ago with the pioneering work of Werner Bergman, when he published 
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reports of unusual arabino- and ribo-pentosyl nucleosides obtained from marine 
sponges collected in Florida, USA.4-6  Moreover, NPs have been used by human 
societies for millennia.  Many NPs and synthetically modified NP derivatives have been 
successfully developed for clinical use to treat human diseases, particularly as 
anticancer drugs and antibiotics.7 
To take advantage of the wealth of chemical diversity found within NPs, we 
conducted a follow-up HTS on a natural product extracts (NPEs) library developed in 
the laboratory of Dr. David Sherman (Life Sciences Institute, University of Michigan Ann 
Arbor).  This NPE library contains over 20,000 NPEs derived from a collection of marine 
organisms (e.g., sponges, sediments, and cyanobacteria) taken from across the globe 
(Papua New Guinea, Costa Rica, US Virgin Islands, Panama, Lake Erie, Lake Huron 
and Antarctica).  For the screening of the NPE library, the small molecule HTS was 
altered to include an optical density reading to monitor bacterial growth levels.  This 
alteration allowed for the detection of both bactericidal/bacteriostatic agents and 
potential virulence inhibitors from the NPE library. 
In this report, we first detail the results of our NPE HTS.  During the HTS, we 
observed not only extracts that inhibited bacterial growth and VirF activity, but also 
extracts that stimulated an increase in β-galactosidase activity, apparently by increasing 
the VirF-driven expression of β-galactosidase.  Investigation of these apparent VirF 
activator extracts might provide insight into the mechanism VirF uses to activate 
transcription.  Therefore, in the second part of this we report, we describe our efforts to 
identify and characterize the active components from an extract that stimulated β-
galactosidase activity and an extract that inhibited β-galactosidase activity.  
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Materials and Methods 
Reagents and General Methods 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO), unless 
otherwise specified. CPRG (chlorophenol red β-D-galactopyranoside) was purchased 
from Roche (Basel, Switzerland). Yeast extract, bactotryptone, carbenicillin, and 
Corning microtiter plates (384 and 96 well) were purchased from Fisher Scientific 
(Hampton, NH).  All NMR spectra were acquired on a Varian INOVA 500 MHz and a 
Varian INOVA 700 MHz spectrometer at the NMR Facility, Department of Chemistry, 
University of Michigan.  High-resolution MS spectra were measured at the University of 
Michigan core facility in the Department of Chemistry using Agilent 6520 Quadruple-
Time of Flight mass spectrometer equipped with Agilent 1290 HPLC system.  RP-HPLC 
was performed using Waters Atlantis® Prep T3 OBD™ 5 µm 19 × 250 mm column and 
Waters XBridge™ 5µM 19 × 150 mm C18 column using solvent system of ACN and 
H2O.  The LCMS analysis of HPLC fractions was performed on a Shimadzu 2010 EV 
APCI spectrometer. 
Strains and Plasmids 
The avirulent strain of S. flexneri, BS103, used in the HTS and reconfirmation 
testing was a generous gift from Dr. Anthony Maurelli (Uniformed Services University of 
the Health Sciences, Bethesda, MD). The construction of the reporter plasmid, 
pMALvirF-LacZ, and positive control plasmid, pMAL(ΔvirF)-LacZ was previously 
reported.2  The following strains used in the minimum inhibitory concentration (MIC) 
study were a generous gift from Dr. Sylvie Garneau-Tsodikova (currently at the 
University of Kentucky): Bacillus subtilis 168, Bacillus cereus ATCC1778, Bacillus 
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anthracis 34F2 Sterne, Escherichia coli MC1061, Enterococcus faecalis ATCC29212, 
Listeria monocytogenes ATCC19115, and Salmonella enterica ATCC14028.  The E. coli 
EC2880 strain (permeable strain with tolC- and imp- mutations) used in the MIC study 
was a generous gift from Dr. Michael Hubband (Pfizer Scientific).  A Vancomycin-
resistant Enterococcus strain and a methicillin-resistant Staphylococcus aureus strain 
were contributed by the Sherman laboratory (University of Michigan, Ann Arbor) and 
were also screened in the MIC study. 
Natural Product Extract Library 
The NPE library contained 20,061 extracts that were derived from a collection of 
various marine organisms sampled from across the globe.  Microbes found in the 
collection of samples were carefully cultured and grown to a suitable cell mass for 
organic extraction.  Each culture underwent organic extractions with three different 
solvents: methanol, acetone, and ethyl acetate.  The extracts generated from the 
cultures were dried, dissolved in DMSO (to a final concentration of 15 mg/mL), and 
stored in plates amenable to high-throughput screening.  The NPE library is stored and 
was screened at the Center for Chemical Genomics (Life Sciences Institute, University 
of Michigan Ann Arbor). 
High-throughput, VirF-driven, β-galactosidase Reporter Assay 
The NPE HTS was performed as previously described 2 with a few modifications.  
Samples containing Shigella flexneri BS103 harboring pMALvirF-LacZ (or the positive 
control for no β-galactosidase activity, pMAL(∆virF)-LacZ) were grown to saturation in 
2xTY at 37°C with shaking.  Extracts from the NPE library were added to 20 µL 2xTY in 
the appropriate wells of each 384-well plate (0.1 mg/mL, n=2, 0.2 μL) by Biomek HDR 
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(Beckman).  Cells were diluted with 2xTY supplemented with 100 µg/mL carbenicillin to 
a final OD600 = 0.004 and 10 µL was added to the 384-well microtiter plates with the 
Multidrop dispenser (Thermo Scientific) (30 µL total volume).  Plates were then 
centrifuged at 1000 rpm for one minute using a Beckman Coulter Allegra Series 
centrifuge before being incubated for 20 hours at 30°C in a humidified incubator (VWR).  
Cell density (OD600) was measured prior to addition of an equal volume (30 µL) of 0.5 
mg/mL CPRG and 0.1% Triton X-100 in Miller’s Z-buffer (60 mM Na2HPO4, pH 7.0; 40 
mM NaH2PO4; 10 mM KCl; 1 mM MgSO4).
8  The samples were incubated at room 
temperature for 10 minutes before measuring chlorophenol red (CPR) absorbance 
(A570) in a PHERAstar (BMG Labtech) plate reader with a narrow band pass filter. 
Selection Criteria 
See Figure VI-1 for a flowchart of the selection and counter screen process.  For 
the VirF inhibition high-throughput screen, extracts were considered hits if they 
produced ≥25% VirF inhibition or their minimum standard deviation was ≥3.0 (calculated 
on a plate by plate basis using the negative controls only) and if they exhibited ≤25% 
cell growth inhibition and ≤25% β-galactosidase inhibition.  Extracts were selected for 
reconfirmation testing if they produced ≥45% VirF inhibition or if two or more extracts 
taken from the same culture both produced ≥30% VirF inhibition. 
For the cell growth inhibition screen, extracts were considered hits if they 
produced ≥25% cell growth inhibition against S. flexneri BS103 cells harboring 
pMALvirF-LacZ.  Extracts were selected for reconfirmation testing if they also produced 
≥25% cell growth inhibition against S. flexneri BS103 cells harboring pMAL(ΔvirF)-LacZ. 
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Extracts were considered hits for VirF activation if they produced a rapid, visual 
increase in CPRG cleavage compared to the negative controls.  Extracts were selected 
for reconfirmation testing if in the dose-response study their pAC50 for VirF activation 
was 0.5 larger than their pAC50 for cell growth inhibition. Note: pAC50 = -log(AC50) 
Counter Screens 
All extracts that met the selection criteria for VirF inhibition were subjected to a β-
galactosidase inhibition screening.  For the screen, cultures of S. flexneri BS103 
harboring either pMALvirF-LacZ or pMAL(ΔvirF)-LacZ were diluted to OD600=1.0 using 
2xTY media supplemented with 100 μg/mL carbenicillin and added to appropriate wells 
of a 384-well plate using the multidrop dispenser (30 μL).  Extracts were added to the 
plates in duplicate at a concentration of 0.1 mg/mL.  Immediately following extract 
addition, CPRG solution was added to each well (30 μL).  After a 10-minute incubation 
period at room temperature, chlorophenol red absorbance (A570) was measured using a 
PHERAstar plate reader to determine if the extracts directly inhibited β-galactosidase.  
All extracts that met the selection criteria for cell growth inhibition were screened again 
against the control strain, S. flexneri BS103 harboring pMAL(ΔvirF)-LacZ, using the 
screening protocol described above. 
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Figure VI-1:  Flow Chart Depicting the Results of the HTS Campaign.  See 
Materials and Methods for details regarding the selection criteria.  
 
All extracts that produced apparent VirF activation in the HTS were subjected to 
two different counter screens.  The first counter screen verified that the extracts were 
not chemically cleaving CPRG.  For this screen 30 μL of 2xTY media supplemented 
with 100 μg/mL carbenicillin was added to appropriate wells of a 384-well plate using 
the multidrop dispenser. Extracts were added to the plates in duplicate at a 
concentration of 0.1 mg/mL. Immediately following extract addition, CPRG solution was 
added to each well (30 μL).  After a 10-minute incubation period at room temperature, 
chlorophenol red absorbance (A570) was measured using a PHERAstar plate reader to 
determine if the extracts could directly cleave CPRG.  The second counter was a dose-
20,061 Extracts Screened 
218 “Hits” For VirF Inhibition 
≥ 25% VirF Inhibition or ≥ 3.0 
Standard Deviations from 
Negative Control Average 
≤ 25% Cell Growth Inhibition 
≤ 25% β-galactosidase Inhibition 
17 Extracts for 
Reconfirmation 
Testing  
≥ 45% VirF Inhibition 
7 Sets of Extracts 
for Reconfirmation 
Testing  
≥ 30% VirF 
Inhibition 
96 “Hits” for Cell 
Growth Inhibition 
≥ 25% Cell Growth 
Inhibition 
9 Extracts for 
Reconfirmation Testing 
≥ 25% Cell Growth 
Inhibition against 
Shigella control strain 
as well 
25 Apparent 
VirF 
Activators 
4 Extracts for 
Reconfirmation 
Testing 
pAC50 VirF - pAC50  
Control  ≥ 0.5   
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response study that followed the screening protocol described above.  However, for the 
dose-response study, the concentration of the extracts was varied using 2-fold serial 
dilutions ranging from 0.3 mg/mL to 0.002 mg/mL.  Note: for the dose response study 
the CPRG incubation time was lowered from 10 min to 2.5 min to ensure that the upper 
detection limit of the spectrophotometer was not reached. 
Active Natural Product Extract Strain Regrowth 
Streptomyces sp. 34443-A2 and Streptomyces sp. 44306-A41 were isolated from 
marine sediments collected at a depth of 15 m during a scuba diving expedition at Playa 
Langosta, Costa Rica (-85o51’41”, 10o16’24.9”) near Diria National Park, Costa Rica.  
The procedure for the isolation of actinomycetes from these samples was previously 
described by Magarvey et al.9  Maintenance and propagation of cultures were 
performed using standard media and protocols where 500 mg of wet sediment was 
diluted in 10 mL of sterile water and vortexed for 10 min.  One mL of this suspension 
was then applied directly to the top of the discontinuous sucrose gradient and 
centrifuged for 30 minutes at 300 x g.  Next, 500 µL of the 20%, 30%, and 40% layers 
were plated on HVA agar supplemented with 10 µg/mL chlortetracycline, 25 µg/mL 
cyclohexamide, and 25 µg/mL of nalidixic acid.  The plates were then incubated at 28 °C 
for one month.  A colony was picked off the plate and streaked onto ISP2 agar until 
pure.  Seed cultures were grown in 17 mL dual position cap tubes containing 2 mL of 
ISP2 and grown for 4 days on a rotary shaker at 200 rpm.  The seed culture was then 
poured into a 250 mL baffled flask containing 100 mL of ISP2 and grown for 10 days on 
a rotary shaker at 200 rpm.  The culture was centrifuged at 4000 rpm for 10 min to 
remove the cells and 2 g of XAD16 resin (Sigma-Aldrich, St. Louis, Mo.) contained 
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within a polypropylene mesh bag was added to the broth and incubated overnight on 
the rotary shaker.  The resin bag was removed and placed into 10 mL of MeOH 
followed by 10 mL of acetone and 10 mL of ethyl acetate.  Each of the three fractions 
was dried in vacuo and reconstituted to a final concentration of 15 mg/mL in DMSO. 
Culture Maintenance and Fermentation 
Seed cultures of 100 mL (×5) of ISP2 media (1% malt extract, 0.4% yeast 
extract, 0.4% dextrose, 3% NaCl) were inoculated with a loopful of vegetative cells from 
an oatmeal plate (6% oatmeal, 1.25% agar, 3% NaCl) culture of Streptomyces sp. 
34443-A2 or Streptomyces sp. 44306-A41 and incubated with shaking (200 rpm) at 
28oC for 8 days.  A 25 mL portion of the seed cultures were transferred to a 2.8 L 
Fernbach flask containing 1.5 L of the ISP2 medium, and the fermentation was carried 
out on a rotary shaker (200 rpm) at 28 °C.  After 8-10 days of growth, the cultures were 
harvested by centrifugation.  The resulting cell free broth was subjected to solid phase 
extraction using 15 g of Amberlite XAD-16.  The resin was then separated by filtration 
and subjected to organic extraction using MeOH: EtOAc (1:1).  
Isolation and Purification of Globomycins A-C (1-3) 
The organic extract from Streptomyces sp. 34443-A2 was concentrated under 
vacuum to afford the crude extracts (~3.2 g).  Crude extracts were dissolved in 30 mL of 
H2O and were applied to a C18-silica gel column (20 × 2.6 cm, YMC Gel ODS-A, 12 
nm, S-150 µm).  The C-18 column was eluted with a stepwise gradient of H2O/ACN 
(100:0 → 0:100) to give eight fractions, which were concentrated in vacuo to yield 
fractionated organic materials, respectively.  All eight fractions were assayed as 
described above.  The bio-active fractions 4 and 5 were further purified by RP-HPLC on 
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an isocratic 50% ACN in H2O and was followed by UV/Vis photodiode array detection at 
210 nm and 254 nm to yield semi-pure compounds 1 (11.2 mg), 2 (6.9 mg) and 3 (5.3 
mg).  These compounds were subjected to re-purification over RP-HPLC using isocratic 
elution with 48% ACN on a Waters XBridge™ 5µM 19 × 150 mm C18 column to yield 
compounds 1 (7.6 mg), 2 (4.3 mg) and 3 (3.6 mg) (Figure VI-2). 
 
Figure VI-2:  HPLC Trace and Yield of Active Peptidic Molecules. 
X-ray Crystallography of Globomycin A (1) 
The entire isolated yield of 1 was dissolved in a small amount of filtered ACN, 
and then MeOH was added at 50 ºC until the saturation point was reached.  Colorless 
needles of 1 were grown from evaporation of an acetonitrile/methanol solution of the 
compound at 4°C.  A crystal of dimensions 0.12 x 0.02 x 0.02 mm was mounted on a 
Rigaku AFC10K Saturn 944+ CCD-based X-ray diffractometer equipped with a low 
temperature device and Micromax-007HF Cu-target micro-focus rotating anode ( = 
1.54187 A) operated at 1.2 kW power (40 kV, 30 mA).  The X-ray intensities were 
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measured at 85°K with the detector placed at a distance 42.00 mm from the crystal.  A 
total of 2911 images were collected.  The exposure time was 5 sec. for the low angle 
images, 15 sec. for high angle.  The integration of the data yielded a total of 128099 
reflections to a maximum 2 value of 136.48° of which 7433 were independent and 
7205 were greater than 2.  The final cell constants (Appendix Table VI-1) were based 
on the xyz centroids 86072 reflections above 10.  Analysis of the data showed 
negligible decay during data collection; the data were processed with CrystalClear 2.0 
(Rigaku Americas and Rigaku Corporation (2011)) and corrected for absorption.  The 
structure was solved and refined with the Bruker SHELXTL (version 2008/4) software 
package, using the space group P6(1) with Z = 6 for the formula C37H57N5O9, C2H3N, 
H2O, 1.25(H2O).  Full matrix least-squares refinement based on F
2 converged at R1 = 
0.0409 and wR2 = 0.1030 [based on I > 2sigma(I)], R1 = 0.0422 and wR2 = 0.1041 for all 
data. 
Isolation and Purification of Desferrioxamine E 
 Desferrioxamine E was isolated and purified from the organic extract of 
Streptomyces sp. 44306-A41 as previously described.10  Structure was confirmed via 
HRMS, 1H NMR, 13C NMR, and 2D COSY NMR.   
Activation versus Growth Inhibition Dose-Response Study 
For this study, the screening protocol was modified to a 96-well microtiter plate 
format. Briefly, starter cultures (3 mL) of S. flexneri BS103 harboring either the reporter 
plasmid (pMALvirF-LacZ) or positive control plasmid (pMAL(ΔvirF)-LacZ) were grown 
overnight at 37°C with shaking in 2xTY media (16 g bactotryptone, 10 g yeast extract, 5 
g NaCl per liter of water supplemented with 100 μg/mL carbenicillin).  The following day 
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each culture was diluted with similar media to OD600=0.005 and then added to 
appropriate wells of a 96-well microtiter plate (85 μL). Working stocks of each 
compound were made in 25% DMSO using a two-fold serial dilution approach: 5 μL of 
each compound were added in triplicate to appropriate wells of a 96-well plate resulting 
in final concentrations ranging from 43 μM to 0.34 μM. For the negative controls, 
compound vehicle (25% DMSO) was added to the wells instead of compound.  Plates 
were grown overnight at 37°C for 20 hours in a humidified incubator.  The following day 
the cell density (OD600) for all samples was measured using a BioTek Synergy H1 plate 
reader (Winooski, VT) then 90 μL of CPRG solution was added to each well.  Plates 
were allowed to incubate for 2.5 minutes at room temperature then chlorophenol red 
absorbance (A570) was determined using the BioTek plate reader. 
Minimum Inhibitory Concentration Testing 
Starter cultures (3 mL) of the following strains were grown overnight at 37°C in 
the indicated media: 
S. aureus (MRSA): TSB media (17 g casein peptone, 2.5 g dipotassium hydrogen 
phosphate, 2.5 g glucose, 3 g soya peptone, 5 g sodium chloride/L of water) 
B. cereus ATCC1778, E. faecalis ATCC29212, L. monocytogenes ATCC19115, 
Vancomycin-Resistant Enterococcus (VRE): BHi media (5 g beef heart, 12.5 g 
calf brains, 2.5 g disodium hydrogen phosphate, 2 g glucose, 10 g peptone, 5 g 
sodium chloride/L of water) 
B. subtilis 168, E. coli MC1061, E. coli EC2880, S. enterica ATCC14028, S. flexneri 
BS103, B. anthracis: LB media (10 g bactotryptone, 5 g yeast extract, 5 g sodium 
chloride/L of water) 
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The following day each culture was diluted with similar media to OD600=0.005 
and then added to appropriate wells of a 96-well microtiter plate (85 μL). Working stocks 
of each compound were made in 25% DMSO using a two-fold serial dilution approach; 
5 μL of each compound were added in triplicate to appropriate wells of a 96-well plate 
resulting in final concentrations ranging from 50 μM to 0.39 μM (note: EC2880 was also 
tested with lower compound concentrations ranging from 670 nM to 5 nM).  For the 
negative controls, compound vehicle (25% DMSO) was added to the wells instead of 
compound.  Plates were grown overnight at 37°C for 20 hours in a humidified incubator.  
The following day the cell density (OD600) for all samples was measured using a M5 
SpectraMax plate reader (Molecular Devices, Sunnyvale, CA). 
Desferrioxamine E Electrophoretic Mobility Shift Assay (EMSA) 
EMSAs were performed as described in Chapter IV but with Desferrioxamine E 
(100 μM) present in appropriate reactions. 
Siderophore VirF Inhibition Testing 
Desferrioxamine E and 2,2-bipyridine were tested in the 96-well plate version of 
the β-galactosidase reporter assay.  Both compounds were tested alone (17 μM and 50 
μM, respectively) and in the presence of ferric citrate (20 μM).  The assay was 
performed as described in Chapter II Material and Methods Reconfirmation Screen.   
Results 
Hit Identification 
For the high-throughput screen, 20,061 natural product extracts were tested.  As 
shown in Figure VI-1, the screen produced 218 initial “hits” for VirF inhibition (Z’ factor 
=0.59, average Z’ factor per plate = 0.65, 1.09% hit rate).  Application of more stringent 
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selection criteria (see Figure VI-1) yielded 24 strains (17 single extracts, 7 sets of 
extracts) for reconfirmation testing and extract fractionation.  Of the strains selected for 
reconfirmation only one, 44306-A41, maintained activity throughout the regrowth and 
fractionation process.  The screen also produced 96 “hits” for cell growth inhibition 
(0.48% hit rate).  Of the 96 “hits”, nine inhibited cell growth in both S. flexneri BS103 
cells harboring pMALvirF-LacZ and S. flexneri BS103 cells harboring pMAL(ΔvirF)-
LacZ.  These nine extracts were selected for reconfirmation testing and fractionation; 
however, none displayed activity after regrowth.  The initial screen also identified 25 
extracts that stimulated a greater amount of CPRG cleavage compared to the negative 
controls.  These extracts were further tested in two counter screens.  The first counter 
screen determined if the extracts were chemically cleaving CPRG.  None of the 25 
extracts exhibited CPRG cleavage.  The 25 extracts were then tested in dose-response 
studies similar to the HTS assay.  Of the 25 extracts, four had a pAC50 for VirF 
activation that was at least 1.5-fold larger than their pAC50 for cell growth inhibition (e.g., 
their AC50 for activation was at least 3-fold less than that for toxicity).  These extracts 
were selected for further reconfirmation testing and fractionation, and only one, 34443-
A2, maintained activity throughout the regrowth and fractionation process. 
Isolation and Identification of Globomycins 
The marine actinomycete strain 34443-A2 was isolated from Costa Rica marine 
sediments as described in Material and Methods.  The marine microbe was grown at a 
large scale (6 L) and the active organic extracts were subjected to C18 chromatography 
followed by in vitro biological activity assessment.  The VirF-based β-galactosidase 
reporter assay revealed fractions eluting with 3:2 and 1:1 (H2O: ACN) to contain the 
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active fraction (Figure VI-2).  Both fractions were pooled together based on their similar 
activities and being consecutive C18 fractions.  The pooled active fraction was then 
subjected to RP-18 HPLC purification to yield three active peptidic molecules (1-3) 
(Figure VI-2).  
Compound 1 was purified in greater yield, as a white amorphous solid and 
showed [M+H]+ ion peak at m/z 656.4308 possessing molecular formula of C32H57N5O9 
as suggested by HRMS (Appendix Figure VI-1).  The 1H NMR data recorded in DMSO-
d6, indicated the peptidic nature of 1 and suggested the presence of at least two N-
methyl amide groups at δ 3.29 and eight NH groups at δ 7.23, 7.45, 7.77, 7.96, 8.27, 
8.36 and 8.61 ppm (Appendix Figure VI-4).  Interestingly, the molecular formula 
indicated only five N atoms to be present in molecule.  Furthermore, the 13C NMR 
spectrum (in DMSO-d6, Appendix Figure VI-5) of 1 exhibited the presence of six clear 
carbonyl carbons (with equal number of minor carbonyl carbon signals) attributable to 
ester/amide functionalities along with the possibility of molecule showing conformational 
flexibility in DMSO-d6.  Analyses of 1D and 2D NMR spectra of 1 (Appendix Figures VI-
4 to VI-6) led to the establishment of a hybrid structural framework consisting of five 
proteinogenic amino acids, namely leucine, isoleucine, serine, threonine and glycine 
along with an aliphatic moiety of polyketidic origin.  However, NMR spectra were also 
suggesting double signals for each moiety making it difficult to tether the data with 
HRMS.  
In order to resolve the issue, we resorted to crystallization efforts for the active 
molecule using drops of MeOH in saturated solution of 1 in ACN at 50 ºC followed by 
slow evaporation at 4ºC to produce a small amount of crystals that were adequate for X-
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ray diffraction studies (see Material and Methods).  The resulting structure (Figure VI-3) 
was essentially super-imposable to the predicted residues, which led to the identification 
of 1 as the earlier reported molecule Globomycin A.11, 12 
Globomycins B (2) and C (3) were also isolated from RP-18 HPLC of the same 
C18 fractions containing compound 1. The HRMS of the molecules provided molecular 
formulas of C32H55N5O9 and C30H53N5O9, showing [M+H]
+ ion peaks at 628.3938 and 
642.4130 respectively (Appendix Figures VI-2 and 3). Both these molecules differ by a 
CH2 group and share near identical NMR spectra leading them to be identified as 
reported analogs isolated along with Globomycin A (1), see Figure VI-4.11, 12
 
Figure VI-3:  Crystal Structure (Ellipsoid) of Globomycin A (1). 
Isolation and Identification of Desferrioxamine E 
The marine actinomycete strain 44306-A41 was isolated from Costa Rica marine 
sediments as described in Material and Methods.  The marine microbe was grown at a 
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large scale (6 L) and the active organic extracts were subjected to C18 chromatography 
followed by in vitro biological activity assessment.  A total of three rounds of RP-18 
HPLC purification, followed by in vitro biological activity assessment were needed to 
produce a single active peak.  The structure of the purified compound was then 
determined via 1D and 2D NMR studies and HRMS (see Appendix Figures 7-10).  The 
structure is shown in Figure VI-5. 
Figure VI-4:  Chemical Structures of Globomycins A-C (1, 2, and 3). 
Figure VI-5:  Chemical Structure of Desferrioxamine E.  
Activation versus Growth Inhibition Dose-Response Studies with Globomycins 
Pure samples of compounds 1, 2, and 3 were tested in dose-response studies 
with a modified 96-well microtiter plate version of the screening assay.  Both cell growth 
inhibition and apparent VirF activation were monitored.  As shown in Figure VI-6, as the 
concentration of each compound increased, there was a steep rise in VirF activation 
followed by a steep drop-off due to growth inhibition.  At higher concentrations 
         Globomycin A(1)        Globomycin B(2)              Globomycin C(3) 
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(approximately 20 μM) no VirF activation was seen due to the toxicity of the 
compounds. 
Figure VI-6:  Plots Depicting Fold VirF Activation (solid-line, right y-axis) Versus 
% Growth Inhibition (dotted-line, left y-axis) for Globomycins A-C (1, 
2, and 3).  Each concentration was tested in triplicate (two-fold serial 
dilutions 43-0.33 μM).  A)  Plot for Globomycin A (1), fold activation peaks 
at 2.7 μM B) Plot for Globomycin B (2), fold activation peaks at 11 μM.  C) 
Plot for Globomycin C (3), fold activation peaks at 5.4 μM. 
Minimum Inhibitory Concentration Determination of Globomycin Compounds 
Minimum inhibitory concentration studies were performed with compounds 1, 2, 
and 3 against a panel of bacteria.  Table VI-1 shows the results for the MIC studies.  
A 
C 
B 
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The concentrations listed in Table VI-1 refer to the concentration of each compound that 
produced 90% growth inhibition.  As shown in the table, the compounds were primarily 
active against E. coli and S. flexneri, with slight activity against the various Bacillus 
strains.  The bactericidal effect of each compound against E. coli increased in E. coli 
EC2880, an E. coli strain with the gene encoding for the TolC efflux pump removed.  
The MIC90 of compound 1 decreased approximately 300-fold, the MIC90 of compound 2 
decreased approximately 35-fold, and the MIC90 compound 3 decreased approximately 
70-fold for the tolC knockout strain versus wild-type. 
Desferrioxamine E Electrophoretic Mobility Shift Assay (EMSA) 
 Using the optimized EMSA conditions described in Chapter IV, the assay was 
used to determine if Desferrioxamine E at 100 μM could inhibit the binding of MalE-VirF 
to the virB promoter.  As shown in Figure VI-7, Desferrioxamine E had no effect on the 
binding of MalE-VirF and was indistinguishable from the DMSO negative control. 
Siderophore Testing in the Presence of Ferric Citrate 
 The Shigella-based, VirF-driven, β-galactosidase assay was used to determine 
the effects of 2,2-bipyridine and purified Desferrioxamine E on VirF-driven transcription 
of the virB promoter with and without excess ferric citrate.  As shown in Table VI-2, both 
2,2-bipyridine and Desferrioxamine E had inhibitory effects in the assay.  However, 
these inhibitory effects were offset by the addition of ferric citrate in both cases.  Table 
VI-2 also shows that ferric citrate alone had a negligible effect on VirF-driven 
transcription at the concentrations used in this study. 
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Table VI-1.  MIC90 Values for Compounds 1, 2, and 3. 
 MIC90 (μM) 
Organism 1 2 3 
E. coli MC1061 6.3 25.0 12.5 
E. coli EC2880 
(tolC-, imp-) 
0.02 0.67 0.17 
S. flexneri BS103 25.0 25.0 25.0 
B. subtilis 168 >50.0 >50.0 >50.0 
B. anthracis 34F2 Sterne Not Active >50.0 50.0 
B. cereus ATCC1778 >50.0 >50.0 50.0 
MRSA Not Active Not Active >50.0 
S. enterica ATCC14028 >50.0 Not Active Not Active 
VRE Not Active Not Active Not Active 
L. monocytogenes  
ATCC19115 
Not Active Not Active Not Active 
E. faecalis ATCC29212 Not Active Not Active Not Active 
Note: The highest compound concentration tested was 50 μM.  Therefore, a “Not 
Active” result is defined as a compound producing no growth inhibition at 50 μM, 
while a “>50.0 μM” result is defined as a compound producing some level growth 
inhibition at 50 μM but <90%. 
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Figure VI-7: Electrophoretic Mobility Shift Assay (EMSA) of MalE-VirF Binding to 
pvirB DNA Probe in Presence of Desferrioxamine E (Des).  EMSA 
image shows the retardation of the 5’Cy5-pvirB DNA probe (0.25 μM) 
when incubated in the presence of MalE-VirF (1 μM).  Image also shows 
the effect Desferrioxamine E (100 μM) has on MalE-VirF binding.   
 
Table VI-2.  Results of Siderophore Testing in Presence of Iron. 
% Inhibition in the Shigella-Based, VirF-Driven, β-Galactosidase Reporter Assay 
Des* 
(17 μM) 
Des*(17 μM) + Ferric 
Citrate (20 μM) 
2,2-B* 
(50 μM) 
2,2-B* (50 μM) + Ferric 
Citrate (20 μM) 
Ferric Citrate 
(20 μM) 
77% ± 2% 22% ± 8% 63% ± 3% 43% ± 1% 4% ± 2% 
*Des = Desferrioxamine         *2,2-B = 2,2-bipyridine 
 
Discussion 
The initial objective of the NPE HTS was to identify extracts that either had VirF 
inhibitory properties or bactericidal/bacteriostatic properties.  As shown in Figure VI-1, 
we were able to identify 218 “hits” for VirF inhibition and 96 “hits” for cell growth 
VirF + pvirB 
Free pvirB 
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inhibition from the HTS.  However, during the screen we also observed 25 extracts that 
appeared to increase VirF activity.  This apparent increase in VirF activity was 
evidenced by the rapid turnover of the β-galactosidase substrate, CPRG, to 
chlorophenol red.  Typically, after CPRG is added to each microtiter plate, it is allowed 
to incubate at room temperature for 10 minutes before absorbance is measured at 570 
nm.  During this incubation time, the yellow substrate slowly turns a deep red upon 
hydrolysis by β-galactosidase.  However, for samples containing the apparent VirF 
activating extracts, the red color appeared very rapidly and in most cases reached the 
upper detection limit of the plate reader within five minutes.  Control screens showed 
that the extracts were not chemically cleaving CPRG or directly activating β-
galactosidase (data not shown).  Combined, these results suggested that there was a 
greater amount of β-galactosidase present in these samples, presumably due to an 
increase in VirF activity. 
As with all NPE screens, the extracts contain multiple compounds.  Therefore, 
once a promising extract has been identified, the active component must be isolated 
from the extract and characterized.  To isolate the active component, the producing 
organism is grown on a larger scale and the extraction procedure is repeated.  A series 
of bioassay-guided fractionations on the large-scale extraction are then used to isolate 
the active compounds.  To narrow down our list of hits for reconfirmation and 
fractionation studies, tighter selection criteria were applied to all three sets of hits (as 
shown in Figure VI-1 and described in Methods).  The tighter selection criteria yielded 
24 strains that produced extracts with VirF inhibitory properties, nine strains that 
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produced extracts with bactericidal/bacteriostatic properties, and four strains that 
produced extracts with apparent VirF activation properties. 
Although not the original goal of our HTS, we decided to first follow-up on the 
apparent VirF activators in an attempt to gain insight into the mechanism VirF uses to 
activate transcription.  VirF is classified as a homodimeric, AraC-type transcriptional 
regulator.  There are three classes of AraC-type regulators: chemically-modulated, 
physically-modulated, and monomeric.13  AraC is a member of the first class since it is 
positively regulated by arabinose 14, whereas VirF is a member of the second class 
owing to the fact that VirF is constitutively active and its expression is modulated by 
temperature, pH and osmolarity.15  The exact mechanism and order of events VirF uses 
to activate transcription is poorly understood, but it is clear that VirF must dimerize, bind 
DNA, and recruit RNA polymerase to turn on transcription.  We hypothesized that a 
natural product could be acting as a positive modulator at any of the above listed steps 
for VirF transcriptional activation, much like arabinose is a positive modulator for AraC.  
Identification of a positive modulator of VirF activity would change the current 
understanding of how VirF functions. 
To identify the active component from the hits for apparent VirF activation, the 
four strains that produced the extracts were cultured and the extraction procedures 
were repeated.  Unfortunately, only one of the four strains (a marine actinomycete) 
reconfirmed and produced an extract with apparent VirF activating properties.  This 
strain was subjected to scaled-up growth conditions and a large-scale extraction.  The 
large-scale extract underwent a series of bioassay guided fractionations until three 
active compounds (1, 2, and 3) were isolated via C-18 HPLC.  Once each compound 
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was purified and their molecular weights were determined via high-resolution mass 
spectrometry, the concentration of each compound could be accurately varied in the 
VirF-driven, β-galactosidase reporter assay.  When the pure compounds were tested at 
higher concentrations, there was a sharp drop-off in apparent VirF activation due to S. 
flexneri growth inhibition as shown in Figure VI-6.  These results suggested that the 
apparent VirF activation might be a side effect/response from the cellular stress the 
compounds placed on the bacteria prior to bacteriostasis.  To determine if S. flexneri 
growth inhibition was VirF specific or if the compounds inhibited the growth of other 
bacterial species, minimum inhibitory concentration (MIC) studies were performed 
against a panel of bacteria.  As shown in Table VI-1, the compounds were able to 
successfully inhibit the growth of different bacterial species (primarily E. coli and 
Bacillus strains) that do not express VirF.  This result proved that the growth inhibition 
was not VirF-specific and further suggested that the apparent VirF activation may be a 
side effect from a stress response. 
To confirm the structures of the compounds, compound 1 was successfully 
crystallized and analyzed by X-ray crystallography.  From the crystal structure and a 
series of NMR experiments, the chemical structures of all three compounds were 
determined, see Figure VI-4.  Compound 1 is a known bactericidal agent named 
Globomycin A, while compounds 2 and 3 are also previously discovered naturally 
occurring derivatives, Globomycins B and C.  Globomycin A was initially isolated in 
1978 from a terrestrial actinomycete 11, 12, while its congeners were later isolated in 
1981.16  Globomycin A and its derivatives are known to block prolipoprotein processing 
through the inhibition of signal peptidase II.17  The known antibacterial properties of 
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Globomycin A and its derivatives are similar to the properties we have reported in Table 
VI-1.18-21  However, the data in Table VI-1 suggests that Globomycins are substrates for 
one or more of the E. coli TolC efflux pumps.  TolC forms the outer-membrane channel 
for the majority of pumps associated with the efflux of antibacterial agents in E. coli.22  
The MIC90 values for the Globomycins (1, 2, and 3) were much lower when tested 
against the tolC genetic knockout strain, EC2880, than when tested against wild type E. 
coli (300-fold, 35-fold, and 70-fold lower, respectively).  This characteristic of 
Globomycins has not been previously reported and could aid in developing a more 
potent Globomycin derivative effective against Gram-negative bacteria. 
Globomycin is also a known inducer of the phage shock response pathway in E. 
coli.23  The phage shock response pathway activates the transcription of effector 
proteins to help overcome stressors affecting cell membrane function.24  It is likely that 
the apparent VirF activation seen during the HTS was actually a general upregulation of 
transcription caused by the activation of the phage shock pathway or a similar stress 
response pathway and not a direct effect of the compounds upon VirF. 
After the identification and characterization of the Globomycins, we followed up 
on the hits that displayed VirF inhibition. A total of 15 of the 24 strains that produced 
VirF inhibitory extracts were regrown, extracted, and fractionated.  Unfortunately, only 
one strain, 44306-A41 (a marine actinomycete) reconfirmed and produced an extract 
with VirF inhibitory properties.  This strain was subjected to scaled-up growth conditions 
and large-scale extraction.  The large-scale extract underwent a series of bioassay 
guided fractionations until an active compound was isolated via C-18 HPLC.  A series of 
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NMR and HRMS experiments confirmed the active compound was a known 
siderophore, Desferrioxamine E.10, 25   
Previous studies have determined that iron concentration plays a role in VirF 
transcriptional activation of virB.26, 27  Specifically, when iron levels are depleted, a small 
regulatory RNA, RhyB (encoded on genome), is produced and inhibits VirB expression 
by decreasing the amount of virB mRNA.  Currently, it is believed that RhyB regulates 
VirB expression at the level of virB transcription and that this regulation may be directly 
linked to sequence complementarity to the template strand of virB.26  Yet, there have 
been no reports of iron-levels specifically affecting the activation of the virB promoter. 
Therefore, the inhibition seen in the reporter assay (inhibition of VirF activating pvirB-
lacZ) suggested that Desferrioxamine E could have a direct effect on VirF not related to 
iron chelation. 
To probe if Desferrioxamine E was directly blocking VirF from binding to the virB 
promoter, an EMSA that monitored MalE-VirF binding to the virB promoter was 
performed.  As shown in Figure VI-7, Desferrioxamine E had no effect on VirF binding to 
the virB promoter.  To verify that the depletion of iron was causing the inhibition seen in 
the reporter assay, and not Desferrioxamine E directly, the reporter assay was repeated 
in the presence of excess ferric citrate, as well as, a known iron-chelator, 2,2-bipyridine, 
in place of Desferrioxamine E.  Unfortunately, as shown in Table VI-2, 2,2-bipyridine 
had the same effect on the reporter assay as Desferrioxamine E, and that both of these 
effects could be offset by the addition of excess ferric citrate.  This confirmed that the 
inhibition seen in the reporter assay was due to the depletion of iron and not a direct 
interaction between Desferrioxamine E and VirF.    
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Unfortunately, we were not able to identify any novel compounds from our NPE 
HTS campaign.  This can be attributed to many factors, including poor luck and a very 
low reconfirmation rate when the “active” strains from the HTS were regrown.  It is 
possible that with further optimization of growth conditions, a novel compound may still 
yet be identified.  However, the high-rate at which known natural products are currently 
identified from bacterial HTS,28 has lead us to move on from this endeavor.  The novel 
information that can be taken away from this study is that it appears Globomycin is 
substrate for the E. coli TolC efflux pump and that iron depletion reduces VirF-driven 
transcription of a reporter gene from the virB promoter.   
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Notes to Chapter VI 
The work described in this chapter was based on a collaboration between the 
Sherman laboratory (Life Sciences Institute, University of Michigan Ann Arbor) and the 
Garcia laboratory (College of Pharmacy, University of Michigan Ann Arbor).  All 
structure elucidation work presented in this chapter was done in the Sherman 
laboratory, by Dr. Ashootosh Tripathi.  The remaining experiments (screening and 
biological activity testing) were performed in the Garcia lab, by Anthony Emanuele.  
Other contributors to acknowledge, include: Martha J. Larsen and Tom McQuade at 
Center of Chemical Genomics, Life Sciences Institute, University of Michigan, for high 
throughput screening automation and NPE sample management; Dr. Yi-Chen Chen, for 
technical assistance; and Dr. Jeff W. Kampf, Director, X-ray Services, Department of 
Chemistry, University of Michigan for help with the Globomycin crystal structure 
determination.   
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Appendix 
Appendix Table VI-1.  Crystal Data and Structure Refinement for Globomycin A 
(1).  
   
   
 Identification code:     Globomycin A (1) 
 Empirical formula:       C34 H65.12 N6 O11.25 (with residual solvents)  
 Formula weight:          738.05 (with residual solvents) 
 Temperature:             85o K  
 Wavelength:              1.54178 λ  
 Crystal system, space group:      Hexagonal, P 6(1)  
 Unit cell dimensions:    a = 26.7741(4) A   alpha = 90 deg.  
                               b = 26.7741(4) A    beta = 90 deg.  
                               c = 9.8770(7) A   gamma = 120 deg.  
 Volume:                   6131.8(5) A3  
 Z, Calculated density:            6, 1.199 Mg/m3  
 Absorption coefficient:        0.739 mm-1  
 F(000):                            2407   
 Crystal size:                 0.12 x 0.02 x 0.02 mm  
 Theta range for data collection:   4.87 to 68.22 deg.  
 Limiting indices:                  -32<=h<=32, -32<=k<=32, -11<=l<=11  
 Reflections collected / unique:     128099 / 7433 [R(int) = 0.0657]  
 Completeness to theta:              68.22     99.9 %  
 Absorption correction:              Semi-empirical from equivalents  
 Max. and min. transmission:        0.986 and 0.830  
 Refinement method:                  Full-matrix least-squares on F2  
 Data / restraints / parameters:     7433 / 22 / 539  
 Goodness-of-fit on F2:            1.072  
 Final R indices [I>2sigma(I)]:      R1 = 0.0409, wR2 = 0.1030  
 R indices (all data):               R1 = 0.0422, wR2 = 0.1041  
 Absolute structure parameter:      0.06(14)  
 Largest diff. peak and hole:        0.671 and -0.251 A-3  
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Appendix Table VI-2.  Atomic Coordinates ( x 104) and Equivalent Isotropic 
Displacement Parameters (A2 x 103) for Globomycin A (1). 
________________________________________________________________  
  x y  z U(eq) 
________________________________________________________________  
 O(1) 8517(1) 2956(1) 3528(1) 24(1) 
 O(2) 7666(1) 2145(1) 3859(2) 53(1)  
 O(3) 7780(1) 1102(1) 1355(1) 31(1)  
 O(4) 6463(1) -293(1) 3638(1) 25(1)  
 O(5) 8444(1) 490(1) 4130(1) 29(1)  
 O(6) 7323(1) -397(1) 6843(1) 28(1)  
 O(7) 8549(1) 1569(1) 6099(1) 21(1)  
 O(8) 8970(1) 2620(1) 9879(1) 27(1)  
 O(9) 8276(1) 3238(1) 7028(1) 25(1)  
 O(11) 7370(1) 200(1) -351(1) 28(1)  
 O(10A) 9390(1) 345(1) 4635(5) 58(1)  
 O(10B) 9290(1) 160(1) 4206(5) 62(1)  
 N(1) 8162(1) 1485(1) 3399(1) 21(1)  
 N(2) 7605(1) 450(1) 4662(1) 18(1)  
 N(3) 8046(1) 777(1) 7361(1) 18(1)  
 N(4) 8540(1) 2303(1) 7844(1) 18(1)  
 N(5) 9175(1) 3392(1) 6653(1) 19(1)  
 N(6) 7781(1) -558(1) 747(2) 48(1)  
 C(1A) 7757(2) 4298(2)  -1653(4) 59(1)  
 C(1B) 7580(4) 4136(3) -1852(6) 120(2)  
 C(2) 7299(1) 4069(1) -552(3) 63(1)  
 C(3) 7499(1) 3886(1) 694(2) 53(1)  
 C(4) 7650(1) 3426(1) 456(2) 43(1)  
 C(5) 7745(1) 3171(1) 1734(2) 43(1)  
 C(6) 8207(1) 3601(1) 2686(2) 31(1)  
 C(7) 8286(1) 3326(1) 3954(2) 23(1)  
 C(8) 8166(1) 2385(1) 3525(2) 28(1)  
 C(9) 8470(1) 2080(1) 2974(2) 23(1)  
 C(10) 7820(1) 1048(1) 2593(2) 21(1)  
 C(11) 7454(1) 457(1) 3248(2) 20(1)  
 C(12) 6811(1) 270(1) 3102(2) 21(1)  
 C(13) 6639(1) 662(1) 3827(2) 26(1)  
 C(14) 8100(1) 463(1) 4997(2) 19(1)  
 C(15) 8221(1) 447(1) 6494(2) 19(1)  
 C(16) 7928(1) -173(1) 6977(2) 24(1)  
 C(17) 8274(1) 1345(1) 7157(2) 17(1)  
 C(18) 8183(1) 1701(1) 8221(2) 18(1)  
 C(19) 7545(1) 1533(1) 8393(2) 22(1)  
 C(20) 7500(1) 1930(1) 9437(2) 24(1)  
 C(21) 6902(1) 1682(1) 10049(2) 36(1)  
 C(22) 7268(1) 1539(1) 7053(2) 35(1)  
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 C(23) 8905(1) 2712(1) 8677(2) 20(1)  
 C(24) 9270(1) 3323(1) 8102(2) 20(1)  
 C(25) 9224(1) 3758(1) 9024(2) 26(1)  
 C(26) 9590(1) 4386(1) 8594(2) 36(1)  
 C(27) 10232(1) 4588(1) 8591(2) 45(1)  
 C(28) 9466(1) 4769(1) 9509(3) 59(1)  
 C(29) 9655(1) 3528(1) 5727(2) 26(1)  
 C(30) 8702(1) 3431(1) 6288(2) 21(1)  
 C(31) 8715(1) 3746(1) 4990(2) 22(1)  
 C(32) 8554(1) 4201(1) 5390(2) 30(1)  
 C(33) 7918(1) -727(1) 1657(2) 42(1)  
 C(34) 8078(1) -940(1) 2828(3) 76(1)  
 O(99) 10854(6) 795(6) 5340(19) 146(6)  
 O(99A) 10779(13) 544(10) 6230(40) 112(11)  
________________________________________________________________  
  
  
165 
 
Appendix Table VI-3.  Bond Lengths [Å] and Angles [deg] for Globomycin A (1).  
_____________________________________________________________  
   Bond Lengths 
   O(1)-C(8) 1.3348(17)  
   O(1)-C(7) 1.468(2)  
   O(2)-C(8) 1.206(2)  
   O(3)-C(10) 1.2425(19)  
   O(4)-C(12) 1.4195(17)  
   O(4)-H(4A) 0.86(2)  
   O(5)-C(14) 1.2348(19)  
   O(6)-C(16) 1.4228(18)  
   O(6)-H(6A) 1.04(3)  
   O(7)-C(17) 1.2470(17)  
   O(8)-C(23) 1.2423(19)  
   O(9)-C(30) 1.2306(18)  
   O(11)-H(11B) 0.77(3)  
   O(11)-H(11C) 0.98(2)  
   N(1)-C(10) 1.3300(18)  
   N(1)-C(9) 1.4417(18)  
   N(1)-H(1A) 0.94(2)  
   N(2)-C(14) 1.3491(19)  
   N(2)-C(11) 1.4561(19)  
   N(2)-H(2A) 0.992(19)  
   N(3)-C(17) 1.3402(17)  
   N(3)-C(15) 1.4639(19)  
   N(3)-H(3A) 0.91(2)  
   N(4)-C(23) 1.3280(18)  
   N(4)-C(18) 1.4527(16)  
   N(4)-H(4B) 0.88(2)  
   N(5)-C(30) 1.3710(19)  
   N(5)-C(29) 1.467(2)  
   N(5)-C(24) 1.480(2)  
   N(6)-C(33) 1.146(3)  
   C(1A)-C(2) 1.520(5)  
   C(1A)-H(1B) 0.9800  
   C(1A)-H(1C) 0.9800  
   C(1A)-H(1D) 0.9800  
   C(1B)-C(2) 1.453(7)  
   C(1B)-H(1E) 0.9800  
   C(1B)-H(1F) 0.9800  
   C(1B)-H(1G) 0.9800  
   C(2)-C(3) 1.518(3)  
   C(2)-H(2B) 0.9900  
   C(2)-H(2C) 0.9900  
   C(2)-H(2D) 0.9900  
   C(2)-H(2E) 0.9899  
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   C(3)-C(4)  1.496(3)  
   C(3)-H(3B) 0.9900  
   C(3)-H(3C) 0.9900  
   C(4)-C(5) 1.515(3)  
   C(4)-H(4C) 0.9900  
   C(4)-H(4D) 0.9900  
   C(5)-C(6) 1.521(2)  
   C(5)-H(5A) 0.9900  
   C(5)-H(5B) 0.9900  
   C(6)-C(7) 1.520(2)  
   C(6)-H(6B) 0.9900  
   C(6)-H(6C) 0.9900  
   C(7)-C(31) 1.530(2)  
   C(7)-H(7A) 1.0000  
   C(8)-C(9) 1.513(2)  
   C(9)-H(9A) 0.9900  
   C(9)-H(9B) 0.9900  
   C(10)-C(11) 1.5288(19)  
   C(11)-C(12) 1.541(2)  
   C(11)-H(11A) 1.0000  
   C(12)-C(13) 1.521(2)  
   C(12)-H(12A) 1.0000  
   C(13)-H(13A) 0.9800  
   C(13)-H(13B) 0.9800  
   C(13)-H(13C) 0.9800  
   C(14)-C(15) 1.519(2)  
   C(15)-C(16) 1.5161(19)  
   C(15)-H(15A) 1.0000  
   C(16)-H(16A) 0.9900  
   C(16)-H(16B) 0.9900  
   C(17)-C(18) 1.517(2)  
   C(18)-C(19) 1.5443(19)  
   C(18)-H(18A) 1.0000  
   C(19)-C(22) 1.521(2)  
   C(19)-C(20) 1.528(2)  
   C(19)-H(19A) 1.0000  
   C(20)-C(21) 1.519(2)  
   C(20)-H(20A) 0.9900  
   C(20)-H(20B) 0.9900  
   C(21)-H(21A) 0.9800  
   C(21)-H(21B) 0.9800  
   C(21)-H(21C) 0.9800  
   C(22)-H(22A) 0.9800  
   C(22)-H(22B) 0.9800  
   C(22)-H(22C) 0.9800  
   C(23)-C(24) 1.5340(19)  
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   C(24)-C(25) 1.530(2)  
   C(24)-H(24A) 1.0000  
   C(25)-C(26) 1.524(2)  
   C(25)-H(25A) 0.9900  
   C(25)-H(25B) 0.9900  
   C(26)-C(27) 1.522(3)  
   C(26)-C(28) 1.523(3)  
   C(26)-H(26A) 1.0000  
   C(27)-H(27A) 0.9800  
   C(27)-H(27B) 0.9800  
   C(27)-H(27C) 0.9800  
   C(28)-H(28A) 0.9800  
   C(28)-H(28B) 0.9800  
   C(28)-H(28C) 0.9800  
   C(29)-H(29A) 0.9800  
   C(29)-H(29B) 0.9800  
   C(29)-H(29C) 0.9800  
   C(30)-C(31) 1.525(2)  
   C(31)-C(32) 1.532(2)  
   C(31)-H(31A) 1.0000  
   C(32)-H(32A) 0.9800  
   C(32)-H(32B) 0.9800  
   C(32)-H(32C) 0.9800  
   C(33)-C(34) 1.446(4)  
   C(34)-H(34A) 0.9800  
   C(34)-H(34B) 0.9800  
   C(34)-H(34C) 0.9800  
   
 Bond Angles 
   C(8)-O(1)-C(7) 118.72(11)  
   C(12)-O(4)-H(4A) 107.7(14)  
   C(16)-O(6)-H(6A) 109.1(16)  
   H(11B)-O(11)-H(11C) 105(2)  
   C(10)-N(1)-C(9) 124.06(13)  
   C(10)-N(1)-H(1A) 121.1(12)  
   C(9)-N(1)-H(1A) 114.7(12)  
   C(14)-N(2)-C(11) 120.69(12)  
   C(14)-N(2)-H(2A) 117.3(12)  
   C(11)-N(2)-H(2A) 119.3(11)  
   C(17)-N(3)-C(15) 119.66(12)  
   C(17)-N(3)-H(3A) 121.4(13)  
   C(15)-N(3)-H(3A) 117.7(13)  
   C(23)-N(4)-C(18) 124.21(12)  
   C(23)-N(4)-H(4B) 113.0(12)  
   C(18)-N(4)-H(4B) 122.7(12)  
   C(30)-N(5)-C(29) 123.01(13)  
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   C(30)-N(5)-C(24) 119.05(12)  
   C(29)-N(5)-C(24) 116.81(12)  
   C(2)-C(1A)-H(1B) 109.5  
   C(2)-C(1A)-H(1C) 109.5  
   C(2)-C(1A)-H(1D) 109.5  
   C(2)-C(1B)-H(1E) 109.5  
   C(2)-C(1B)-H(1F) 109.5  
   H(1E)-C(1B)-H(1F)  109.5  
   C(2)-C(1B)-H(1G) 109.5  
   H(1E)-C(1B)-H(1G) 109.5  
   H(1F)-C(1B)-H(1G) 109.5  
   C(1B)-C(2)-C(3) 120.8(4)  
   C(1B)-C(2)-C(1A) 9.0(3)  
   C(3)-C(2)-C(1A) 111.5(3)  
   C(1B)-C(2)-H(2B) 116.6  
   C(3)-C(2)-H(2B) 109.3  
   C(1A)-C(2)-H(2B) 109.3  
   C(1B)-C(2)-H(2C) 90.3  
   C(3)-C(2)-H(2C) 109.3  
   C(1A)-C(2)-H(2C) 109.3  
   H(2B)-C(2)-H(2C) 108.0  
   C(1B)-C(2)-H(2D) 106.9  
   C(3)-C(2)-H(2D) 107.5  
   C(1A)-C(2)-H(2D) 125.7  
   H(2B)-C(2)-H(2D) 91.1  
   H(2C)-C(2)-H(2D) 19.4  
   C(1B)-C(2)-H(2E) 106.7  
   C(3)-C(2)-H(2E) 107.4  
   C(1A)-C(2)-H(2E) 95.9  
   H(2B)-C(2)-H(2E) 16.4  
   H(2C)-C(2)-H(2E) 122.7  
   H(2D)-C(2)-H(2E) 106.9  
   C(4)-C(3)-C(2) 115.01(19)  
   C(4)-C(3)-H(3B) 108.5  
   C(2)-C(3)-H(3B) 108.5  
   C(4)-C(3)-H(3C) 108.5  
   C(2)-C(3)-H(3C) 108.5  
   H(3B)-C(3)-H(3C) 107.5  
   C(3)-C(4)-C(5) 114.59(18)  
   C(3)-C(4)-H(4C) 108.6  
   C(5)-C(4)-H(4C) 108.6  
   C(3)-C(4)-H(4D) 108.6  
   C(5)-C(4)-H(4D) 108.6  
   H(4C)-C(4)-H(4D) 107.6  
   C(4)-C(5)-C(6) 115.44(15)  
   C(4)-C(5)-H(5A) 108.4  
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   C(6)-C(5)-H(5A) 108.4  
   C(4)-C(5)-H(5B) 108.4  
   C(6)-C(5)-H(5B) 108.4  
   H(5A)-C(5)-H(5B) 107.5  
   C(7)-C(6)-C(5) 113.61(13)  
   C(7)-C(6)-H(6B) 108.8  
   C(5)-C(6)-H(6B) 108.8  
   C(7)-C(6)-H(6C) 108.8  
   C(5)-C(6)-H(6C) 108.8  
   H(6B)-C(6)-H(6C) 107.7  
   O(1)-C(7)-C(6) 107.36(14)  
   O(1)-C(7)-C(31) 105.88(12)  
   C(6)-C(7)-C(31) 115.50(12)  
   O(1)-C(7)-H(7A) 109.3  
   C(6)-C(7)-H(7A) 109.3  
   C(31)-C(7)-H(7A) 109.3  
   O(2)-C(8)-O(1) 124.55(16)  
   O(2)-C(8)-C(9) 124.40(14)  
   O(1)-C(8)-C(9) 110.97(12)  
   N(1)-C(9)-C(8) 109.02(12)  
   N(1)-C(9)-H(9A) 109.9  
   C(8)-C(9)-H(9A) 109.9  
   N(1)-C(9)-H(9B) 109.9  
   C(8)-C(9)-H(9B) 109.9  
   H(9A)-C(9)-H(9B) 108.3  
   O(3)-C(10)-N(1) 123.25(13)  
   O(3)-C(10)-C(11) 119.28(12)  
   N(1)-C(10)-C(11) 117.46(13)  
   N(2)-C(11)-C(10) 112.40(11)  
   N(2)-C(11)-C(12) 110.99(12)  
   C(10)-C(11)-C(12) 109.30(12)  
   N(2)-C(11)-H(11A) 108.0  
   C(10)-C(11)-H(11A) 108.0  
   C(12)-C(11)-H(11A) 108.0  
   O(4)-C(12)-C(13) 107.03(12)  
   O(4)-C(12)-C(11) 110.03(12)  
   C(13)-C(12)-C(11) 113.98(11)  
   O(4)-C(12)-H(12A) 108.6  
   C(13)-C(12)-H(12A) 108.6  
   C(11)-C(12)-H(12A) 108.6  
   C(12)-C(13)-H(13A) 109.5  
   C(12)-C(13)-H(13B) 109.5  
   H(13A)-C(13)-H(13B) 109.5  
   C(12)-C(13)-H(13C) 109.5  
   H(13A)-C(13)-H(13C) 109.5  
   H(13B)-C(13)-H(13C) 109.5  
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   O(5)-C(14)-N(2) 121.78(14)  
   O(5)-C(14)-C(15) 120.92(13)  
   N(2)-C(14)-C(15) 117.30(13)  
   N(3)-C(15)-C(16) 109.28(12)  
   N(3)-C(15)-C(14) 114.51(13)  
   C(16)-C(15)-C(14) 109.64(11)  
   N(3)-C(15)-H(15A) 107.7  
   C(16)-C(15)-H(15A) 107.7  
   C(14)-C(15)-H(15A) 107.7  
   O(6)-C(16)-C(15) 106.82(12)  
   O(6)-C(16)-H(16A) 110.4  
   C(15)-C(16)-H(16A) 110.4  
   O(6)-C(16)-H(16B) 110.4  
   C(15)-C(16)-H(16B) 110.4  
   H(16A)-C(16)-H(16B) 108.6  
   O(7)-C(17)-N(3) 119.73(14)  
   O(7)-C(17)-C(18) 121.32(12)  
   N(3)-C(17)-C(18) 118.94(12)  
   N(4)-C(18)-C(17) 107.26(11)  
   N(4)-C(18)-C(19) 111.67(12)  
   C(17)-C(18)-C(19) 113.26(11)  
   N(4)-C(18)-H(18A) 108.2  
   C(17)-C(18)-H(18A) 108.2  
   C(19)-C(18)-H(18A) 108.2  
   C(22)-C(19)-C(20) 111.88(14)  
   C(22)-C(19)-C(18) 111.99(13)  
   C(20)-C(19)-C(18) 109.44(11)  
   C(22)-C(19)-H(19A) 107.8  
   C(20)-C(19)-H(19A) 107.8  
   C(18)-C(19)-H(19A) 107.8  
   C(21)-C(20)-C(19) 113.38(12)  
   C(21)-C(20)-H(20A) 108.9  
   C(19)-C(20)-H(20A) 108.9  
   C(21)-C(20)-H(20B) 108.9  
   C(19)-C(20)-H(20B) 108.9  
   H(20A)-C(20)-H(20B) 107.7  
   C(20)-C(21)-H(21A) 109.5  
   C(20)-C(21)-H(21B) 109.5  
   H(21A)-C(21)-H(21B) 109.5  
   C(20)-C(21)-H(21C) 109.5  
   H(21A)-C(21)-H(21C) 109.5  
   H(21B)-C(21)-H(21C) 109.5  
   C(19)-C(22)-H(22A) 109.5  
   C(19)-C(22)-H(22B) 109.5  
   H(22A)-C(22)-H(22B) 109.5  
   C(19)-C(22)-H(22C) 109.5  
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   H(22A)-C(22)-H(22C) 109.5  
   H(22B)-C(22)-H(22C) 109.5  
   O(8)-C(23)-N(4) 123.10(13)  
   O(8)-C(23)-C(24) 119.24(12)  
   N(4)-C(23)-C(24) 117.64(13)  
   N(5)-C(24)-C(25) 113.45(13)  
   N(5)-C(24)-C(23) 115.70(11)  
   C(25)-C(24)-C(23) 109.85(12)  
   N(5)-C(24)-H(24A) 105.6  
   C(25)-C(24)-H(24A) 105.6  
   C(23)-C(24)-H(24A) 105.6  
   C(26)-C(25)-C(24) 114.89(14)  
   C(26)-C(25)-H(25A) 108.5  
   C(24)-C(25)-H(25A) 108.5  
   C(26)-C(25)-H(25B) 108.5  
   C(24)-C(25)-H(25B) 108.5  
   H(25A)-C(25)-H(25B) 107.5  
   C(27)-C(26)-C(28) 110.35(16)  
   C(27)-C(26)-C(25) 112.51(15)  
   C(28)-C(26)-C(25) 109.96(16)  
   C(27)-C(26)-H(26A) 108.0  
   C(28)-C(26)-H(26A) 108.0  
   C(25)-C(26)-H(26A) 108.0  
   C(26)-C(27)-H(27A) 109.5  
   C(26)-C(27)-H(27B) 109.5  
   H(27A)-C(27)-H(27B) 109.5  
   C(26)-C(27)-H(27C) 109.5  
   H(27A)-C(27)-H(27C) 109.5  
   H(27B)-C(27)-H(27C) 109.5  
   C(26)-C(28)-H(28A) 109.5  
   C(26)-C(28)-H(28B) 109.5  
   H(28A)-C(28)-H(28B) 109.5  
   C(26)-C(28)-H(28C) 109.5  
   H(28A)-C(28)-H(28C) 109.5  
   H(28B)-C(28)-H(28C) 109.5  
   N(5)-C(29)-H(29A)  109.5  
   N(5)-C(29)-H(29B) 109.5  
   H(29A)-C(29)-H(29B) 109.5  
   N(5)-C(29)-H(29C)  109.5  
   H(29A)-C(29)-H(29C) 109.5  
   H(29B)-C(29)-H(29C) 109.5  
   O(9)-C(30)-N(5) 120.67(14)  
   O(9)-C(30)-C(31) 119.37(13)  
   N(5)-C(30)-C(31) 119.88(13)  
   C(30)-C(31)-C(7) 110.78(11)  
   C(30)-C(31)-C(32) 106.58(13)  
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   C(7)-C(31)-C(32) 110.57(13)  
   C(30)-C(31)-H(31A) 109.6  
   C(7)-C(31)-H(31A) 109.6  
   C(32)-C(31)-H(31A) 109.6  
   C(31)-C(32)-H(32A) 109.5  
   C(31)-C(32)-H(32B) 109.5  
   H(32A)-C(32)-H(32B) 109.5  
   C(31)-C(32)-H(32C) 109.5  
   H(32A)-C(32)-H(32C) 109.5  
   H(32B)-C(32)-H(32C) 109.5  
   N(6)-C(33)-C(34) 178.4(3)  
   C(33)-C(34)-H(34A) 109.5  
   C(33)-C(34)-H(34B) 109.5  
   H(34A)-C(34)-H(34B) 109.5  
   C(33)-C(34)-H(34C) 109.5  
   H(34A)-C(34)-H(34C) 109.5  
   H(34B)-C(34)-H(34C) 109.5  
  _____________________________________________________________  
   
  Symmetry transformations used to generate equivalent atoms  
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Appendix Table VI-4.  Hydrogen Coordinates ( x 104) and Isotropic Displacement 
Parameters (A2 x 103) for Globomycin A (1).  
 
________________________________________________________________  
 
  x y z  U(eq)  
________________________________________________________________  
   
 H(4A) 6427(9) -536(9) 3020(20) 45(6)  
 H(6A) 7105(11) -807(11) 7280(30) 77(9)  
 H(11B) 7440(10) -32(11) -100(30) 66(8)  
 H(11C) 7550(8) 514(8) 310(20) 35(5)  
 H(1A) 8206(8) 1425(8) 4320(20) 41(6)  
 H(2A) 7299(7) 314(8) 5360(20) 29(5)  
 H(3A) 7844(8) 604(8) 8120(20) 35(5)  
 H(4B) 8524(8) 2435(8) 7040(20) 34(5)  
 H(1B) 8119 4610 -1284 89  
 H(1C) 7630 4446 -2405 89  
 H(1D) 7816 3986 -1979 89  
 H(1E) 7919 4522 -1913 179  
 H(1F) 7310 4083 -2582 179  
 H(1G) 7700 3846 -1937 179  
 H(2B) 7207 4372 -298 76  
 H(2C) 6942 3734 -906 76  
 H(2D) 6885 3786 -685 76  
 H(2E) 7326 4444 -344 76  
 H(3B) 7841 4230 1071 63  
 H(3C) 7190 3747 1385 63  
 H(4C) 8006 3590  -98 52  
 H(4D) 7337 3112  -74 52  
 H(5A) 7851 2879 1471 52  
 H(5B) 7376 2969 2235 52  
 H(6B) 8578 3802 2193 37  
 H(6C) 8103 3894 2956 37  
 H(7A) 7903 3084 4400 28  
 H(9A) 8483 2102 1973 27  
 H(9B) 8871 2269 3317 27  
 H(11A) 7523  173 2745 24  
 H(12A) 6720  263 2117 25  
 H(13A) 6240  548 3595 39  
 H(13B) 6896 1063 3547 39  
 H(13C) 6671  629 4808 39  
 H(15A) 8646  614 6604 22  
 H(16A) 8051 -400 6420 29  
 H(16B) 8028 -191 7934 29  
 H(18A) 8325 1640 9108 21  
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 H(19A) 7332 1131 8758 26  
 H(20A) 7781 2007 10172 29  
 H(20B) 7607 2303 8999 29  
 H(21A) 6620 1594 9326 54  
 H(21B) 6896 1965 10670 54  
 H(21C) 6806 1329 10547 54  
 H(22A) 6859 1407 7196 52  
 H(22B) 7307 1281 6410 52  
 H(22C) 7461 1932 6688 52  
 H(24A) 9679 3414 8170 24  
 H(25A) 8815 3660 9060 31  
 H(25B) 9339 3716 9952 31  
 H(26A) 9476 4422 7650 43  
 H(27A) 10448 4991 8291 67  
 H(27B) 10307 4347 7973 67  
 H(27C) 10354 4558 9508 67  
 H(28A) 9598 4760 10430 88  
 H(28B) 9051 4628 9519 88  
 H(28C) 9671 5166 9167 88  
 H(29A) 9508 3425 4801 39  
 H(29B) 9843 3309 5991 39  
 H(29C) 9935 3942 5772 39  
 H(31A) 9112 3940 4598 26  
 H(32A) 8623 4460 4622 44  
 H(32B) 8791 4425 6161 44  
 H(32C) 8145 4010 5643 44  
 H(34A) 8459 -644 3149 115  
 H(34B) 8091 -1288 2580 115  
 H(34C) 7793 -1033 3548 115  
________________________________________________________________  
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Appendix Table VI-5.  Torsion Angles [deg] for Globomycin A (1).  
________________________________________________________________  
   
 C(1B)-C(2)-C(3)-C(4) -40.6(4)  
 C(1A)-C(2)-C(3)-C(4) -59.2(3)  
 C(2)-C(3)-C(4)-C(5) -169.52(17)  
 C(3)-C(4)-C(5)-C(6) -57.1(2)  
 C(4)-C(5)-C(6)-C(7) 179.85(17)  
 C(8)-O(1)-C(7)-C(6) -105.26(15)  
 C(8)-O(1)-C(7)-C(31) 130.83(14)  
 C(5)-C(6)-C(7)-O(1) 66.40(18)  
 C(5)-C(6)-C(7)-C(31) -175.78(16)  
 C(7)-O(1)-C(8)-O(2) -0.5(3)  
 C(7)-O(1)-C(8)-C(9) 176.38(13)  
 C(10)-N(1)-C(9)-C(8) 104.00(18)  
 O(2)-C(8)-C(9)-N(1) -22.3(3)  
 O(1)-C(8)-C(9)-N(1) 160.81(13)  
 C(9)-N(1)-C(10)-O(3) 7.7(3)  
 C(9)-N(1)-C(10)-C(11) -170.88(14)  
 C(14)-N(2)-C(11)-C(10) -73.04(17)  
 C(14)-N(2)-C(11)-C(12) 164.21(12)  
 O(3)-C(10)-C(11)-N(2) 172.65(14)  
 N(1)-C(10)-C(11)-N(2) -8.7(2)  
 O(3)-C(10)-C(11)-C(12) -63.65(19)  
 N(1)-C(10)-C(11)-C(12) 114.99(15)  
 N(2)-C(11)-C(12)-O(4) -58.71(16)  
 C(10)-C(11)-C(12)-O(4) 176.77(12)  
 N(2)-C(11)-C(12)-C(13)  61.52(16)  
 C(10)-C(11)-C(12)-C(13) -63.01(17)  
 C(11)-N(2)-C(14)-O(5) 1.0(2)  
 C(11)-N(2)-C(14)-C(15) -179.28(11)  
 C(17)-N(3)-C(15)-C(16) 177.04(12)  
 C(17)-N(3)-C(15)-C(14) -59.54(16)  
 O(5)-C(14)-C(15)-N(3) 141.69(13)  
 N(2)-C(14)-C(15)-N(3) -38.06(16)  
 O(5)-C(14)-C(15)-C(16) -95.09(15)  
 N(2)-C(14)-C(15)-C(16) 85.17(15)  
 N(3)-C(15)-C(16)-O(6) 61.85(15)  
 C(14)-C(15)-C(16)-O(6) -64.42(15)  
 C(15)-N(3)-C(17)-O(7) 12.8(2)  
 C(15)-N(3)-C(17)-C(18) -167.87(12)  
 C(23)-N(4)-C(18)-C(17) -129.21(15)  
 C(23)-N(4)-C(18)-C(19) 106.15(16)  
 O(7)-C(17)-C(18)-N(4) -8.80(18)  
 N(3)-C(17)-C(18)-N(4) 171.87(12)  
 O(7)-C(17)-C(18)-C(19) 114.87(14)  
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 N(3)-C(17)-C(18)-C(19) -64.46(17)  
 N(4)-C(18)-C(19)-C(22) 68.28(16)  
 C(17)-C(18)-C(19)-C(22) -52.94(17)  
 N(4)-C(18)-C(19)-C(20) -56.38(16)  
 C(17)-C(18)-C(19)-C(20) -177.60(12)  
 C(22)-C(19)-C(20)-C(21) 75.82(18)  
 C(18)-C(19)-C(20)-C(21) -159.45(14)  
 C(18)-N(4)-C(23)-O(8) -1.1(2)  
 C(18)-N(4)-C(23)-C(24) 177.47(13)  
 C(30)-N(5)-C(24)-C(25) -49.31(15)  
 C(29)-N(5)-C(24)-C(25) 118.92(13)  
 C(30)-N(5)-C(24)-C(23) 78.97(17)  
 C(29)-N(5)-C(24)-C(23) -112.80(14)  
 O(8)-C(23)-C(24)-N(5) 178.51(14)  
 N(4)-C(23)-C(24)-N(5) -0.1(2)  
 O(8)-C(23)-C(24)-C(25) -51.46(19)  
 N(4)-C(23)-C(24)-C(25) 129.91(15)  
 N(5)-C(24)-C(25)-C(26) -51.42(17)  
 C(23)-C(24)-C(25)-C(26) 177.34(13)  
 C(24)-C(25)-C(26)-C(27) -61.8(2)  
 C(24)-C(25)-C(26)-C(28) 174.78(16)  
 C(29)-N(5)-C(30)-O(9) 169.87(13)  
 C(24)-N(5)-C(30)-O(9) -22.66(19)  
 C(29)-N(5)-C(30)-C(31) -13.5(2)  
 C(24)-N(5)-C(30)-C(31) 153.96(12)  
 O(9)-C(30)-C(31)-C(7) -69.67(18)  
 N(5)-C(30)-C(31)-C(7) 113.66(15)  
 O(9)-C(30)-C(31)-C(32) 50.68(16)  
 N(5)-C(30)-C(31)-C(32) -125.99(14)  
 O(1)-C(7)-C(31)-C(30) -68.50(15)  
 C(6)-C(7)-C(31)-C(30) 172.86(14)  
 O(1)-C(7)-C(31)-C(32) 173.56(12)  
 C(6)-C(7)-C(31)-C(32) 54.92(18)  
________________________________________________________________  
 
Symmetry transformations used to generate equivalent atoms 
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 Appendix Table VI-6.  Hydrogen Bonds for Globomycin A (1) [d = Å and < = deg.].  
______________________________________________________________________ 
   
 D-H...A d(D-H) d(H...A) d(D...A) <(DHA)  
   
 O(4)-H(4A)...O(8)#1 0.86(2) 1.91(2) 2.7679(15) 175(2)  
 O(6)-H(6A)...O(7)#2 1.04(3) 1.66(3) 2.6534(14) 158(3)  
 N(1)-H(1A)...O(7) 0.94(2) 1.93(2) 2.8300(17) 159.0(16)  
 N(3)-H(3A)...O(11)#3 0.91(2) 1.92(2) 2.8238(16) 175.9(18)  
 N(4)-H(4B)...N(5) 0.88(2) 2.299(18) 2.7965(16) 115.9(15)  
 N(4)-H(4B)...O(9) 0.88(2) 2.55(2) 3.0330(17) 115.5(17)  
 
______________________________________________________________________   
 Symmetry transformations used to generate equivalent atoms 
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Appendix Figure VI-1:  HRMS Spectrum of Globomycin A (1). 
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Appendix Figure VI-2:  HRMS Spectrum of Globomycin B (2). 
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Appendix Figure VI-3:  HRMS Spectrum of Globomycin C (3).  
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Appendix Figure VI-4:  1H NMR Spectrum of Globomycin A (1) Recorded at 700 
MHz (in DMSO-d6). 
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Appendix Figure VI-5:  13C NMR Spectrum of Globomycin A (1) Recorded at 700 
MHz (in DMSO-d6). 
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Appendix Figure VI-6: g-COSY Spectrum of Globomycin A (1) Recorded at 700 
MHz (in DMSO-d6). 
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Appendix Figure VI-7:  HRMS Spectrum of Desferrioxamine E. 
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Appendix Figure VI-8:  1H NMR Spectrum of Desferrioxamine E Recorded at 700 
MHz (in DMSO-d6). 
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Appendix Figure VI-9:  13C NMR Spectrum of Desferrioxamine E Recorded at 700 
MHz (in DMSO-d6). 
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Appendix Figure VI-10:  g-COSY Spectrum of Desferrioxamine E Recorded at 700 
MHz (in DMSO-d6). 
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CHAPTER VII 
Concluding Summary 
In developing nations, diarrheal diseases are a leading cause of illness for 
children under five years of age and are responsible for 10% of all deaths of children in 
this age group.1  It is estimated that 20% of all diarrheal diseases are caused by 
Shigella spp. infections.2  Recent outbreaks of multi-drug resistant strains of Shigella in 
day care centers across developed nations has made evident that drug-resistant 
shigellosis is no longer a concern for only the developing world.3-6  Clearly, new 
treatments are needed.  A recent trend in discovering new treatments for bacterial 
infections is to target virulence over bacterial viability.7  In theory, targeting virulence will 
produce less selective pressure for the emergence of resistance since virulence is not 
required for bacterial viability and anti-virulence therapies should not affect non-
pathogenic organisms.  Based on previous gene disruption studies,8-12 we hypothesize 
that inhibiting VirF, the main transcriptional activator of the Shigella spp. pathogenesis 
cascade, with a small molecule will attenuate the virulence of Shigella flexneri and not 
affect bacterial viability.  The purpose of this dissertation study was to identify and 
characterize inhibitors of VirF and determine their potential as anti-virulence agents for 
treating shigellosis. 
 As shown in Figure VII-1, VirF is known to activate the transcription of two genes, 
virB (encodes for a secondary transcriptional activator necessary for activating virulence  
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Figure VII-1:  Genes Regulated by VirF and their Roles in Pathogenesis. 
genes responsible for host cell invasion and macrophage escape) and icsA (encodes 
for an outer membrane protein that assembles actin polymerase and allows the 
bacterium to spread to adjacent host cells).13, 14  To identify inhibitors of VirF, we utilized 
a Shigella-based, VirF-driven, β-galactosidase reporter assay that monitored the 
transcriptional activation from the virB promoter.  Using this assay, we followed up on 
our 42,000 compound pilot high-throughput screen (HTS),15 and screened an additional 
100,000 compounds and 20,000 natural product extracts.  Following a series of control 
screens and reconfirmation assays, we identified five compounds with IC50 values for 
VirF transcriptional activation ranging from 14 to 66 μM.  Although the compounds do 
not have great potency, we believe that their efficacy could be increased in future 
structure optimization studies.  Also, previous studies have shown that if VirF 
expression levels are lowered by only 60% that S. flexneri displays an avirulent 
phenotype;16 therefore, it might not be necessary to have an extremely potent 
compound to produce a therapeutic effect in vivo. 
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S. flexneri is known to only infect the colonic epithelium in human and nonhuman 
primates.  Therefore, to validate our HTS approach and test our hypothesis, we 
screened our inhibitors in Caco-2 monolayer models (derived from human epithelial 
colorectal adenocarcinoma cells) of the S. flexneri infection process.  The compounds 
were tested in two different assays, a gentamicin protection invasion assay (model for 
initial host cell invasion) and a plaque formation assay (model for the cell-to-cell spread 
of an active infection).  At concentrations that were not toxic to the bacteria or the Caco-
2 monolayers, two compounds, 19615 and 144092, significantly reduced the ability of S. 
flexneri to initially invade the monolayers, while three compounds 19615, 144092, and 
144143, modestly reduced the ability of S. flexneri to spread from cell-to-cell after initial 
invasion.  Interestingly, compound 144143 only showed activity in the plaque formation 
assay.  It is possible, since the cell-to-cell spread of an active infection relies on 
activation of the icsA promoter, that compound 144143 may have a preferential effect 
on inhibiting VirF transcriptional activation of the icsA promoter over the virB promoter.  
Our initial HTS assay only monitored activation of the virB promoter (required for initial 
host cell invasion, but not cell-to-cell spread).  In the future, we plan on constructing an 
assay similar to our HTS reporter that monitors activation of the icsA promoter to test 
this theory.  Nevertheless, the fact that the compounds attenuated the virulence of S. 
flexneri validates our HTS approach and confirms our hypothesis. 
Next, to further characterize our compounds we sought to identify their 
mechanisms of inhibition.  The exact process of how VirF activates transcription is not 
known.  It is predicted that VirF must bind to its promoter region, dimerize, and recruit 
RNA polymerase.  It is possible that our compounds could be inhibiting any of these 
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steps.  The lack of information regarding VirF transcriptional activation is partly due to 
how difficult VirF is to study outside of the bacterial cell.  VirF expresses poorly in 
recombinant systems, has a tendency to aggregate, and is fairly insoluble.  To enable in 
vitro studies of isolated VirF, we developed a novel Shigella-based homologous 
expression system to express and purify MalE-VirF.  Using this system, we were able to 
obtain pure MalE-VirF preparations with sufficient yields to enable the development of 
two in vitro DNA binding assays (an EMSA and FP assay) and report the first KD (to our 
knowledge) for VirF binding to the virB promoter (2.8 ± 1.0 μM).  Using these assays, 
along with a fluorescence intercalator displacement assay, we were able to demonstrate 
that 19615 attenuates the virulence of S. flexneri by decreasing VirF transcriptional 
activation via direct inhibition of VirF-DNA binding.  Using the FP assay we were also 
able to determine a Ki for 19615 (5.6 μM) and identify valuable structure-activity 
relationship trends to be incorporated into future generations of 19615 analogs.  
Unfortunately, we were unable to identify the mechanisms of inhibition of the remaining 
four compounds.  It is possible that they could be inhibiting VirF dimerization, RNA 
polymerase recruitment, or acting through an unpredicted mechanism.  We are currently 
developing assays to probe the other potential mechanisms of inhibition (e.g. an SPR 
platform that monitors VirF dimerization and/or RNA polymerase recruitment, an in vitro 
transcription assay, and other reporter systems). 
In conclusion, we have developed tools, a novel homologous expression system 
and multiple assays, that have enabled us to study the activity of VirF at multiple levels 
(i.e. biochemical, bacterial, and cellular).  Using these tools we have 
identified/characterized inhibitors of VirF transcriptional activation (see Table VII-1 for 
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summary of most promising compounds) and validated VirF as an anti-virulence target 
for a small molecule therapeutic to treat shigellosis. In the future, we plan on conducting 
synthetic structure-activity relationship studies to improve the potency of our leads, 
developing assays to probe the mechanisms of inhibition of our remaining compounds, 
and screening our inhibitors against additional AraC family regulators that control 
virulence in other organisms.  Previous studies have shown that inhibitors of AraC 
family regulators have the potential to inhibit multiple different family members.17-21  It is 
possible that our lead compounds could not only be developed into an anti-virulence 
therapy to treat shigellosis, but into a broad-spectrum anti-virulence therapeutic agent. 
Table VII-1.  Summary of Most Promising Compounds Identified in this Work. 
Compound 
Reporter 
Assay IC50 
%Inhibition 
at 6.25 μM in 
Invasion 
Assay 
%Inhibition 
at 6.25 μM 
in Plaque 
Assay 
Inhibits VirF 
from binding 
to virB 
promoter? 
 
19615 
14 μM 77% 19% 
Yes  
(Ki = 5.6 μM) 
 
144092 
23 μM 63% 25% 
No, negligible 
effect 
 
144143 
23 μM 
Negligible 
effect 
42% 
No, negligible 
effect 
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